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Cover photo: Earth, moon, and stars in a patient with gouty arthritis 
The patient, a 55-year-old man who was undergoing a course of anti-tuberculosis treatment, abruptly 
developed severe pain and swelling in the right knee and both ankles. Joint aspiration revealed thick, 
white material, which was confirmed by polarizing microscopy to be monosodium urate monohydrate 
crystals. The aggregate of crystals (right panels) resembled the painting “Starry Night” by Vincent van 
Gogh and the NASA photograph “Earth-Moon Conjunction” (courtesy NASA/JPL-Caltech) (left panels). 
Copyright 2007, reproduced with permission from Wiley InterScience Group 
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Introduction 
Gouty arthritis is among the earliest diseases that have been recognised as a clinical entity. 
First identified by the Egyptians in 2640 BC, podagra (acute gout occurring in the first 
metatarsophalangeal joint) was later recognised by Hippocrates in the fifth century BC, who 
referred to it as ‘the unwalkable disease’. Hippocrates also noted the link between the disease 
and an intemperate lifestyle, referring to podagra as an ‘arthritis of the rich’, as opposed to 
rheumatism, an ‘arthritis of the poor’ [1]. 
In history, gout seems a common disease, and many historic figures were suffering from gout 
[2-9]. Factors that might increase gout incidence back then, were lead contamination of water 
and a “bourgondic” lifestyle. In 1679, Van Leeuwenhoek observed microscopic gouty crystals. 
These crystals result from urate deposition in tissues in presence of hyperuricemia. They induce 
episodic arthritis, which initially are infrequent, usually affecting the foot, and respond well to 
anti-inflammatory medications such as colchicine and non-steroidal anti-inflammatory drugs. 
However, these measures do not stop urate deposition from progressing. More frequent and 
widespread attacks may develop, with increasing resistance to anti-inflammatory therapy. 
Permanent joint damage may result from gouty erosions, and tophi formation may be 
complicated by ulcerations and sepsis. Thus, optimal management requires timely introduction 
of antihyperuricemic therapy to provide a gradient for resorption of the crystals [10]. 
In the 1950s-1970s, several antihyperuricemic drugs became available for treatment of gout, 
such as allopurinol, benzbromarone, and probenecid. Allopurinol acts by inhibiting xanthine 
oxidase, thereby preventing formation of urate (uric acid). Benzbromarone and probenecid act 
by enhancing the renal excretion of urate. However, a lack of information exists on the risk-
benefit ratios of these drugs for the treatment of gout [11]. In a meta-analysis published in 2006, 
only one randomised controlled trial of good quality assessing antihyperuricemic drugs was 
found [11]. 
In 2003, benzbromarone was withdrawn from the global market because of reports of severe 
hepatotoxicity [12]. In 2004, it returned in The Netherlands (and Spain), but its use was 
restricted to patients allergic to allopurinol. Recently, reports state that allopurinol is the most 
common cause of Stevens-Johnson syndrome and toxic epidermal necrosis [13]. 
No consensus exists to what extent sUr should be lowered. For instance, the recent European 
recommendations use a target sUr concentration of 0.36 mmol/l (6.1 mg/dl), the recent British 
guideline uses 0.30 mmol/l, and the Dutch practitioners standard uses 0.38 mmol/l [14-16]. It is 
sometimes believed that values below the threshold of monosodium urate at body temperature 
(37 °C), 0.41 mmol/l are good enough. However, gout symptoms usually occur in the 
extremities where body temperature is lower than in the centre, and therefore solubility of 
monosodium urate is lower than 0.41 mmol/l [17]. In addition, solubility of monosodium urate in 
synovial fluid is influenced by other factors, like pH, concentration of cations, level of articular 
dehydration, and the presence of such nucleating agents as non-aggregated proteoglycans, 
insoluble collagens, and chondroitin sulphate [18]. 
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From prospective observational and retrospective data, a strict control of sUr is necessary to 
successfully diminish tophi and prevent recurrent gout attacks [19-23]. 
Numerous publications identify that gout management is often sub-optimal, despite detailed 
understanding of the pathogenesis and pathophysiology of the disorder, the ability to establish 
the diagnosis with certainty, and the expected effectiveness of lifestyle and pharmacological 
interventions. Barriers to successful gout management include diagnostic inaccuracy, a paucity 
of guidelines, sub-optimal patient education and patient adherence, co-morbidities and drug-
drug interferences that complicate treatment of gout, and limited urate-lowering alternatives 
[24]. 
 
Objective of the thesis 
The objective of this thesis is to study the pharmacological and clinical aspects of 
antihyperuricemic dugs in the treatment of gout in clinical practice, with the focus on efficacy 
and tolerability. 
 
Outline of the thesis 
This thesis comprises of four parts: (1) management of gout, (2) outcome research with 
antihyperuricemic drugs, (3) therapeutic drug monitoring of allopurinol, and (4) rasburicase for 
treatment of gout. 
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Abstract 
Gout is characterised by the formation and deposition of monosodium urate (MSU) crystals 
attributable to the metabolism of purines or uric acid. The disease is associated with recurrent 
episodes of acute joint pain caused by the deposition of MSU crystals in the joints. As well as 
affecting the joints, skin/subcutaneous tissue and kidneys are also affected by tophaceous 
deposits, cellulitis, urate nephropathy and kidney stones, respectively. In most cases the cause 
of gout is not easily identifiable, but there are a number of factors that could contribute to 
increases in urate (uric acid) levels, such as renal function disorders, obesity, and use of 
diuretics. Primary gout tends to involve low uric acid excretion, the cause of which originates 
primarily in the proximal tubulus. Only a minority of gout cases involve overproduction of uric 
acid. 
There are several classes of drugs available for the treatment of gout. These include anti-
inflammatory drugs (glucocorticosteroids, colchicine, and non-steroidal anti-inflammatory 
drugs), and antihyperuricemic drugs (allopurinol, benzbromarone, probenecid, and the novel 
urate-lowering drug febuxostat, which is currently under review by the EMEA). In addition, 
lifestyle changes can also help to prevent the occurrence of gout or reduce the likelihood of 
recurrent disease. This review summarises the use of these drugs in the prevention and 
treatment of the disease, applies data from current recommendations, and provides an overview 
for clinical practice. 
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Introduction to gout 
Gout is the collective name for several disorders that are characterised by the formation and 
deposition of monosodium urate (MSUr) crystals [1]. The condition is associated with recurrent 
episodes of acute joint pain due to the deposition of MSUr crystals in the joints. In addition to 
the effects observed in the joints, skin/subcutaneous tissue and kidneys are also affected by 
tophaceous deposits, cellulitis, urate nephropathy and kidney stones, respectively. In most 
cases, no identifiable underlying cause of gout is present, but evident factors are usually 
present that could contribute to increases in urate (uric acid) levels, such as renal function 
disorders, obesity, and the use of thiazide diuretics. 
The annual incidence of gout is 0.1% in men with serum urate (sUr) <0.42 mmol/l (7.1 mg/dL) 
rising to 7.0% in those with sUr >0.60 mmol/l (10.1 mg/dL). The condition is less common at sUr 
levels <0.35 mmol/l (5.9 mg/dL), but regularly occurs at levels >0.55 mmol/l (9.3 mg/dL). In 
2006, the European League against Rheumatism (EULAR) released recommendations for the 
diagnosis and treatment of gout [2-3]. 
 
Gout pathophysiology 
Uric acid is formed from nucleic acid either endogenously from cell breakdown or exogenously 
from metabolism of food. The solubility of MSUr is reduced by cooling and acidification of the 
microenvironment, which can result in acute formation of urate crystals. One-third of urate is 
excreted by the gut and two-thirds are excreted renally. In the kidney, uric acid is mainly filtered 
in the glomerulus and then almost entirely reabsorbed in the proximal tubulus by the urate anion 
transporter 1 (URAT-1). Finally, 75% of uric acid is excreted by the distal tubulus. Some drugs, 
such as cyclosporine A and diuretics, can inhibit this excretion. Excessive consumption of 
alcohol (particularly beer), sweetened soft drinks, fructose, meat, and seafood can also increase 
levels of sUr [4]. 
Uric acid is reabsorbed via the URAT-1 by utilisation of lactate, pyruvate or other compounds. 
Inhibition of URAT-1 can be achieved by uricosurics, and endogenous production can be 
inhibited using xanthine oxidase inhibitors (XOi), such as allopurinol. Febuxostat may become 
the alternative XOi, as it is currently under review by the EMEA. Uric acid deposits can also be 
lysed by the enzyme uricase, the gene for which is defective in humans because of an 
evolutionary mutation. The combined absence of uricase and almost total reabsorption of 
filtered urate, explains that humans have 10-fold higher sUr levels than other mammals. 
 
Characteristics of gout presentation 
Before gout can be diagnosed, it must be established whether the symptoms are caused by 
disrupted uric acid metabolism (chronic gout), and/or tophaceous deposits of MSUr crystals 
(micro-tophi) in joints, and other tissues that are observed during acute attacks of gout. The 
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clinical practitioner can confirm the presence and type of crystals by polarisation microscopy 
[1, 5-6]. 
The characteristic profile of gout is that of severe monoarthritis occurring within several hours. 
The first metatarsophalangeal joint is affected in 50% of gout attacks, and this is known as 
podagra. Gout may be localised in other joints, but shoulders, hips and the vertebral column are 
rarely affected. The initial gout attack usually involves monoarthritis, but long-term gout over 
several years may become polyarticular and could lead to increasing joint damage. Similarly, a 




Primary gout tends to involve low urate excretion, which is primarily originated in the proximal 
tubulus. Only a minority of cases involve overproduction of urate. In some treatments of cancer 
(particularly lymphomas and leukemias), patients can develop tumour lysis syndrome including 
severe hyperuricemia with risk of urate nephropathy. By definition, overproducers of urate 
excrete >6.0 mmol/l (1 g) in urine per 24 hours on a normal diet, or >3.6 mmol (600 mg) per 
24 hours after five days on a low-purine diet. Patients have a low excretion of urate when less 
than half of the threshold value is present in a 24-hour urine sample, and the combination of low 
excretion with hyperuricemia lies between the threshold values (without a low-purine diet: 3-
6 mmol/24 hours). Based on clinical observations, the author recommends that the patient’s 
urate excretion status should be taken into account for choice of antihyperuricemic drug. 
However, no evidence for this approach is available in the literature. 
 
Urate nephropathy in gout 
Aggressive chemotherapy among patients with chronic leukemia or malignant lymphoma could 
cause an excessive supply of uric acid resulting in acute urate nephropathy due to the 
deposition of sodium urate crystals in collection ducts and ureters. 
In chronic hyperuricemia, the risk of developing renal calculi increases as serum urate 
concentrations rise. The risk is about 10% with serum urate 0.42-0.48 mmol/l, but can rise to 
50% with serum urate concentrations >0.70 mmol/l. In the absence of stones or other risk 
factors (such as hypertension), the risk of urate nephropathy has generally been considered low 
[7]. 
 
Radiographic presentations of gout 
X-ray examination at the initial onset of gout has revealed no abnormalities except for possible 
pre-existing arthrosis and soft tissue edema. Cartilage and bone might be affected by chronic 
and/or recurring arthritis, and subsequently exhibit narrowing of the joint cavity because of the 
disappearance of cartilage, and erosions or cysts because of contact with juxta-articular bone. 
These abnormalities and the appearance of the erosions may raise suspicions of gout, but 
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erosions are a secondary manifestation and non-diagnostic characteristic of gout. These 
variations in the presentations of gout mean that treatment should be tailored accordingly 
(Table 1). 
 




Prevention 1 Antihyperuricemic 
treatment 
1. Asymptomatic 
(a) no history 










2. Crystal-induced gouty arthritis 
(a) frequency of attacks <2 per annum 










3. Tophaceous gout - + + 
4. Radiographic lesions due to gout/tophi - + + 
1 Lifestyle changes and elimination of hyperuricemic factors in secondary gout. 
2 Only upon evidence of crystal formation, e.g. swelling. 
 
Treatment strategies for gout 
Several approaches to the treatment of gout are available depending on the patient’s 
presentation of the disease. Optimal treatment often requires a combination of pharmacological 
intervention and lifestyle changes. Treatment should be tailored to the patient’s specific risk 
factors (high sUr, previous attacks and radiographic signs), the clinical phase of the disease 
(acute, recurrent, tophaceous) and general risk factors, such as obesity and alcohol 
consumption. Primary prevention of gout often involves changes in lifestyle, such as a low-
purine/weight-reducing diet or restricting alcohol intake; however, many patients are unlikely to 
undertake such changes until they are diagnosed with the disease, which often occurs when the 
symptoms are presented in the form of an attack of gout. Acute gout is usually treated by 
reducing the inflammation of the affected joint with non-steroidal anti-inflammatory drugs 
(NSAIDs), colchicine, corticosteroids, and cooling. Once the acute gout has subsided the 
objective is to prevent disease recurrence. This might involve lifestyle changes and low doses of 
NSAIDs or colchicine. In patients with high sUr levels who suffer from frequent attacks of gout, 
the use of urate-lowering drugs is warranted. Antihyperuricemic drugs include XOi (such as 
allopurinol), which act by inhibiting uric acid production thereby reducing serum urate 
concentrations. Other antihyperuricemic therapies include uricosuric drugs, such as benz-
bromarone and probenecid, which inhibit the reabsorption of uric acid mediated by URAT-1. 
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Table 2. Antihyperuricemic drugs in gout 
Drug Action: indication Daily dose: standard 
Allopurinol p.o. XOi: all 100-900 mg: 300 mg 
Benzbromarone p.o. URAT-1: low excretor, subject to intolerance 
or allergy to allopurinol (as per p.i.l.) 
50-200 mg: 100 mg 
Febuxostat p.o. XOi: all 80-120 mg: 80 mg 
Probenecid p.o. URAT-1: low excretor 500-2,000 mg: 1,000 mg 
Sulphinpyrazone p.o. URAT-1: low excretor 100-800 mg: 600 mg 
Rasburicase i.v. UrO: lytic effect on tophi Compassionate use: e.g. 0.2 mg/kg in 
60
 
min. infusion on day 1, then 1x per 
week; (+ methylprednisolone 100 mg i.v.) 
Legend: i.v.: intravenous; p.i.l.: patient information leaflet; p.o.: oral; UrO: urate oxidase; URAT-1: urate anion transporter 1; XOi: 
xanthine oxidase inhibitor. 
 
 
Table 3. Suggested strategy for initiation of antihyperuricemic therapy 
1. Confirmation of diagnosis: detect crystals by means of polarisation microscopy 
2. >2 gout flares per annum or tophi/joint destruction due to gout attacks 
3. Therapeutic advice 1: allopurinol 100-300 mg/day 2 
4. Laboratory monitoring of effectiveness at 6-8 weeks: 3 
(a) sUr <0.30 mmol/l, then continue with this 
(b) sUr >0.30 mmol/l, but no further attacks (without colchicine/NSAID), then continue with this 
(c) sUr >0.36 mmol/l plus gout attacks and uUr >4.0 mmol/24 hours, go to 5 
(d) sUr >0.36 mmol/l plus gout attacks/persistent tophi with uUr <4.0 mmol/24 hours, go to 6 
5. Therapeutic advice: increase allopurinol with 100 mg/day or double the dose b 
6. Therapeutic advice: add uricosuricum, e.g. benzbromarone 100 mg/day, or probenecid 1,000 mg/day 
7. Laboratory monitoring of effectiveness sUr and uUr (possibly, pH 4) after 6 months: see 5 
8. N.B.: when trying to clear tophi, target value sUr <0.30 mmol/l 
Legend: sUr: serum urate; uUr: 24-hour excretion of urate in urine; NSAID: non-steroidal anti-inflammatory drug. 
1 Subject to motivation and tolerance by patient. 
2 Subject to calculated creatinine clearance (cCC) >50 ml/min, if cCC <50 ml/min, then only increase allopurinol with 
100 mg/day. Serum oxipurinol concentrations might be measured in patients with renal insufficiency. 
3 Target value for sUr ≤0.36 mmol/l might be sufficient when there are no further gout attacks despite withdrawing 
colchicine/NSAID, otherwise lower target value of 0.30 mmol/l. 
4 If experiencing kidney stones or uUr >6.0 mmol/24 hours and pH <7.0 consider alkalising with sodium bicarbonate. 
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The following is an overview of the different drug classes and their potential use as part of the 
treatment strategies for gout. Information on these drugs is presented in Table 2 and the current 
therapeutic strategy is summarised in Table 3. 
 
Primary prevention of gout 
Primary prevention of gout involves changes in lifestyle, such as changes to diet (low-
purine/weight-reducing diet) and restricting alcohol consumption. No randomised studies have 
been conducted evaluating the effect of lifestyle changes on the incidence of attacks in patients 
with gout. Nevertheless, experts agree that lifestyle changes have some effect. Lifestyle advice 
is also given by physicians in daily practice when gout symptoms appear. However, fewer than 
20% of patients with gout seeking medical advice are prepared to make long-term changes in 
lifestyle [8]. Recently, the negative role of meat, seafood and beer consumption, and the 
protective role of dairy products in the development of gout were demonstrated in a prospective 
study over a 12-year period among a population of around 47,000 healthy male subjects [9]. 
 
Reducing the symptoms of acute gout 
Treatment of a gout attack involves reducing the symptoms of inflammation that are responsible 
for the pain associated with the condition. The following section outlines the treatment options 
available for acute gout. 
 
Cooling 
Some evidence from a small-scale controlled study indicates that local ice therapy could be of 
additional benefit in conjunction with a systemic treatment [10].  
 
Corticosteroids 
For many years, the evidence for treatment of acute gout with glucocorticosteroids was 
inconclusive [11]. Several open-label studies suggest efficacy of intra-articular injection of 
corticosteroids in major joints presenting with gout, which is in line with the author’s 
observations in daily practice. The incidence of severe gouty attacks when using 7.5-15 mg 
prednisone daily among patients treated with cyclosporin A suggests that relatively high doses 
of corticosteroids (e.g. >40 mg prednisone/day) might be required to treat acute gout [12]. 
However, primary treatment of gout using systemic corticosteroids could be linked with rebound 
flares, therefore combination therapy of corticosteroid with colchicine is recommended [13]. 
Corticosteroids administered via intra-articular injection and by systemic administration should 
preferably used only temporarily because of their associated risk factors on glucose metabolism 
and the decalcification of bones. Presently, predniso(lo)ne is recommended at a dose of 10 mg 
once daily for 1 week, then 5 mg once daily until sUr is at target level (for a maximum of 
3 weeks). 
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Recently, it was shown in a randomised controlled, double-blinded trial that oral predniso(lo)ne 
35 mg per day and naproxen 500 mg twice daily were equally effective in the initial treatment of 
gouty arthritis over 4 days [14]. 
 
Colchicine 
This alkaloid is prepared from autumn crocus (Colchicum autumnale). Colchicine has a high 
tissue distribution and tissue bond, and persists in the leukocyte for 10 days. It is excreted in 
bile (enterohepatic circulation) and urine. In the acute phase (first two days) of a gout attack, 
colchicine can powerfully reduce the symptoms of gout. Therefore, colchicine is often used as a 
first-line treatment for acute attacks of gout [3]. Currently, one placebo-controlled study is 
conducted in which 1 mg colchicine is initially administered followed by 0.5 mg every 2 hours 
until pain disappears or toxicity occurs. After 24 hours, there was a >50% reduction in pain in 
42% of the patients in the colchicine group compared with 9% in the placebo group. After 48 
hours, the percentages were 73% and 36%, respectively (p<0.05). However, in the colchicine 
group, all patients developed symptoms of toxicity (nausea, vomiting, or diarrhoea), most of 
which started within 24 hours of receiving the drug. Clinical improvement was observed in 41% 
of patients before the onset of toxicity [15]. Consequently, this colchicine programme was 
abandoned. In addition, in patients with renal/hepatic function disorders or among patients 
receiving substances inhibiting the CYP3A4 enzyme, such as erythromycin, verapamil and 
grapefruit juice, increased toxicity can occur following treatment with colchicine [16]. 
When administered at doses of 0.5 mg one- to four-times daily (maximum 0.5 mg six times 
daily), the drug inhibits the phagocytosis of crystals and has no direct effect on the metabolism 
of uric acid. The current dosing regimen is 0.5 mg four-times daily, then after 3 days 0.5 mg 
three-times daily, and then after 6 days 0.5 mg twice daily. This regimen is continued until the 
uric acid level has reached the ‘target’ concentration after the first attack, or as a means of 
reducing annual attacks in the absence of sUr-lowering therapy. In patients with a (calculated) 
creatinine clearance of <50 ml/min, dosage must be reduced to 0.5 mg/day. In the event of 
(pre)terminal renal insufficiency with a creatinine clearance of <10 ml/min, it is advisable to 
avoid colchicine to prevent toxicity and specific adverse events (AEs), such as myopathy and 
neuropathy [17]. Otherwise, a positive reaction of arthritis to colchicine might be mistaken as 
evidence of gout. 
No controlled trials have been conducted to assess the prophylactic use of colchicine as a 
single agent; however, it has been shown to reduce the likelihood of recurrent gout for up to 
6 months during the initiation of allopurinol treatment. As a preventative measure, colchicine is 
recommended at a dose of 0.5 mg once or twice daily, dosed in such a way as to avoid nausea 
or diarrhoea [18]. In this instance, NSAIDs are only indicated if colchicine monotherapy is 
inadequate, or when there are contra-indications for colchicine. 
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Non-steroidal anti-inflammatory drugs (NSAIDs) 
Non-steroidal anti-inflammatory drugs are often the first choice for the treatment of acute gout. 
A placebo-controlled study of reasonable quality compared 30 mg/day tenoxicam with placebo 
in the treatment of gout [19]. After 24 hours, a reduction in pain of >50% was achieved in 67% in 
the tenoxicam group compared with 26% in the placebo group (p<0.05). However, after 4 days 
there was no longer any difference between the two groups. The effectiveness of different 
NSAIDs was compared in nine more studies. Two high-quality studies demonstrated 
equivalence for etoricoxib compared with indomethacin in the treatment of gout from days 2-5. 
Fewer drug-related adverse effects were found in the etoricoxib group [20-21]. 
Current dosing strategies for NSAIDs include indomethacin 50 mg three-times daily, naproxen 
500 mg twice daily, ibuprofen 600 mg three-times daily, or diclofenac 50 mg three-times daily, 
and possibly etoricoxib 120 mg once daily for a maximum of 1 week. 
 
Treatment options for prevention of recurrence of gout 
When gout has subsided, it is important to reduce the sUr concentration to prevent recurrence 
of gouty attacks. This involves restriction of alcohol, weight-loss in cases of obesity (not too 
rapidly as this can trigger gout), and ensuring adequate diuresis. Dietary measures are very 
important: the risk of gout increases by extra consumption of meat, fish, and beer, but is 
reduced by dairy products [9]. However, a strict low-purine diet can achieve only a limited 
reduction in sUr levels (≤0.10 mmol/l or 1.7 mg/dl), and many patients have difficulty with 
adhering to long-term dietary changes [8]. If possible, it is recommended that patients should 
discontinue diuretics. However, the effectiveness of these measures is limited and is not 
supported by controlled studies. 
With tophaceous or recurrent gout (>2 attacks per annum) the use of urate-lowering therapy 
may be warranted [22]. Achieving lower sUr, particularly <0.36 mmol/l (6.1 mg/dl), is associated 
with a reduced chance of recurrent gout attacks [23-24]. Achieving sUr levels of <0.30 mmol/l 
(5.0 mg/dl) in tophaceous gout might be associated with a faster disappearance of tophi [25-26]. 
In contrast, asymptomatic hyperuricemia requires no treatment. The maintenance dose of urate-
lowering drugs is preferably adjusted to the clinical effect: (1) prevention of gout attacks without 
using colchicine and/or NSAIDs, (2) disappearance of tophi based on the sUr-concentration with 
tophaceous deposits. 
It is plausible that for tophi to disappear, lower sUr target values must be achieved to at least 
“normal” levels, but preferably low to normal (≤0.30 mmol/l) [25, 27]. In order to prevent further 
attacks of gout, stable sUr target values of at least ≤0.36 mmol/l are required, but in the event of 
frequent or prolonged attacks, ≤0.30 mmol/l is preferable [23-25, 28]. 
Two main classes of drugs that reduce serum urate concentrations exist: xanthine oxidase 
inhibitors (XOi), such as allopurinol and febuxostat, and uricosuric drugs, such as 
benzbromarone and probenecid. Xanthine oxidase inhibitors work by inhibiting uric acid 
production, thereby reducing serum urate concentrations. Uricosuric drugs inhibit the 
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reabsorption of uric acid mediated by the URAT-1. Few comparative randomised studies have 
been carried out comparing the effectiveness of these drugs, Table 4 [27, 29-31]. 
 
Table 4. Effect of antihyperuricemic treatment on sUr in short-term studies. 






Allopurinol 200-300 mg 
+ probenecid 1,000 mg 
































Legend: ∆sUr: change in serum urate concentration compared to baseline; sUr: serum urate concentration 
 
 
Xanthine oxidase inhibitors 
Allopurinol 
Allopurinol is a purine-analogue XOi. Presently, allopurinol is the only available XOi. Allopurinol 
(100-900 mg daily) is rapidly metabolised into oxipurinol, a xanthine analogue that also inhibits 
xanthine oxidase, and is excreted in urine. A reduction in sUr concentrations to normal values 
can be achieved in 85% of cases using monotherapy of 300 mg allopurinol per day [24]. There 
are several studies with long-term data on the use of allopurinol in patients suffering from 
recurring attacks of gout, but they are of moderate quality [23, 32]. In a retrospective study, it 
appeared that 23% of patients had suffered a gout flare despite using allopurinol to reduce sUr 
to ≤0.36 mmol/l; 33% had an attack despite sUr level between 0.12-0.48 mmol/l), and 45% had 
an attack at sUr >0.48 mmol/l. The median allopurinol dosage was 300 mg/day, and only 34% 
achieved sUr levels ≤0.36 mmol/l [23]. 
Common AEs following treatment with allopurinol include hypersensitive skin reactions 
(exanthema in around 2% of cases) and occasionally short-term leukopenia, dizziness or 
nausea [33]. Severe AEs, such as systemic vasculitis, are possible in cases of renal 
insufficiency; therefore, the maintenance-dosing schedule should be adjusted in patients with 
impaired renal function [34]. When allopurinol is combined with azathioprine or mercaptopurine, 
the dosage of azathioprine or mercaptopurine should be reduced by 30% because of drug 
interaction. Mycophenolate mofetil may be considered for use in place of azathioprine in view of 
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a report that allopurinol has been safely combined with mycophenolate mofetil in five kidney 
transplant patients [35]. A rare but notorious AE of allopurinol is toxic epidermal necrolysis. 
Sporadic cases of neuritis or bone marrow suppression have also been observed. 
As a prophylaxis for acute urate nephropathy among patients with chronic leukemia or 
malignant lymphoma undergoing aggressive chemotherapy, the advice is to start with high 
doses of allopurinol at least 3 days before the treatment with cytostatics and to ensure adequate 
diuresis. Rasburicase (recombinant uricase) may also be considered for this indication. 
 
Febuxostat 
Febuxostat 80-120 mg once daily is currently being developed for treatment of hyperuricemia in 
patients with gout. Unlike allopurinol, which is an analogue of the purine hypoxanthine, 
febuxostat has a non-purine-like structure. It is a selective inhibitor to xanthine oxidase. To date, 
the drug has shown efficacy in several studies [30, 36-38]. In a phase-II dose-response study 
the efficacy of 40 mg, 80 mg and 120 mg per day febuxostat was evaluated in 153 patients with 
hyperuricemia (baseline sUr ≥0.48 mmol/l) and gout [37]. Significantly more patients receiving 
febuxostat than placebo achieved an sUr level of ≤0.36 mmol/l) at each visit (p<0.001 for each 
comparison). The target sUr level (≤0.36 mmol/l) was achieved at study end in 0% of patients in 
the placebo group and 56%, 76% and 94% of patients in the 40 mg, 80 mg and 120 mg 
febuxostat groups, respectively. Gout attacks occurred with a similar frequency in the placebo 
(37%) and 40 mg febuxostat groups (35%), and with an increased frequency in the 80 mg and 
120 mg febuxostat groups (43% and 55%, respectively). However, during colchicine 
prophylaxis, gout attacks occurred less frequently (8-13%). 
In a phase-III trial comparing febuxostat with allopurinol in patients (n=762) with gout and 
hyperuricemia (sUr levels >0.48 mmol/l), significantly more patients febuxostat 80 mg and 
120 mg reached sUr levels below 0.36 mmol/l than those receiving 300 mg allopurinol (80 mg 
febuxostat, 53%; 120 mg 62% and 300 mg allopurinol 21%; p<0.001 for each comparison). The 
overall incidence of gout attacks during weeks 9 through to week 52 was similar in all groups: 
64% and 70% in the 80 mg and 120 mg febuxostat groups, and 64% of patients receiving 
allopurinol. Febuxostat also reduced the median tophus area by 83% and 66% in patients in the 
80 mg and 120 mg groups compared with 50% in patients receiving allopurinol [30]. 
In terms of safety, to date, results from clinical trials have shown that febuxostat is well tolerated 
with a safety profile comparable to that of placebo and allopurinol [30, 36]. In a long-term phase-
II extension study (n=116), the most common adverse events (AEs) were diarrhoea (which 
occurred in ten patients (9%) and was attributed to concomittant colchicine administration) and 
headache in five patients (4%). Five patients (4%) also had abnormal liver function tests, which 
were attributed to concomittant use of colchicine [36]. In the large phase-III comparator trial, the 
most frequent drug-related AEs were liver function abnormalities (4% in the 80 mg, 5% in the 
120 mg febuxostat group, and 4% in the allopurinol group), diarrhoea (4%, 5%, and 4%, in each 
treatment group, respectively), joint-related signs and symptoms (<1%, 2%, and 2%), and 
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musculoskeletal/connective tissue signs (2%, 1%, and 2%). Most AEs were mild to moderate in 
intensity and the incidence of serious AEs was similar in all groups [30]. 
The drug profile of febuxostat also suggests a potential role in the presence of allopurinol 




Benzbromarone is a long-acting, uricosuric drug. In the short term, sUr levels fall sharply with 
benzbromarone 100 mg/day, and decline to a lesser extent with 300 mg/day allopurinol [25-26]. 
There are 10-year data available from 200 patients on benzbromarone 80-125 mg/day in which 
sUr levels were reduced by an average 54%; the severity and incidence of gout attacks was 
reduced within 1 year by 75%; tophi disappeared in all cases within 18 months; and in 96% of 
patients, benzbromarone was well tolerated [40]. Among the 35% of patients who overproduce 
uric acid, with liberal hydration and alkalisation, acute events in the urinary tract occurred in only 
3%, despite a history of urolithiasis in 33% [40]. Benzbromarone causes tophi to disappear 
more quickly than allopurinol; a fact that is explained by a stronger urate-lowering effect 
following treatment with benzbromarone 100-200 mg/day compared with allopurinol 300 mg/day 
[27]. However, benzbromarone has been shown to cause serious liver damage in some patients 
[41-42]. Consequently, liver function should be monitored during the first six months of 
treatment. With uricosurics, patients are advised to ensure diuresis of ≥2 l/day. In cases of 
severe renal insufficiency (glomerular filtration rate <20 ml/min), no therapeutic effect is to be 
expected from benzbromarone. 
In terms of drug interactions, benzbromarone enhances the effect of coumarin derivatives by 
inhibiting the liver enzyme cytochrome P450 2C9 (CYP2C9) [43]. Theoretically, all drugs that 
are substrate of CYP2C9 (e.g. phenytoin), are prone to having an enhanced effect when 
combined with benzbromarone; however, there are no available data to verify this. 
Benzbromarone is not available in the USA and the UK, and marketing was stopped in other 
countries in 2003 because of reports of serious liver damage in patients administered the drug. 
The drug is still available in the Netherlands, and can be prescribed in cases of intolerance or 
allergy to allopurinol. 
 
Probenecid 
Probenecid is an alternative URAT-1 inhibitor and is available in the US, Canada, France and 
Germany; it is not routinely available in the Netherlands and the UK. As far as we know, no 
long-term data are available on probenecid. A few studies have looked at combination therapy 
with both an XOi (i.e. allopurinol) and a uricosuric drug, such as probenecid or benzbromarone. 
It is a successful option in cases of severe tophaceous gout, or when allopurinol monotherapy is 
not effective [26]. 
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Because of its renal action, probenecid increases the serum level of many drugs, such as 
thiazide diuretics, furosemide, beta-lactam antibiotics, indomethacin, and naproxen. Probenecid 
is usually dosed 500-1,000 mg twice daily. 
 
Uricase analogues 
Pegylated uricase is still at the research phase because it has been associated with antibody 
formation. Rasburicase is available in the European Union (EU) for the indication of tumour lysis 
syndrome. Rasburicase oxidises uric acid into allantoin, which is a highly hydrophilic molecule. 
Rasburicase has been used successfully in some cases with therapy-resistant gout [44-45]. 
Rasbruicase is not licensed for treatment of gout; therefore, local authorisation procedures are 
demanded. 
 
Special considerations when treating gout 
Antihyperuricemic therapy might provoke arthritis or induce an attack of gout. For safety 
reasons, antihyperuricemic therapy should only be given after a gout attack, preferably with 
protection from colchicine, which should be initiated several days to two weeks earlier (0.5 mg 
twice daily). With normal renal function, administration of allopurinol could be started at a dose 
of 100-300 mg once daily, probenecid 250 mg twice daily and benzbromarone 100 mg 
once daily. After two weeks, the dose can be increased if necessary. Standard maintenance 
doses are allopurinol 200-600 mg once daily, benzbromarone 100-200 mg once daily and 
probenecid 500-1,000 mg twice daily. 
When frequent attacks of gout without joint damage or tophi are present in patients with 
intolerance or allergy to allopurinol and uricosurics, prophylaxis with colchicine at low doses can 
be prescribed, e.g. 0.5 mg once or twice daily in patients with good renal function. In 
exceptional cases, corticosteroids, or a combination of a uricosuricum and allopurinol, may be 
indicated for maintenance therapy. When a history of urolithiasis is present, adequate diuresis 
should be ensured and alkalisation should be considered, especially if a uricosuricum is 
prescribed. 
Compliance is also a special consideration when supervising gout patients, and it is crucial to 




The limited information on drugs indicated for the treatment of gout, makes it difficult for 
physicians to compose informed treatment decisions. The current therapeutic strategy is often 
based on clinical experience. The value of lifestyle advice is limited in the prevention of gout, 
particularly with regard to restriction of alcohol, weight-loss in case of obesity, ensuring 
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adequate diuresis and adherence to a low-purine diet, as most patients are reluctant to make 
such changes. Therefore, the condition is often treated with pharmacological therapies. 
Presently, oral colchicine and NSAIDs are first-line agents for systemic treatment of acute gout. 
In the absence of contra-indications, NSAIDs are a convenient and well-accepted option for 
treatment of acute gout. In case of tophaceous or recurrent gout, the use of urate-lowering 
drugs is recommended. Currently, allopurinol is the first choice antihyperuricemic drug. Many 
treatment options for gout have unwanted side effects, which highlights the importance of the 
development of new agents therapeutics for the treatment of gout. 
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Abstract 
Benzbromarone is an old, but very potent urate-lowering drug. New pharmacological data of 
clinical importance have become available, since its last drug profile was published in the early 
1980s. Benzbromarone is predominantly metabolised by cytochrome P450 iso-enzyme 2C9 
(CYP2C9) to the active metabolite 6-hydroxybenzbromarone, which is thought - because of its 
long half-life - to substantially account the uricosuric activity of benzbromarone. 
Benzbromarone is a strong inhibitor of CYP2C9 leading to clinically important drug-drug 
interactions with acenocoumarol, phenprocoumon and warfarin, and theoretically with 
phenytoin, tolbutamide and other CYP2C9 substrates like some NSAIDs. Depending on the 
allele form of CYP2C9, the metabolism may be inhibited or activated. 
Benzbromarone was tested in several clinical trials. However, most trials had poor quality: no 
randomisation, small number of patients, short duration, low dose of benzbromarone, or no 
clinical outcome. In general, benzbromarone 100 mg/day was found to be more effective (for 
control of serum urate) and better tolerated than allopurinol 300 mg/day or probenecid 
1,000 mg/day. 
Benzbromarone is well tolerated in general. Occasionally, gastro-intestinal complains and 
urolithiasis occur. In the last decade, benzbromarone was associated with a very rare, but life-
threatening fulminant hepatitis. It was shown that mitochondrial toxicity might play a role in the 
mechanism and recently it was proposed from newly discovered glutathione adjunct 
metabolites, that a reactive quinone intermediate is formed by CYP2C9. In addition, since the 
adverse drug event is very rare, a genetic component (e.g. CYP2C9 allelic variants) and drug-
drug interactions at CYP2C9 might play a role. 
The hepatotoxicity risk led to a worldwide withdrawal of benzbromarone in 2003. However, 
because of requests of physicians, benzbromarone became available again in 2004 for 
treatment of gout patients who could not be treated with allopurinol. At present, benzbromarone 
has been incorporated in several guidelines and recommendations on the treatment of gout. 
In conclusion, benzbromarone is an old, but very potent urate-lowering drug, and possesses 
some distinct, recently discovered pharmacological features, which are important for effective 
and safe use in treatment of gout. 
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Introduction 
Benzbromarone is a uricosuric agent that is licensed in several countries for maintenance 
therapy in gout. In the international literature, the last drug profile on benzbromarone (3,5-
dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone, Figure 1) was published in the early 
1980s [1-4]. Many reviews about antihyperuricemic drugs were recently published, but 
information on benzbromarone was limited [5-9]. After the worldwide withdrawal of 
benzbromarone in 2003, the interest in benzbromarone seemed to increase [10]. The reason for 
the withdrawal was - according to the information given by the manufacturer - the potential risk 
of fulminant hepatitis. Since the introduction of benzbromarone in the early 1970s, four cases of 
severe hepatitis have been published [11-14]. Additionally, eleven cases were reported by the 
company, but these are not available in the public domain [15]. Benzbromarone, however, 
seems well tolerated in general [16], and has been considered as the most potent oral 
antihyperuricemic drug. Because of requests of physicians, benzbromarone became available 
again in 2004 for treatment of gout patients who could not be treated with allopurinol. The use of 
benzbromarone has been advised in recent European and South African guidelines on 
treatment of gout [17-20]. 
In this review, new information regarding the pharmacology and therapeutic use of 
benzbromarone is presented. This information is of interest for rheumatologists and other 
health-care workers involved in the treatment of patients with gout, for utilising benzbromarone 
safely and effectively. 
 




Urate is the product of purine degradation in man. It is converted from xanthine and 
hypoxanthine by xanthine oxidase (XO). Xanthine oxidase and xanthine dehydrogenase are 
interconvertible forms of the same enzyme, known as xanthine oxidoreductase. It is a 
molybdenum-containing enzyme present in several organs, including liver and intestine. Urate is 
excreted by the kidneys for approximately two thirds and by the gut for one-third [21]. 
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Figure 2. Model of indirect coupling of sodium and urate transport via URAT-1 
Coupling of anions to sodium uptake along the luminal membrane and later exchange of the anions for urate by 
URAT-1 in the proximal tubulus. Drugs or agents with affinity for URAT-1 will be uricosuric when acting from the 
lumen, whereas they will be anti-uricosuric by driving the influx of urate when acting from the intracellular space, 
consequently regulating blood urate levels. The organic anions that are actively pumped into the proximal tubular 
cells from apical (or basolateral) sides or those produced in the cells should favour urate reabsorption, by leaving the 
cells in exchange with luminal urate. Transporters responsible for the urate excretion are basolateral OAT-1, OAT-3 
and luminal OATv1/NPT1, MRP-4, OAT-4 and UAT. Two sodium-anion co-transporters that are expressed in the 
luminal membrane have been identified as SMCT1/2 (Slc5a8/Slc5a12) [24]. 
Copyright 2007, reproduced with permission from Lippincott Williams & Wilkins. 
 
Hyperuricemia occurs when excretion of uric acid (urate) is lower than production (synthesis, 
cell turn over and dietary intake). This may be due to overproduction of urate, underexcretion of 
urate or a combination of both [22]. Overproduction of urate can be determined by measuring 
the total amount of urate excreted in urine per day. Overproduction of urate may occur in case 
of (treatment of) malignancies and purine-rich diet, such as red meat, fish, and beer. Alcoholic 
beverages may cause hyperuricemia by (1) increase of uric acid production by net adenosine 
triphosphate (ATP) degradation to adesine monophosphate (AMP), and (2) decreased urinary 
excretion because of dehydration and metabolic acidosis. 
Underexcretion of urate can be determined by calculating the renal clearance of urate (about 6 
ml/min per 1.73 m2 in normal situation [23]). In 90% of gout patients, a diminished renal urate 
clearance is present [21]. Underexcretion of urate may be caused by genetic factors, clinical 
disorders (renal insufficiency), and endogenous (lactate, nicotinate, β-hydroxybutyrate, aceto-
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acetate) or exogenous substances (cyclosporine A, tacrolimus, low dose salicylates, thiazides, 
pyrazinamide, ethambutol, beta-blockers) [21]. 
The proximal tubulus is the major site of urate handling by the kidney. Both reabsorption and 
excretion occur in this segment by several organic anion transporters (OATs, gene family 
SLC22A), with the net effect being the reabsorption of most of the filtered urate (Figure 2) [24-
28]. OATs are expressed in the renal epithelial cells to regulate the excretion and reabsorption 
of endogenous and exogenous organic anions. These OATs are crucial components in the 
renal handling of drugs and their metabolites, and they are implicated in various clinically 
important drug interactions, and their adverse reactions. In 2002, the predominant urate re-
uptake transporter in the proximal tubulus was identified as urate transporter-1 (URAT-1) 
(SLC22A12) [28]. Recently, it was shown that polymorphisms in the N-terminus of the URAT-1 
gene were significantly associated with reduced renal uric acid excretion [29]. Thiazide-induced 
hyperuricemia is associated with modification of urate transport by OAT-4 [30]. 
When hyperuricemia is present for a longer period, it can manifest with symptoms caused by 
deposition of monosodium urate crystals, such as gout attacks, tophi, urate urolithiasis and 
urate nephropathy. Other factors influencing deposition of urate crystals include temperature, 
pH, concentration of cations, level of articular dehydration, and the presence of such nucleating 
agents as non-aggregated proteoglycans, insoluble collagens, and chondroitin sulphate. Drugs 
that lower serum urate, include xanthine oxidase (XO) inhibitors (allopurinol, febuxostat), 




Xanthine oxidase (XO) inhibitors prevent the formation of urate and hydrogen peroxide from 
xanthine and hypoxanthine by inhibiting the enzyme XO. Consequently, concomitant effects of 
XO-inhibitors are (1) increase of serum and urinary xanthine concentrations, which may cause 
xanthinuria, and (2) increase of serum concentrations of drugs metabolised by XO, such as 
mercaptopurines (azathioprine, 6-mercaptopurine) and didanosine, which may lead to toxicity. 
Inhibitors of xanthine oxidase used in clinical practice or tested in clinical studies include 
allopurinol (licensed), febuxostat, oxipurinol, and Y-700 [32]. 
 
Uricosurics 
Uricosurics prevent the re-uptake of urate in the proximal tubulus predominantly by inhibiting the 
URAT-1 transporter resulting in an increased renal urate clearance [27]. Uricosurics can also 
modify other OATs [25]. Some drug-drug interactions of uricosurics can be explained by the 
latter, such as the increase of methotrexate blood levels by probenecid [31]. Efficacy of 
uricosurics is diminished in renal insufficiency. Licensed uricosuric drugs include 
benzbromarone, probenecid and sulfinpyrazone. Some drugs have a (modest) concomitant 
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uricosuric effect, such as losartan, amlodipine, fenofibrate, tienilic acid, and high-dose 
salicylates, but these drugs are not primarily used for treatment of gout [33-35]. 
 
Uricolytics 
Uricases represents a group of enzymes from non-human origin, which can convert urate to 
allantoin and hydrogen peroxide. Uricolytics used in clinical practice or tested in clinical studies 
include uricase, rasburicase, and pegylated uricase (pegloticase) [36]. 
 
 
Characteristics of benzbromarone 
Clinical pharmacokinetics, pharmacodynamics and metabolism 
After oral intake of a single dose of 100 mg benzbromarone, about 50% is absorbed [37]. 
Following absorption, benzbromarone undergoes extensive conversion in the liver, mainly to 
two active metabolites: 1’-hydroxybenzbromarone and 6-hydroxybenzbromarone [38-40]. About 
75% of the absorbed drug is converted to 6-hydroxybenzbromarone, predominantly by 
cytochrome P450 2C9 (CYP2C9) [41-42]. CYP2C19 is a minor benzbromarone-converting 
enzyme [43]. 
In addition, several minor metabolites are identified in plasma and urine [38-46]. Previously, it 
was assumed that benzbromarone was predominantly debrominated [1], but this is not correct 
as proven by mass-spectrometry analysis of patient serum samples [38-44]. Benzbromarone is 
largely bound to proteins in serum (99%). Benzbromarone and metabolites are predominantly 
excreted in the bile; 6% of benzbromarone is excreted in urine as glucuronidated conjugates 
[47]. 
In a study of 11 healthy volunteers (10 “normal” metabolisers), the following elimination half life 
(t½) values were found: benzbromarone 3.3 [± 1.1] h (mean [± standard deviation]), 1’-hydroxy-
benzbromarone 20.1 [± 9.8] h and 6-hydroxybenzbromarone 17.2 [± 5.2] h [48]. In another study 
of 11 healthy volunteers (9 “normal” metabolisers), t½ values were: benzbromarone 5.4 [± 1.9] h; 
1’-hydroxybenzbromarone 18.5 [± 16.3] h and 6-hydroxybenzbromarone 23.3 [± 24.8] h [49]. 
URAT-1 mediated urate uptake is inhibited by 6-hydroxybenzbromarone in vitro in a dose-
related manner, with a half maximal inhibitory concentration (IC50) of 0.20 [± 0.06] µM, whereas 
the IC50 of benzbromarone was found to be 0.035 [± 0.003] µM [45]. It is suggested that, given 
the pharmacokinetic profile of 6-hydroxybenzbromarone, this metabolite particularly contributes 
to the duration of the uricosuric effect [45]. 
In patients with compensated liver cirrhosis Child A and B, pharmacokinetics and efficacy of 
benzbromarone after a single dose of 100 mg was investigated by Walter-Sack et al. [50]. They 
did not observe any important differences compared to values obtained in healthy subjects, and 
suggested that dose adjustment was not necessary. 
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In patients with renal impairment, efficacy of uricosurics is generally reduced because of a lower 
drug concentration at the site of action. It is shown that benzbromarone is effective in patients 
with calculated creatinine clearances (cCrCl) of 20-80 ml/min per 1.73 m2 [51]. 
In addition, benzbromarone 100 mg was effective in renal transplant patients taking 
cyclosporin A, and a relation between antihyperuricemic efficacy and renal function was 
observed, Figure 3 [52]. When efficacy of benzbromarone is insufficient in patients with renal 
function impairment, increase of dosage might be effective, especially when cCrCl is 20-
40 ml/min per 1.73 m2. Otherwise, combination therapy with a XO-inhibitor is useful [53]. 
 
Figure 3: Effectiveness of benzbromarone in renal function impairment 
Relative decrease (in percent of initial values) of plasma urate in function of calculated creatinine clearance in 
patients on cyclosporine A taking benzbromarone 100 mg daily [52]. 
Copyright 1994, reproduced with permission from Oxford University Press. 
 
Drug-drug interactions 
Benzbromarone is a potent inhibitor of CYP2C9 with a Ki of 20 nM in vitro [54-57]. The inhibition 
profile of 6-hydroxybenzbromarone has not been studied. Theoretically, several clinically 
relevant interactions could occur with drugs predominantly metabolised by CYP2C9: coumarins 
(acenocoumarol, phenprocoumon, and warfarin), some angiotensin-II antagonists (losartan, 
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irbesartan), fluvastatin, glipizide, phenytoin, several NSAIDs (diclofenac, ibuprofen, and 
naproxen), sulfamethoxazole, tamoxifen, tolbutamide, and torsemide [58-59]. Especially the 
interactions with low therapeutic index substrates - coumarins, phenytoin, and tolbutamide - 
require attention. However, only a clinical interactive effect of benzbromarone with warfarin has 
been reported in literature [54-60]. 
Substrate-specific differences on CYP2C9 mediated metabolism are described for benz-
bromarone: activation of CYP2C9 mediated naproxen O-demethylase activity occurred (to a 
maximum of 250% at approximately 1 µM), whereas potent inhibition of diclofenac ’4-
hydroxylation was observed (IC50, apparent at 0.04 µM) [57]. 
Furthermore, benzbromarone inhibits reabsorption of oxipurinol (the active metabolite of 
allopurinol) by the URAT-1 transporter. Consequently, the effect of allopurinol therapy is 
diminished due to decreased oxipurinol concentrations in the body [61-64]. This interactive 
effect has also been described for allopurinol with probenecid [63]. 
The antihyperuricemic activity of benzbromarone is largely diminished when pyrazinamide is co-
administered, presumably because the active metabolite pyrazinoate blocks the excretion of 
urate in the proximal tubulus, which cannot be fully compensated by the inhibition of URAT-1 by 
benzbromarone [65]. The same interactive effect has been described for salicylates (>300 mg 
dose) with benzbromarone [1, 3]. 
 
Pharmacogenetics 
Two types of slow benzbromarone eliminators have been identified [48-49, 66-67]. The first one, 
“type 1”, eliminated benzbromarone as well as the metabolites 1’-hydroxybenzbromarone and 
6-hydroxybenzbromarone slowly [48]. The “type 2” eliminator showed a delayed elimination of 
benzbromarone and 1’-hydroxybenzbromarone, but a reduced formation of 6-hydroxy-
benzbromarone [49]. The type 2 poor elimination profile is consistent with a 64% reduction of 
the AUC ratio of 6-hydroxybenzbromarone to benzbromarone in one patient with CYP2C9*3/*3 
genotype compared to wild-type patients (CYP2C9*1/*1) [68]. Patients with CYP2C9*1/*3 did 
not have important alterations in this study. 
In another study with CYP2C9*3 genotype patients, it was found that benzbromarone inhibited 
the CYP2C9-mediated ’4-hydroxylation of flurbiprofen in CYP2C9*1, but unexpectedly activated 
’4-hydroxylation in the CYP2C9*3 genotype [69]. The same pattern was shown with naproxen 
and desmethylnaproxen [70]. 
 
Adverse effects, contra-indications and precautions 
Most clinical trials of benzbromarone have reported little or no adverse reactions. Metabolism of 
benzbromarone was studied in two persons intoxicated (suicidally) with high doses of 
benzbromarone [46]. Information on incidence of adverse effects is available from several large 
observational studies (Table) and from a 10-year follow-up study [16]. Discontinuation of 
treatment due to intolerance is usually because of diarrhoea, and has been reported in 3.5% of 
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patients [16]. Another common side effect of benzbromarone is the occurrence of urolithiasis 
related to formation of urate stones (3%) [16]. The risk of urolithiasis is higher when the urinary 
urate concentration increases, which is inherent to the working mechanism of benzbromarone, 
or in presence of renal function impairment. Patients with a urinary urate excretion (uUr) 
>4.2 mmol/day are (relatively) contra-indicated for using benzbromarone [90]. Excretion of urate 
in urine can be diminished by applying a diet low in purines or by treatment with allopurinol. 
Otherwise, the risk of urate urolithiasis might be lowered by intake of fluids (>2 l/day), use of 
diuretics or increase of a low urine pH [90]. 
Acute gout attacks are common side effects during the initiation of any antihyperuricemic 
therapy due to urate mobilisation, and have been reported with benzbromarone therapy [16]. 
Prevention of acute gout attacks evoked by urate lowering therapy might be accomplished by a 
stepwise increase of benzbromarone dosage, and by adding colchicine or NSAIDs until serum 
urate levels are stabilised. Other adverse reactions such as temporary impotence, allergic 
conjunctivitis and severe skin rash have also been reported, but only in sporadic cases [2, 16]. 
Concerns on the safety of benzbromarone focus on cases of severe hepatotoxicity diagnosed 
several months after start of benzbromarone [11-14]. Results from clinical trials showed about 
0.5% of patients with “elevated liver enzymes”, but no jaundice [90]. It must be taken into 
account that up to 2.5% of healthy individuals will have an abnormal test result of a given liver 
chemistry test, based on the definition of the upper limit of the normal range. No complication 
was found in eight patients with liver cirrhosis receiving benzbromarone [50]. However, given 
the infrequent and idiosyncratic nature of hepatotoxicity, tolerance in this small group is not 
unexpected. Causes of benzbromarone hepatotoxicity might exist in CYP2C9 allelic variants 
(formation of toxic metabolites, diminished elimination) or in CYP2C9 interactions with 
concomitant drugs known to cause hepatotoxicity, such as diclofenac. No information about the 
toxicity of the metabolites of benzbromarone, such as 1’-hydroxybenzbromarone and 6-hydroxy-
benzbromarone is available. It is advised to monitor liver function before and at regular intervals 
during benzbromarone therapy, at least during the first six months; benzbromarone therapy 
must be stopped when elevated liver functions are present [90-91]. 
In in vitro studies, benzbromarone, benzarone and amiodarone - structural analogues - were 
shown to inhibit the mitochondrial respiratory chain and β-oxidation and are uncouplers of 
oxidative phosphorylation. Furthermore, they can induce reactive oxygen species (ROS) 
production and mitochondrial swelling, which may lead to apoptosis and necrosis of cells [93]. 
Furthermore, a series of toxicological studies demonstrated proliferation of peroxisomes in the 
liver of the rat dosed with benzbromarone [94-96]. This is a mechanism associated with 
carcinogenesis, although the same effect could not be demonstrated in human hepatocytes. 
The peroxisome proliferation property of benzbromarone in rat hepatocytes was further 
investigated. Benzbromarone is a ligand of PPAR-α but not PPAR-γ. PPAR-γ is associated with 
apoptosis and is thought to be the mechanism of troglitazone-induced fulminant hepatitis [97]. 
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Table. Clinical trials of benzbromarone in hyperuricemic or gouty patients 
 Dosage 
 (mg/day) 











 100 Baseline RCT 20 7 days 46% vs 0% NA [71] 
 25-100 Baseline CT 55 2-6 years 48% vs 0% NA [72] 
 100-200 Baseline b CT 6 3 weeks 42% vs 0% NA [73] 
 100 Baseline b CT 43 24 weeks 54% vs 0% NA [74] 
 50-100 Baseline CT 2220 8 weeks 26% vs 0% NA [75] 
 40-80 Baseline CT 408 42 weeks 34% vs. 0% 36% vs. 0% [76] 
 50-100 Baseline CT 6 1 year 25% vs. 0% 54% vs. 0% [77] 
 100 Allopurinol 200 mg/day RCT 20 7 days 34% vs. 37% 
(p>0.05) 
NA [78] 
 50 Allopurinol 300 mg/day CCT 28 7 days 45% vs. 38% NA [79] 
 100 Allopurinol 300 mg/day CCT 6 7 days 51% vs. 14% NA [80] 
 100 Allopurinol 300 mg/day CCT 86 1 year 58% vs. 36% NA [81] 
 100-200 Allopurinol 300 mg/day b RCT 36 9-24 months 56% vs. 33# NS [51] 
 100 Allopurinol 300 mg/day CCT 14 4 weeks 58% vs. 45% NA [82] 
 100 Probenecid 1,000 mg/day RCT 6 1 week 51% vs. 23% NA [80] 
 50 Probenecid 500-1,000 
mg/day 
RCT 74 12 weeks 40% vs. 32% NA [83] 
 Comb c Allopurinol 300 mg/day CCT 67 1 week 36% vs. 40% NA [84] 
 Comb c Allopurinol 100 mg/day RCT 12 4 weeks 35% vs. 21% NA [85] 
 Comb c Benzbromarone 20 mg/day RCT 12 4 weeks 35% vs. 20% NA [85] 
 Comb c Allopurinol 300 mg/day RCT 80 36 weeks 40% vs. 40% NA [86] 
 Comb c Allopurinol 300 mg/day RCT 60 24 weeks 27% vs. 20% NA [87] 
 Comb c Allopurinol 300 mg/day CCT 94 4 weeks 26% vs. 40% NA [88] 
Abbreviations: CT: clinical trial (within person comparison); CCT: controlled clinical trial; NA: not assessed; NS: non-significant 
difference; RCT: randomised controlled trial. 
a Order of comparison is “effect of benzbromarone” vs. “effect of drug in comparison”, followed by p-value in brackets; p value 
between all serum urate reductions were significant (p<0.05) unless otherwise stated. 
b Trials conducted in patients with renal impairment, calculated creatinine clearance (cCrCl) 20-80 ml/min. 
c Allopurinol 100 mg and benzbromarone 20 mg. 
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Clinical efficacy 
Preferably, the efficacy of antihyperuricemic drugs should be tested on prevention of gouty 
arthritis and joint damage in randomised controlled trials (RCT). Very few RCTs of good quality 
have been done with antihyperuricemic drugs, and none with benzbromarone [98-99]. On the 
other hand, some comparative clinical trials provide useful information about the 
antihyperuricemic efficacy of several drugs and dosages. Since frequency of gouty attacks and 
diminishing of tophi are related to serum urate levels, this parameter is considered a next best 
measure for determination of clinical success of antihyperuricemic drugs. 
Benzbromarone is compared with other urate lowering drugs in dosages of 20-200 mg daily in a 
number of trials (Table), trials were identified from Medline and Embase using “benzbromarone” 
and “clinical trial”, and from a recent review [15]. Most trials have deficits regarding number of 
patients, treatment duration or benzbromarone dosage. Results of relative sUr decrease with 
benzbromarone ranges from 25 to 58%. Differences in effectiveness can occur because of 
variation in dosage, treatment duration, and renal function. For instance, Ferber et al. used a 
dosage of 100 mg in just 330 of 1,984 patients [75]. Usual maintenance dosage of 
benzbromarone in clinical practice is 100 mg, generally demonstrating around 50% decrease of 
serum urate, and showing significant better results than allopurinol 300 mg daily [81-82]. 
Theoretically, a difference in time to reach (initial) steady state of serum urate levels - 
dependent on serum elimination half-life of urate (~3-5*t½) - exists between uricosuric drugs and 
xanthine oxidase inhibitors,. Steady state is more rapidly reached in case of better renal urate 
clearance, thus when using uricosurics. In normal patients urate t½ = 3.5 days. In underexcretor-
type gout patients urate t½ can be prolonged to as long as 12 days, whereas it can be 
diminished to as short as 12 hours by using benzbromarone. Thus, when comparing uricosurics 
with xanthine oxidase inhibitors, allopurinol results can only be properly evaluated after 
treatment of 1-2 months. 
 
Conclusion 
Benzbromarone is an old, but very potent urate-lowering drug, and possesses some distinct, 
recently discovered pharmacological features, which are important for effective and safe use in 
treatment of gout. Although benzbromarone is on the market for several decades, its place in 
treatment of gout compared to allopurinol is unclear, because of insufficient trials of good 
quality. The toxicity of benzbromarone is generally limited, but serious benzbromarone-induced 
hepatic failure is reported in rare cases. The underlying mechanism has not yet been fully 
explained, but formation of reactive metabolites by CYP2C9 resulting in mitochondrial toxicity, 
and CYP2C9 polymorphisms might play a role. Important drug-drug interactions may occur with 
CYP2C9-metabolised drugs, but clinical data are lacking for most drugs. 
 
 Chapter 2.2 
40 
References 
1. Sinclair DS, Fox IH. The pharmacology of hypouricemic effect of benzbromarone. J Rheum 1975;2: 
437-45. 
2. Heel RC, Brogden RN, Speight TM, et al. Benzbromarone: a review of its pharmacological properties 
and therapeutic use in gout and hyperuricaemia. Drugs 1977;14:349-66. 
3. Sorensen LB, Levinson DJ. Clinical evaluation of benzbromarone: a new uricosuric drug. Arthritis 
Rheum 1976;19:183-90. 
4. Yü TF. Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone. J Rheumatol 
1976;3:305-12. 
5. Pea F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib 
Nephrol 2005;147:35-46. 
6. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51. 
7. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 
2004;64:2399-416. 
8. Teng GG, Nair R, Saag KG. Pathophysiology, clinical presentation and treatment of gout. Drugs 
2006;66:1547-63. 
9. Underwood M. Diagnosis and management of gout. BMJ 2006;332:1315-9. 
10. Jansen TL, Reinders MK, van Roon EN, et al. Benzbromarone withdrawn from the European market: 
another case of “absence of evidence is evidence of absence”? Clin Exp Rheumatol 2004;22:651. 
11. Van der Klauw MM, Houtman PM, Stricker BH, et al. Hepatic injury caused by benzbromarone. J 
Hepatol 1994;20:376-9. 
12. Suzuki T, Suzuki T, Kimura M, et al. A case of fulminant hepatitis, possibly caused by benzbromarone. 
Nippon Shokakibyo Gakkai Zasshi 2001;98:421-5 (Article in Japanese). 
13. Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with 
benzbromarone. J Hepatol 2000;32:874. 
14. Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone 
treatment: a case report. J Gastroenterol Hepatol 2002;17:625-6. 
15. Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the 
treatment of gout: was its withdrawal from the market in the best interest of patients? Drug Saf 
2008;31:643-65. 
16. Masbernard A, Giudicelli CP. Ten years’ experience with benzbromarone in the management of gout 
and hyperuricaemia. S Afr Med J 1981;59:701-6. 
17. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: 
Management. Report of a task force of the EULAR Standing Committee for International Clinical 
Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. 
18. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health 
Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology 2007; 
doi:10.1093/rheumatology/kem056b. 
19. Dutch College of General Practitioners’ “Gout” Standard, 2nd ed. 2004; 
Http://nhg.artsennet.nl/upload/104/ standaarden/M72/start.htm (September 19th, 2007). 
20. Meyers OL, Cassim B, Mody GM. Hyperuricaemia and gout: clinical guideline 2003. S Afr Med J 
2003;93:961-71. 
21. Choi KH, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516. 
22. Pérez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients 
with apparent high urinary uric acid output. Arthritis Rheum 2002;47:610-3. 
 Benzbromarone: an old drug with new perspectives. Update of its clinical pharmacology 
41 
23. Kaehny WD, Tangel DJ, Johnson AM, et al. Uric acid handling in autosomal dominant polycystic 
kidney disease with normal filtration rates. Am J Med 1990;89:49-52. 
24. Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol. 
2007;19:151-7. 
25. Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, 
physiological, and pathological roles. Pharm Res 2007;24:450-70. 
26. Mount DB, Kwon CY, Zandi-Nejad K. Renal urate transport. Rheum Dis Clin North Am 2006;32:313-
31. 
27. Anzai N, Enomoto A, Endou H. Renal urate handling: clinical relevance of recent advances. Curr 
Rheumatol Rep 2005;7:227-34. 
28. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger 
that regulates blood urate levels. Nature 2002;417:447-52. 
29. Grässler J, Grässler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal 
uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006; 
54:292-300. 
30. Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric 
urate transporter. J Am Soc Nephrol 2007;18:430-9. 
31. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half 
a century after the discovery of allopurinol. Pharmacol Rev 2006;58:87-114. 
32. Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug 
interactions with human organic anion transporters. J Pharmacol Exp Ther 2002;302:666-71. 
33. Takahashi S, Moriwaki Y, Yamamoto T, et al. Effects of combination treatment using anti-
hyperuricaemic agents with fenofibrate and/or losartan on urate metabolism. Ann Rheum Dis 
2003;62:572-5. 
34. Sica DA, Schoolwerth CA. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475-
82. 
35. Chanard J, Toupance O, Lavaud S, et al. Amlodipine reduces cyclosporin-induced hyperuricaemia in 
hypertensive renal transplant recipients. Nephrol Dial Transplant 2003;18:2147-53. 
36. Terkeltaub R. Learning how and when to employ uricase as bridge therapy in refractory gout. J 
Rheumatol 2007;34:1955-8. 
37. Broekhuysen J, Pacco M, Sion R, et al. Metabolism of benzbromarone in man. Eur J Clin Pharmacol 
1972;4:125-30. 
38. De Vries JX, Walter-Sack I, Ittensohn A, et al. The isolation, identification and structure of a new 
hydroxylated metabolite of benzbromarone in man. Xenobiotica 1989;19:1461-70. 
39. Arnold PJ, Guserle R, Luckow V, et al. Liquid chromatography-mass spectrometry in metabolic 
research. I. Metabolites of benzbromarone in human plasma and urine. J Chromatogr 1991;554:267-
80. 
40. De Vries JX, Walter-Sack I, Voss A, et al. Metabolism of benzbromarone in man: structures of new 
oxidative metabolites, 6-hydroxy- and 1'-oxo-benzbromarone, and the enantioselective formation and 
elimination of 1'-hydroxybenzbromarone. Xenobiotica 1993;23:1435-50. 
41. Locuson CW 2nd, Suzuki H, Rettie AE, et al. Charge and substituent effects on affinity and metabolism 
of benzbromarone-based CYP2C19 inhibitors. J Med Chem 2004;47:6768-76. 
42. Kunishima C, Inoue I, Oikawa T, et al. The metabolism, toxicity and pharmacological studies of 
benzbromarone (Urinorm). The Journal of Saitama Medical School 2003;30:187-94 (Article in 
Japanese). 
 Chapter 2.2 
42 
43. McDonald MG, Rettie AE. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: 
Chem Res Toxicol 2007;20:1833-42. 
44. Oikawa T, Kunishima C, Adachi Y, et al. Metabolism study of benzbromarone: in vitro metabolism and 
pharmacokinetics in healthy volunteers. J New Rem Clin 2004;53:682-91 (Article in Japanese). 
45. Oikawa T, Kunishima C, Matsumoto K, et al. The Inhibitory Effect of Benzbromarone and 6-
Hydroxybenzbromarone on Urate Transporter (URAT1). J New Rem Clin 2005;54:645-50 (Article in 
Japanese). 
46. Maurer H, Wollenberg P. Urinary metabolites of benzbromarone in man. Arzneimittelforschung 
1990;40:460-2. 
47. Walter-Sack I, de Vries JX, Ittensohn A, et al. Biliary excretion of benzbromarone and its hydroxilated 
main metabolites in humans. Eur J Med Res 1998;3:45-9. 
48. Walter-Sack I, de Vries JX, Ittensohn A, et al. Rapid and slow benzbromarone elimination phenotypes 
in man: benzbromarone and metabolite profiles. Eur J Clin Pharmacol 1990;39:577-81. 
49. De Vries JX, Walter-Sack I, Ittensohn A, et al. Benzbromarone hydroxylation in man: defective 
formation of the 6-hydroxybenzbromarone metabolite. Clin Investig 1993;71:947-52. 
50. Walter-Sack I, de Vries JX, von Bubnoff A, et al. Biotransformation and uric acid lowering effect of 
benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites. Eur J 
Med Res 1995;1:16-20. 
51. Pérez-Ruiz F, Clabozo M, Fernandez-Lopez M, et al. Treatment of chronic gout in patients with renal 
function impairment. J Clin Rheumatol 1999;5:49-55. 
52. Zürcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated 
renal transplant patients: a prospective study. Nephrol Dial Transplant 1994;9:548-51. 
53. Ohno I, Okabe H, Yamaguchi Y, et al. [Usefulness of combination treatment using allopurinol and 
benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of 
oxypurinol]. Nippon Jinzo Gakkai Shi 2008;50:506-12. 
54. Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant effect of warfarin caused by 
enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 
1999;66:569-81. 
55. Locuson CW, Wahlstrom JL, Rock DA, et al. A new class of CYP2C9 inhibitors: probing 2C9 specificity 
with high-affinity benzbromarone derivatives. Drug Metab Dispos 2003;31:967-71. 
56. Locuson CW 2nd, Rock DA, Jones JP. Quantitative binding models for CYP2C9 based on 
benzbromarone analogues. Biochemistry 2004;43:6948-58. 
57. McGinnity DF, Tucker J, Trigg S, et al. Prediction of CYP2C9-mediated drug-drug interactions: a 
comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 
2005;33:1700-7. 
58. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and 
pharmacogenetics. Annu Rev Pharmacol Toxicol 2005;45:477-94. 
59. Http://medicine.iupui.edu/flockhart/clinlist.htm (September 19th, 2007). 
60. Shimodaira H, Takahashi K, Kano K, et al. Enhancement of anticoagulant action by warfarin-
benzbromarone interaction. J Clin Pharmacol 1996;36:168-74. 
61. Iwanaga T, Kobayashi D, Hirayama M, et al. Involvement of uric acid transporter in increased renal 
clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. 
Drug Metab Dispos 2005;33:1791-5. 
62. Colin JN, Farinotti R, Fredj G, et al. Kinetics of allopurinol and oxipurinol after chronic oral 
administration. Interaction with benzbromarone. Eur J Clin Pharmacol 1986;31:53-8. 
 Benzbromarone: an old drug with new perspectives. Update of its clinical pharmacology 
43 
63. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effects of pyrazinamide, probenecid, and 
benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis 1991;50:631-3. 
64. Muller FO, Schall R, Groenewoud G, et al. The effect of benzbromarone on allopurinol/oxypurinol 
kinetics in patients with gout. Eur J Clin Pharmacol 1993;44:69-72. 
65. Moriwaki Y, Yamamoto T, Takahashi S, et al. Analysis of uric acid transport in renal tubules using 
benzbromarone and pyrazinamide. Int J Clin Pharmacol Ther Toxicol 1990;28:84-8. 
66. Walter-Sack I, Gresser U, Adjan M, et al. Variation of benzbromarone elimination in man--a population 
study. Eur J Clin Pharmacol 1990;39:173-6. 
67. Gresser U, Adjan M, Zollner N. Deficient benzbromarone elimination from plasma: evidence for a new 
genetically determined polymorphism with an autosomal recessive inheritance. Adv Exp Med Biol 
1991;309A:157-60. 
68. Uchida S, Shimada K, Misaka S, et al. PI 23: Influences of CYP2C9 genotype on pharmacokinetics 
and pharmacodynamics of benzbromarone. Clin Pharmacol Ther 2006;79:P13. 
69. Hummel MA, Locuson CW, Gannett PM, et al. CYP2C9 genotype-dependent effects on in vitro drug-
drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 
variant. Mol Pharmacol 2005;68:644-51. 
70. Kumar V, Locuson CW, Sam YY, et al. Amiodarone analog-dependent effects of CYP2C9 mediated 
metabolism and kinetic profiles. Drug Met Disp 2006;34:1688-96. 
71. Nakamura N. Efficacy of benzbromarone for hyperuricemia. Rinsho to Kenkyu 1971;48:2956-60 
(Article in Japanese). 
72. De Gery A, Auscher C, Saporta L, et al. Treatment of gout and hyperuricaemia by benzbromarone, 
ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran. Adv Exp Med Biol 1974;41:683-9. 
73. Ravera R. Benzbromarone in the treatment of hyperuricemias. Minerva Med 1975;66:783-800 (Article 
in Italian). 
74. Didier M, Olmer M. [Hypouricemic effect of benzbromarone especially in kidney failure]. Sem Hop 
1978;54:463-5. 
75. Ferber H, Bader U, Matzkies F. The action of benzbromarone in relation to age, sex and 
accompanying diseases. Adv Exp Med Biol 1980;122A:287-94. 
76. Bluestone R, Klinenberg J, Lee IK. Benzbromarone as a long-term uricosuric agent. Adv Exp Med Biol 
1980;122A:283-6. 
77. Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. N Z Med J 
2005;118:U1528. 
78. Nakamura N. Efficacy of Benzbromarone for Hyperuricemia (Part 2): Comparison with Allopurinol. 
Rinsho to Kenkyu 1972;49:1381-4 (Article in Japanese). 
79. Mertz DP. The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. 
Comparative studies. MMW Munch Med Wochenschr 1978;120:1387-90 (Article in German). 
80. Schepers GW. Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and 
probenecid. J Int Med Res 1981;9:511-5. 
81. Pérez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the 
control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann 
Rheum Dis 1998;57:545-9. 
82. Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol 
in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai 2002;85:S40-7. 
83. Liang L, Xu N, Zhang H, et al. A randomized controlled study of benzbromarone and probenecid in the 
treatment of gout. West China Medical Journal 1994;9:405-8 (Article in Chinese). 
 Chapter 2.2 
44 
84. Mertz DP. Reducing the risks in the treatment of gout and hyperuricaemia. Dtsch Med Wochenschr 
1976;101:1288-92 (Article in German). 
85. Arntz HR, Dreykluft HR, Leonhardt H. Effect of uric acid lowering drugs in low dosage in patients with 
hyperuricemia and hypertriglyceridemia in a randomized group study. Fortschritte der Medizin. 
1979;97:1212-4 (Article in German). 
86. Frerick H, Schäfer J, Rabinovici K, et al. Longterm treatment of hyperurikemia and gout; randomised 
study. Therapiewoche 1987;37:3379-84 (Article in German. 
87. Berg H. Effectiveness and tolerance of long-term uricosuric treatment. Z Gesamte Inn Med 
1990;45:719-20 (Article in German). 
88. Akkasilpa S, Osiri M, Deesomchok U, et al. The efficacy of combined low dose of allopurinol and 
benzbromarone compared to standard dose of Allopurinol in hyperuricemia. J Med Assoc Thai 
2004;87:1087-91. 
89. Matzkies F. Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. 
Results of a field study on 3899 patients. Fortschr Med 1978;96:1619-21 (Article in German). 
90. Product information Desuric®. http://www.cbg-meb.nl/IB-teksten/h06334.pdf (October 1st, 2007). 
91. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30:277-94. 
92. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating 
allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32. 
93. Kaufmann P, Torok M, Hanni A, et al. Mechanisms of benzarone and benzbromarone-induced hepatic 
toxicity. Hepatology 2005;41:925-35 
94. Parzefall W, Schuppler J, Barthel G, et al. Toxicological studies on a benzofurane derivative. I. A 
comparative study with phenobarbital on rat liver. Toxicol Appl Pharmacol 1990;106:482-99 
95. Butler EG, Ichida T, Maruyama H, et al. Toxicological studies on a benzofurane derivative. II. Demon-
stration of peroxisome proliferation in rat liver Toxicol Appl Pharmacol 1990;106:500-8. 
96. Bichet N, Cahard D, Fabre G, et al. Toxicological studies on a benzofuran derivative. III. Comparison of 
peroxisome proliferation in rat and human hepatocytes in primary culture Toxicol Appl Pharmacol 
1990;106:509-17. 
97. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9. 
98. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and 
prevention of recurrent gout--a systematic review. Rheumatology (Oxford) 2006;45:1422-31. 
99. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous 

















Biochemical effectiveness of  
allopurinol and allopurinol-probenecid 
in previously benzbromarone-treated gout patients 
 
 
M.K. Reinders 1,2, E.N. van Roon 1,2, P.M. Houtman 3, 
J.R.B.J. Brouwers 1,2, T.L.Th.A. Jansen 3 
 
 
1  Department of Hospital Pharmacy and Pharmacology, Medisch Centrum Leeuwarden, Leeuwarden 
2  Department of Pharmacy, Division of Pharmacotherapy and Pharmaceutical Care, University of 
Groningen, Groningen, 














Clin Rheumatol 2007;26:1459-65 
 




In 2003, the uricosuric drug benzbromarone was withdrawn from the market. The first 
alternative drug of choice was the xanthine oxidase inhibitor allopurinol. The purpose was to 
investigate (1) the efficacy of allopurinol (standard dosage) compared with previous treatment 
with benzbromarone; and (2) the combination therapy allopurinol-probenecid as an effective 
alternative treatment compared with previous benzbromarone treatment. 
Methods 
A prospective, open study was carried out in a cohort of 51 gout patients who discontinued 
benzbromarone therapy because of market withdrawal. Patients were given 200-300 mg 
allopurinol (stage 1). When allopurinol failed to attain the target serum urate (sUr) levels 
≤0.30 mmol/l, probenecid 1,000 mg/day was added (stage 2). 
Results 
Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) 
resulted in 92% of patients reaching target levels sUr ≤0.30 mmol/l with a decrease of 61% 
[± 11%] (mean [± standard deviation]) compared to baseline. In stage 1, 32 patients completed 
treatment with allopurinol monotherapy (range 200-300 mg/day; mean 256 mg/day); this 
resulted in 25% of patients attaining sUr target levels. Decrease in sUr levels was 36% [± 11%], 
which was significantly less compared to treatment with benzbromarone (p<0.001). In stage 2, 
14 patients received allopurinol-probenecid combination therapy, which resulted in 86% of 
patients attaining target sUr levels (after failure on allopurinol monotherapy), which was 
comparable to previous treatment with benzbromarone (p=0.81). Decrease in sUr levels was 
53% [± 9%] (CI95% 48-58%), which was a non-significant difference compared to previous 
treatment with benzbromarone (p=0.23). 
Conclusions 
Benzbromarone is a very effective antihyperuricemic drug with 92% success in attainment of 
target sUr levels ≤0.30 mmol/l. Allopurinol 200-300 mg/day was shown to be a less potent 
alternative for most selected patients to attain target sUr levels (25% success). In patients 
failing on allopurinol monotherapy, the addition of probenecid proves to be an effective 
treatment strategy for attaining sUr target levels (86% success). 
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Introduction 
In 2003, benzbromarone was withdrawn from the European market [1]. The reason for the 
withdrawal was the risk of fulminant hepatitis according to the information given by the 
manufacturer. Since the introduction of benzbromarone in the early 1970s, four cases of severe 
hepatitis have been published [2-5]. On the other hand, benzbromarone seems well tolerated in 
general use [6] in contrast to allopurinol, which causes frequently (25%) allergic skin reactions. 
The uncertainty remains whether the efficacy-safety balance of benzbromarone really is 
unfavourable, compared to the other antihyperuricemic drugs available like allopurinol, 
probenecid and sulphinpyrazone [7]. In Europe, benzbromarone was available only as a 
prescription uricosuric drug in a limited number of countries. In the Netherlands, the only 
licensed alternative for patients with chronic gout was allopurinol, a uricostatic drug acting by 
inhibition of xanthine oxidase. 
The goal of antihyperuricemic treatment is to reduce the serum urate (sUr) level below the 
threshold of supersaturation to allow the dissolution of existing monosodium urate (MSUr) 
crystals in the joints and to stop the deposition of new crystals [8-11]. The solubility of urate in 
joint fluids is influenced by temperature, pH, concentration of cations, level of articular 
dehydration and the presence of nucleating agents such as insoluble collagens, chondroitin 
sulphate and non-aggregated proteoglycans [8]. 
The treatment goal of antihyperuricemic therapy is usually supposed to reach sUr levels below 
0.36 mmol/l [9-11]. It is shown that recurrent gouty attacks are better prevented [13-14] and that 
tophi dissolve more quickly [16] in the presence of sUr levels ≤0.30 mmol/l, compared with 
levels 0.30-0.36 mmol/l. Thus, we aimed the sUr treatment goal for gout patients at 
≤0.30 mmol/l. 
The amount of urate in the body depends on dietary intake, synthesis and excretion. 
Hyperuricemia results from the overproduction of urate (10%), from the underexcretion of urate 
(90%) or often a combination of the two [15]. Therefore, theoretically, the urate balance, in 
terms of the ratio of overproduction and underexcretion of urate, may be clinically important for 
the rational choice of a uricostatic drug, a uricosuric drug or a combination of both. However, 
there are no trials to support or refute this theory [7]. From observational studies, it is concluded 
that benzbromarone 75-120 mg/day is very effective in the control of hyperuricemia, and better 
than allopurinol 300-450 mg/day [6, 17-18]. 
We carried out an observational study to evaluate the effectiveness of allopurinol monotherapy 
and combination therapy of allopurinol with the uricosuric drug probenecid in underexcretor-type 
and overproducer-type gout patients previously treated with benzbromarone. Because 
allopurinol is reported to be less potent than benzbromarone in lowering sUr, we investigated 
the combination allopurinol-probenecid as an alternative treatment when allopurinol failed. 
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Methods 
Patients and inclusion criteria 
A prospective, open label study was carried out in patients who had to discontinue 
benzbromarone therapy and contacted the rheumatology department in the period July-
December 2003. The inclusion criteria were the following: (1) diagnosis of gout proven by 
presence of MSUr crystals in the synovial fluid [19] or otherwise complying with the American 
Rheumatism Association criteria [20]; (2) pre-treatment with benzbromarone monotherapy of 
100-200 mg/day for at least 2 months with available sUr efficacy results; (3) no relevant liver 
disease and (4) no relevant renal disease, defined as glomerular filtration rate (GFR) 
>50 ml/min per 1.73 m2. 
 
Study design and data collection 
Before entering the study, liver function, serum creatinine (sCr), sUr, urinary creatinine excretion 
(uCr) and urinary urate excretion (uUr) on unrestricted purine diet were measured after 
benzbromarone was stopped for at least 1 month. GFR was estimated from the simplified 
Modification of Diet in Renal Disease (MDRD) formula [21]. Underexcretion of urate was defined 
as a urate clearance (ratio uUr/sUr) <6.0 ml/min per 1.73 m2 [22]. Results of pre-treatment with 
benzbromarone were collected from the patient’s chart. 
In stage 1, patients were given allopurinol with a maximum of 200-300 mg once a day in a step-
up dosage scheme; maximum dosage prescribed depended on kidney function, tolerability and 
prescriber’s preference. When the treatment goal of sUr ≤0.30 mmol/l was not reached with 
allopurinol after 2 months, patients were included in stage 2, and probenecid 500 mg twice daily 
was added to allopurinol. Each treatment regimen was evaluated after a treatment period of 
>2 months, and sCr, sUr, uCr and uUr were measured. Prophylaxis of gouty episodes with 
colchicine was prescribed to all patients until target sUr level was reached (sUr ≤0.30 mmol/l). 
Primary endpoints for stages 1 and 2 were the percentages of patients attaining sUr target 
≤0.30 mmol/l and the relative decrease in sUr attained with each treatment regimen.  
 
Statistical analyses 
Statistical Package for the Social Sciences (SPSS) 14.0 for Windows (SPSS Inc., Chicago, IL, 
USA) was used for data collection, data validation, data selection and statistical analysis. 
Student’s two-sided paired t test and chi-squared test were used to compare the effectiveness 
of benzbromarone, allopurinol and allopurinol-probenecid therapy. Yates’s continuity correction 
was used where appropriate. Normality was verified with Kolmogorov-Smirnov analysis. A p-
value <0.05 was considered statistically significant. 
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Ninety patients made an appointment with the rheumatology department because of 
benzbromarone withdrawal. Fifty patients (55%) were assigned to stage 1 treatment and 
received allopurinol 200-300 mg/day, Figure 1. Table 1 shows demographic data, urate results 
on benzbromarone therapy and urate results at baseline >4 weeks after discontinuation of 
benzbromarone therapy. Thirty-two patients (64%) completed stage 1 and were included in the 
analysis. Eight patients attained target serum levels on allopurinol 200-300 mg/day and 
completed the study. Fourteen patients were assigned to and completed the combination 
therapy allopurinol-probenecid 500 mg twice daily (stage 2) and were included in the analysis. 
 
Figure 1. Enrolment and assignment of patients to stage 1 and stage 2 treatment 
Legend: GFR = Glomerular filtration rate. 
90 Assessed for eligibility
Enrollment
phase 1
53 Assigned to treatment protocol
 37  Excluded:
   2  No documented diagnosis of gout
 13  cGFR <50 ml*min-1*(1.73m2)-1
5  No benzbromarone monotherapy 100-200 mg/day
   6  No efficacy data of benzbromarone therapy
 11  Protocol violation
 21  Lost to follow-up:
   8  Adverse events related to allopurinol
   8  Unknown reason
   5  Protocol violation
Follow-up
phase 1
32 Completed phase 1
  18 Excluded:
    8 Success after phase 1
  10 Protocol violation
Enrollment
phase 2
14 Assigned to treatment protocol
Follow-up
phase 2
14 Completed phase 2
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Table 1: Demographic data of patients enrolled in stage 1 (allopurinol) and in 
stage 2 (allopurinol-probenecid) 





Age (y) mean [± SD] 
range 
57 [± 10] 
41-84 
55 [± 8] 
46-74 
Male gender 92% 93% 
Tophaceous gout 23% 14% 
Underexcretor-type 95% 92% 






History of allopurinol use 20% 14% 
Baseline urate characteristics 
Baseline sUr (mmol/l) mean [± SD] 
range 
0.55 [± 0.08] 
0.41-0.69 
0.54 [± 0.08] 
0.42-0.68 
Baseline uUr (mmol/day) mean [± SD] 
range 
3.7 [± 1.3] 
1.6-6.8 
3.8 [± 1.7] 
1.6-6.8 
Baseline UrCl (ml/min) mean [± SD] 
range 
4.8 [± 1.9] 
1.8-11.2 
5.0 [± 2.5] 
1.8-10.4 
Previous benzbromarone results 1 
Dosage (mg/day) mean [± SD] 
range 
137 [± 49] 
100-200 
143 [± 51] 
100-200 
sUr (mmol/l) mean [± SD] 
range 
0.21 [± 0.07] 
0.09-0.38 
0.23 [± 0.06] 
0.14-0.31 
Decease of sUr mean [± SD] 
range 
61% [± 11%] 
41-76% 
58% [± 8%] 
48-73% 
uUr (mmol/day) mean [± SD] 
range 
5.0 [± 1.7] 
2.4-8.5 
5.3 [± 1.7] 
2.4-8.0 
UrCl (ml/min) mean [± SD] 
range 
16.1 [± 4.6] 
6.2-24.5 
16.3 [± 4.9] 
6.2-22.2 
Treatment goal reached: sUr ≤0.30 mmol/l 





Legend: SD = standard deviation; sUr = serum urate; uUr = urate excreted in urine; UrCl = urate clearance. 
1 Latest results before benzbromarone withdrawal 
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Biochemical efficacy 
Urate results after allopurinol (stage 1) and allopurinol-probenecid (stage 2) treatment are 
presented in Table 2 and Figure 2. With allopurinol monotherapy, the sUr reached was 0.36 
[± 0.07] mmol/l, and eight (25%) patients reached target sUr ≤0.30 mmol/l. Compared to 
treatment with benzbromarone 100-200 mg/day, significantly less patients attained target sUr 
levels (p<0.001). With allopurinol-probenecid, sUr reached was 0.25 [± 0.04] mmol/l, and 
12 (86%) patients reached target sUr after failure on allopurinol monotherapy. No significant 
difference was found compared to treatment with benzbromarone (p=0.81). 
Using allopurinol monotherapy, sUr decreased 36% [± 11%] compared to baseline. This was 
significantly less than relative sUr decrease attained with benzbromarone in this group 
(p<0.001). With allopurinol-probenecid treatment, sUr decreased 53% [± 9%] (CI95% 48-58%), 
which did not significantly differ from benzbromarone (p=0.23). 
Figure 3 shows cumulative probability plots of target sUr selected and percentage of treatment 
success found in stages 1 and 2 for selected target sUr and different treatment regimens. 
 
Table 2. Effectiveness of allopurinol (stage 1) and allopurinol-probenecid 
combination therapy (stage 2) 






Dosage allopurinol (mg/day) mean [± SD] 
range 
256 [± 50] 
200-300 
243 [± 51] 
200-300 
Dosage probenecid (mg/day) - 1,000 
sUr reached (mmol/l) mean [± SD] 
range 
0.36 [± 0.07] 
0.24-0.57 
0.25 [± 0.04] 
0.20-0.35 
Decrease of sUr from baseline 
from allopurinol 
from benzbromarone 
–36% [± 11%] 
- 
+78% [± 60%] 
–53% [± 9%] 
–33% [± 10%] 
+19% [± 43%] 
uUr (mmol/day) mean [± SD] 
range 
2.3 [± 0.8] 
0.8-4.3 
3.1 [± 0.9] 
1.5-4.4 
UrCl (ml/min) mean [± SD] 
range 
4.4 [± 1.3] 
2.3-7.7 
8.8 [± 2.4] 
4.5-13.9 
Treatment goal reached: sUr ≤0.30 mmol/l 





Legend: sUr = serum urate; uUr = urate excreted in urine; UrCl = urate clearance. 
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Figure 2. Box-plot diagram for sUr results of (a) stage 1, n=32; (b) stage 2, n=14. 
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Figure 3. Cumulative probability plot of variable target sUr concentrations and 
treatment success of target sUr for (a) stage 1, n = 32 (b) stage 2, n=14. 
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Discussion 
First, this study shows that benzbromarone is a very potent antihyperuricemic drug; in this 
cohort of patients using benzbromarone 100-200 mg/day, more than 90% of the patients have 
optimal sUr levels. With allopurinol standard dosage 200-300 mg/day, comparable effectiveness 
cannot be achieved for this group. The average allopurinol dosage (mean 243 mg/day) might be 
considered relatively low; however, (1) no efficacy data on allopurinol ≥600 mg/day are 
available in the literature; (2) dosages >300 mg/day are generally not advised because of 
increased risk of adverse drug reactions [23]; (3) benzbromarone (mean 138 mg/day) and 
probenecid (1,000 mg/day) could also be dosed higher. 
It must be noted that every patient in this study was previously treated with benzbromarone, 
thereby introducing the possibility to overestimate the percentage of responders to 
benzbromarone. Furthermore, a dropout occurred in stage 1 of 38%, which may have 
influenced the outcome. The relatively high dropout rate was mainly due to the design of the 
study (cohort) in combination with the sudden need for alternative treatment. On the other hand, 
we found a mean relative decrease in sUr of 61% for benzbromarone and 36% for allopurinol, 
which corresponds well with values published in the literature of 54-58% for benzbromarone 80-
125 mg/day and 27-44% for allopurinol 300 mg/day in patients that were not previously treated 
with benzbromarone [6, 17-18, 24-25]. 
This cohort consisted of more than 90% patients of uric acid underexcretor type. From a 
pathogenic point of view, it is suggested that allopurinol, as an inhibitor of uric acid production, 
would be more effective in overproducer-type gout. However, this is not supported by clinical 
data [17]. Previous findings indicate that even in patients with apparently high uUr, a relative 
underexcretion of urate is present [26]. Thus, when treatment goals are not achieved with 
allopurinol in this group of patients, combination with a uricosuric drug (e.g. benzbromarone, 
probenecid) might be very useful. 
Adding probenecid to allopurinol contributed an additional 33% [± 10%] (CI95% 28-38%) 
decrease in sUr on average, resulting in reaching the target sUr for most patients (87% 
success). Thus, in finding an appropriate alternative therapy for benzbromarone, adding 
probenecid to allopurinol was proven an effective strategy. An interaction between allopurinol 
and probenecid is described in the literature [15], resulting in an increased clearance of 
oxipurinol, the active metabolite of allopurinol. However, our data do not support this finding to 
be clinically important, as the addition of probenecid to allopurinol decreased sUr with 31% on 
average. 
In stage 1, five patients (10%) stopped allopurinol therapy because of adverse events related to 
allopurinol. Reported events were rash, pruritus, diarrhoea, nausea and dizziness, which are all 
well known side effects of allopurinol. Becker et al. [24] found a similar rate (12%) of adverse 
events related to allopurinol. 
There are few therapeutic options available to lower sUr to target levels other than the drugs 
used in this study. The uricosuric drug sulphinpyrazone is not widely used due to its adverse 
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effects profile [27]. Minor additive serum-lowering effects may be achieved by losartan or 
fenofibrate [27-28]. The uricostatic febuxostat may be available soon. Recently, it was shown 
that when using febuxostat 80-120 mg/day, 47-66% of the patients reached sUr levels 
≤0.30 mmol/l compared to 13% with allopurinol 300 mg/day [24]. A new promising treatment 
option for patients with severe tophaceous gout is the development of recombinant uricase [29-
30] and pegylated recombinant uricase. Uricase-based drugs are potentially very effective but 
also very expensive drugs, so further (pharmaco-economic) studies on optimizing 
antihyperuricemic antihyperuricemic therapy with old (out of patent) drugs, like benzbromarone, 
are warranted. At this moment, benzbromarone seems to be the most effective 
antihyperuricemic drug, and from our point of view, availability of benzbromarone in other 
countries would make treatment of difficult gout more successful [31]. 
 
Conclusion 
Benzbromarone is a very effective antihyperuricemic drug with 91% success in attainment of 
target sUr levels ≤0.30 mmol/l. Allopurinol 200-300 mg/day was shown to be a less potent 
alternative for most selected patients to attain target sUr levels (25% success). In patients 
failing on allopurinol monotherapy, the addition of probenecid proves to be an effective 
treatment strategy for attaining sUr target levels (86% success). 
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The purpose of this study was to investigate the efficacy and tolerability of allopurinol as the 
first-choice antihyperuricemic treatment for gout, and compare the efficacy and tolerability of 
benzbromarone and probenecid as second-choice treatment. 
Methods 
Prospective, multi-centre, open-label, two-stage, randomised controlled trial in gout patients 
with normal renal function. Enrolled patients were given 300 mg allopurinol for 2 months 
(stage 1). Those patients who could not tolerate allopurinol or who did not attain the target 
serum urate concentration (sUr) ≤0.30 mmol/l (5.0 mg/dl), which was defined as successful, 
were randomised to benzbromarone 200 mg/day or probenecid 2,000 mg/day for another 
2 months (stage 2). 
Results 
Ninety-six patients were enrolled in stage 1. Eighty-two patients (85%) were eligible for analysis 
at the end of stage 1. There was a mean [± SD] decrease in sUr concentration of 35% [± 11%] 
from baseline; 20 patients (24%) attained target sUr (0.30 mmol/l); and 9 patients (11%) 
stopped allopurinol because of adverse drug reactions. 
Sixty-two patients were enrolled in stage 2: 27 patients received benzbromarone (with 3 
excluded from analysis) and 35 received probenecid (with 4 excluded from analysis). Treatment 
with benzbromarone was successful in 22/24 patients (92%) and with probenecid in 20/31 
patients (65%) (p=0.03 compared with benzbromarone). Compared with baseline values, a 
mean [± SD] decrease of sUr concentration of 64% [± 9%] occurred with benzbromarone and 
50% [± 7%] with probenecid (p<0.001). 
Conclusion 
This study showed that allopurinol 300 mg/day has a poor efficacy and tolerability profile when 
used to attain a biochemical predefined target level of sUr ≤0.30 mmol/l, following 2 months of 
treatment. In stage 2, benzbromarone 200 mg/day was more effective and better tolerated than 
probenecid 2,000 mg/day. Trial registration number: ISRCTN21473387. 
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Introduction 
Allopurinol is the drug of choice for long-term urate lowering therapy in the 2006 European 
League Against Rheumatism (EULAR) evidence-based recommendations for gout. Uricosuric 
agents such as probenecid and sulfinpyrazone can be used as alternatives, and 
benzbromarone is only recommended in patients with mild to moderate renal insufficiency. 
Given the scarce clinical trial data, it remains questionable whether the efficacy-safety balance 
of benzbromarone and probenecid is unfavourable compared with the first-choice treatment, 
allopurinol [1]. 
Since the introduction of benzbromarone in the early 1970s, four cases of severe hepatitis have 
been published [2-5]. Benzbromarone, however, seems well tolerated in general use [6]. In 
contrast, allopurinol rather frequently causes allergic skin reactions (2-5%), and in rare cases 
causes even a life-threatening hypersensitivity syndrome [7-11]. In Europe, benzbromarone 
used to be available as a prescription drug in a limited number of countries. In the Netherlands, 
the only alternative in chronic gout was allopurinol. When allopurinol treatment was 
unsuccessful, the uricosuric drug probenecid was available for restricted use. Benzbromarone 
was withdrawn from the market in Europe in 2003, but was licensed again in some countries in 
2004 [12]. Its use is now restricted for patients with gout who are allergic to allopurinol or those 
in whom allopurinol is contra-indicated. 
The goal of antihyperuricemic treatment is to reduce the serum urate (sUr) level below the 
threshold of supersaturation to prevent any gouty attack by allowing the dissolution of existing 
monosodium urate (MSUr) crystals in the joints and to prevent the deposition of new crystals in 
cases of severe tophaceous accumulation [9-11]. The solubility of urate in joint fluids is 
influenced by temperature, pH, concentration of cations, level of articular dehydration and the 
presence of nucleating agents such as insoluble collagens, chondroitin sulphate and non-
aggregated proteoglycans [8]. 
According to the EULAR recommendations, the treatment goal of antihyperuricemic lowering 
therapy is to reach target serum urate levels below 0.36 mmol/l (6.1 mg/dl) [13]. Recurrent 
gouty attacks are better prevented and tophi dissolve more quickly with target serum urate 
concentrations below 0.30 mmol/l (5.0 mg/dl) rather than 0.30-0.36 mmol/l [14-18]. The British 
Guideline (2007) sets the sUr treatment goal for gout patients at ≤0.30 mmol/l [19]. 
With the aim of collecting more evidence-based data, in the present study we: (1) investigated 
the efficacy and tolerability of allopurinol as first-choice sUr-lowering treatment for gout; (2) 
compared the above with the efficacy and tolerability of benzbromarone and probenecid as 
second-choice treatments. 
 Chapter 3.2 
62 
Methods 
Patients and inclusion criteria 
This prospective, multi-centre, open label, randomised controlled trial was carried out in patients 
recently diagnosed with gout by a rheumatologist. Eligibility criteria were [20-23]: (1) a diagnosis 
of gout confirmed by microscopic evidence of urate crystals or complying with the American 
Rheumatology Association (ARA) criteria otherwise; (2) no history of use of one of the study 
drugs; (3) no relevant liver disease; (4) no relevant renal disease - defined as calculated 
creatinine clearance (cCrCl) ≥50 ml/min, using the Cockcroft and Gault formula; and (5) an 
indication for antihyperuricemic therapy - presence of tophi or frequent attacks (≥2/year). Before 
a patient was entered the study, we measured their liver function, serum creatinine (sCr), sUr, 
urinary creatinine excretion (uCr), and urinary urate excretion (uUr) on unrestricted purine diet. 
Underexcretion of urate was defined as urate clearance (UrCl) <6.0 ml/min per 1.73 m2 [24]. 
Urate clearance was calculated by urinary volume (ml/min) * urinary urate concentration / sUr 
and normalised for a body surface area of 1.73 m2. Overproduction of urate was defined as uUr 
>6.0 mmol/day. Normal excretion of urate was defined as UrCl ≥6.0 ml/min per 1.73 m2 and uUr 
≤6.0 mmol/day. 
At the time of inclusion in the study, patients were assigned an inclusion number by the 
rheumatologist (blinded), and consequently randomised to stage 2 treatment. A computer-
generated central randomisation schedule with a block size of six was used. The period of study 
recruitment and follow-up was from June 2005 until January 2007. 
 
Study design and data collection 
In stage 1, patients were given allopurinol 300 mg once daily in a step-up dosage scheme (100-
200-300 mg/day, with the dose increased every week), which is a common fixed-dose regimen 
used in clinical practice in Europe and in other gout studies [13, 25-27]. When allopurinol was 
not tolerated or when the treatment goal of sUr ≤0.30 mmol/l was not reached after 2 months, 
patients were switched to stage 2 treatment: benzbromarone 200 mg once daily (Desuric®; OTL 
Pharma, Breda, The Netherlands) - step-up 100-200 mg/day, dose increased after 1 week - or 
probenecid 1,000 mg twice daily (Probenecid Weimer®; Biokanol Pharma, Rastatt, Germany) - 
step-up 500-1,000 mg twice daily, dose increased after 1 week. 
Defined daily doses are allopurinol 400 mg/day, benzbromarone 100 mg/day and probenecid 
1,000 mg/day. We used a fixed dosage in the upper dosage range of benzbromarone and 
probenecid, because (1) adequate treatment of patients refractory to allopurinol (standard) 
treatment was warranted, and (2) benzbromarone 200 mg/day had not been tested in a clinical 
controlled trial before. Colchicine 0.5-1 mg/day was prescribed fot prophylaxis of gouty 
episodes, until target sUr level was reached (sUr ≤0.30 mmol/l); when colchicine was not 
tolerated, a non-steroidal anti-inflammatory drug was prescribed. 
Each treatment regimen was evaluated after a treatment period of 2 months by measuring sCr, 
sUr, uCr and uUr. To evaluate patient adherence for allopurinol, we measured the serum 
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oxipurinol level by using a validated high-pressure liquid chromatography with ultraviolet 
detector (HPLC-UV) method [28]. Patients with serum oxipurinol concentrations below the lower 
limit of quantification (<1.0 mg/l) were excluded from the analysis. 
The primary endpoint for stages 1 and 2 was the percentage of patients tolerating the 
antihyperuricemic medication and attaining an sUr concentration below 0.30 mmol/l. Our 
secondary end point was the relative decrease of sUr concentration attained with each 
treatment regimen. 
The study was approved by the medical ethical committees of both centres and informed 
consent was obtained from all participating patients. 
 
Statistics 
A power calculation indicated that at least 29 evaluable patients were needed in each treatment 
arm in stage 2 to prove a statistically significant difference between benzbromarone and 
probenecid (based on an estimated 90% success rate for benzbromarone versus 60% for 
probenecid, α=0.05, β=0.20) [29]. We expected a success percentage of 20% with allopurinol 
and a loss to follow-up of 25%, rendering 96 patients for the study. 
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was used for data collection, data validation, 
data selection, and statistical analysis. The Student two-sided t-test and Fisher exact test were 
used to compare the effectiveness of benzbromarone and probenecid; 95%-confidence 
intervals of proportions were calculated using binomial distribution. Normality was verified with 
Kolmogorov-Smirnov analysis. A p-value <0.05 was considered statistically significant. 
 
Results 
We enrolled 96 patients in stage 1 (Figure 1). Three patients did not fulfil the inclusion criteria 
because of an estimated CrCl <50 ml/min (protocol violation), leaving ninety-three patients for 
analysis of baseline characteristics (Table 1). Of these, 82 patients (88%) were eligible for 
analysis of stage 1; five patients were lost to follow-up and six patients were excluded because 
of poor adherence based on non-measurable serum oxipurinol levels. 
Results of stages 1 and 2 are presented in Table 2 and Figure 2. The treatment was successful 
in 20 patients (24%), defined as tolerance of allopurinol and attainment of target sUr 
concentrations (≤0.30 mmol/l). Nine patients (11%) stopped taking allopurinol because of 
adverse drug reactions (ADRs) (Table 3). In stage 1, the mean [± SD] decrease in sUr 
concentration with allopurinol was 35% [± 11%]. The mean serum oxipurinol concentration 
measured was 13.2 [± 7.1] mg/l. Of patients whose sUr concentrations did not reach 
≤0.30 mmol/l, 92% had serum oxipurinol concentrations >5.0 mg/l. 
Sixty-two patients entered stage 2 of the study: 27 patients received benzbromarone (with 3 
excluded from analysis), and 35 received probenecid (with 4 excluded from analysis). In the 
benzbromarone group, 22/24 patients (92%) were treated successfully in terms of tolerance of 
study medication and attainment of target sUr concentrations. In the probenecid group, 20/31 
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patients (65%) were treated successfully, which was significantly less than the treatment 
success attained with benzbromarone (p=0.026). The success ratio benzbromarone:probenecid 
was 1.42 (CI95% 1.07-1.89). With benzbromarone 200 mg/day, the sUr concentration decreased 
by a mean [± SD] of 64% [± 9%] compared with a decrease of 50% [± 7%] with probenecid 
2,000 mg/day (p<0.001). 
 
Figure 1. Flow of participants through each stage of the study 
 
96 Assigned to treatment protocol 
stage 1
 
   14  Excluded from analysis: 
         6  Poor adherence: plasma oxipurinol <1.0 mg/l 
         5  Lost to follow-up 




  82 Included for analysis 
       73  Completed 
         9  Adverse events 




62 Randomly assigned to treatment 
protocol stage 2 
Follow-up 
stage 2 
  24  Included for analysis 
        23  Completed 
          1  Gout flares
 
  3 Excluded from analysis: 
     2  Lost to follow-up 
     1  Protocol violation 
27 Benzbromarone 35 Probenecid 
Assignment 
stage 2 
  4  Excluded from analysis: 
      1  Poor compliance 
      2  Lost to follow-up 
      1  Protocol violation 
  31  Included for analysis 
        23  Completed 
          8  Adverse events
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Table 1. Demographic and clinical characteristics of patients 









Age (y) mean [± SD] 
range 
58 [± 14] 
29-86 
55 [± 16] 
29-86 
58 [± 12] 
32-77 
NS 
Male gender 92% 100% 94% NS 
Tophaceous gout 41% 30% 54% NS 
Frequency of gout 














Body mass index 
(kg/m2) 
mean [± SD] 
range 
29.3 [± 4.6] 
19.4-48.9 
29.6 [± 3.4] 
24.8-39.2 






























Urate characteristics at baseline 
sUr (mmol/l) mean [± SD] 
range 
0.53 [± 0.07] 
0.39-0.76 
0.55 [± 0.09] 
0.43-0.76 
0.54 [± 0.07] 
0.39-0.72 
NS 
uUr (mmol/day) mean [± SD] 
range 
3.6 [± 1.6] 
1.2-10.0 
4.1 [± 1.8] 
2.2-9.8 




(ml/min per 1.73 m2) 
mean [± SD] 
range 
3.8 [± 1.7] 
1.4-10.4 
4.4 [± 1.9] 
1.4-7.9 













  3% 




Legend: NS = non-significant (p>0.05); SD = standard deviation; sUr = serum urate; uUr = urate excreted in urine; UrCl = urate 
clearance; y = year(s). 
1 Comparison of stage 2 groups. 
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Figure 2. Box-plot for serum urate concentration (sUr) results of stage 1 and stage 2 
antihyperuricemic medication. 
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Table 2. Efficacy of allopurinol as first-line sUr lowering treatment (stage 1) and 
benzbromarone versus probenecid as second-line treatment (stage 2). 








Treatment success results (n=82) (n=24) (n=31)  
Treatment goal reached 















Treatment goal not reached: 
withdrawn due to ADR 
sUr 0.31-0.36 mmol/l 
sUr >0.36 mmol/l 
 













Urate results (n=73) (n=23) (n=23)  
sUr reached (mmol/l) mean [± SD] 
range 
0.34 [± 0.06] 
0.23-0.46 
0.19 [± 0.07] 
0.12-0.46 
0.27 [± 0.05] 
0.20-0.40 
<0.001 
sUr decrease from baseline 35 [± 11] % 64 [± 9] % 50 [± 7] % <0.001 
uUr (mmol/day) mean [± SD] 
range 
2.2 [± 1.2] 
0.8-6.6 
5.3 [± 1.9] 
2.6-9.3 
4.7 [± 1.7] 
0.5-8.1 
NS 
UrCl (ml/min/1.73m2) mean [± SD] 
range 
3.6 [± 1.8] 
1.3-7.3 
17.7 [± 7.2] 
6.7-33.4 
10.1 [± 4.5] 
1.2-23.2 
<0.001 
Drug serum concentrations 
Serum oxipurinol (mg/l) mean [± SD] 
range 
13.2 [± 7.1] 
2.5-39.2 
- - - 
Legend: CI95% = 95% confidence interval; NS = non-significant (p>0.05); sUr = serum urate; uUr = urate excreted in urine; UrCl = 
urate clearance. ADR = adverse drug reaction 
1 Comparison of stage 2 groups. 
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Table 3. Reported adverse drug reactions (ADRs): leading to withdrawal, and 
total ADRs. 1 







Number of patients with ADRs 
  CI95% 
9 (11%) / 18 (22%) 
5-20% / 14-32% 
1 (4%) / 5 (20%) 
0-19% / 6-38% 
8 (26%) / 12 (39%) 
12-45% / 22-58% 
Type of ADR 
  Dizziness - / - - / - 1 (3%) / 2 (6%) 
  Fatigue 1 (1%) / 1 (1%) - / - 3 (10%) / 3 (10%) 
  Gastro-intestinal 1 (1%) / 6 (7%) - / 3 (12%) 5 (16%) / 7 (23%) 
  Gout flares 2 - / 2 (2%) 1 (4%) / 2 (8%) - / 1 (3%) 
  Headache - / - - / - 1 (3%) / 2 (6%) 
  Muscle pain/cramps - / 3 (4%) - / - - / - 
  Rash 6 (7%) / 6 (7%) - / - 1 (3%) / 1 (3%) 
  Flushing - / 1 (1%) - / - 1 (3%) / 2 (6%) 
  Vision disorder 1 (1%) / 1 (1%) - / - - / - 
Legend: CI95% = 95% confidence interval;  
1 ADRs expressed as ADR leading to withdrawal (n(%)) / total ADR (n(%)) reported; every patient could report >1 ADR. 
2 Gout flares might be caused by starting sUr lowering therapy due to mobilisation of urate related to rapid decline of sUr. 
 
Discussion 
This study shows that allopurinol 300 mg/day has a poor efficacy and tolerability profile in 
patients with normal renal function at 2 months of follow-up. With a treatment target sUr 
concentration of ≤0.30 mmol/l, 24% of patients were treated successfully with allopurinol 
300 mg/day. The target sUr concentration is still being debated [31]. In the recent EULAR 
recommendations a more conservative target sUr concentration of ≤0.36 mmol/l is proposed for 
gout treatment in general, whereas in patients with severe gout the treatment target might be 
lower [13]. If we had set a target of ≤0.36 mmol/l in the present study, we would have achieved 
a treatment success of 56% using allopurinol 300 mg/day. A higher success rate with allopurinol 
300 mg/day might be achieved in patients with less severe gout who have a lower baseline sUr, 
and in overproducer-type patients. 
The limited efficacy and modest antihyperuricemic effect of allopurinol with the recommended 
dose of 300 mg/day is consistent with previous findings [25-27, 29]. Recent guidelines 
recommend increasing the allopurinol dosage, when necessary, until the target sUr is attained, 
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with a licensed maximum dosage of 900 mg/day [13, 19]. However, switching to a uricosuric 
therapy might be preferable, because of several reasons. First, considering that steady state 
serum urate concentrations depend on the mass balance (difference between input and output) 
of urate in the body, the sUr-lowering potential of xanthine oxidase inhibitors is limited 
compared to uricosurics, especially in underexcretor-type gout patients with a mean uUr of 
2.2 mmol/day. Second, uncertainty exists about the efficacy-safety balance of higher doses of 
allopurinol. Lastly, in routine clinical practice and in virtually all clinical research, the commonly 
used dosage is 300 mg/day. In one case-series, 19 gout patients were treated with allopurinol 
600 mg/day: serum urate concentrations decreased with a mean [± SD] of 44% [± 13%], and 
10 (52%) patients attained the target level serum urate concentration ≤0.30 mmol/l [32]. No 
evidence exists for a direct relationship between allopurinol or oxipurinol concentrations and the 
occurrence of adverse effects in patients with normal renal function [33]. On the other hand, in 
patients with renal insufficiency, accumulation of oxipurinol is considered a crucial factor in the 
development of allopurinol hypersensitivity syndrome, which leads to tissue damage by toxic, 
immunological and/or genetic mechanisms [34-37]. 
In our study, 11% did not tolerate allopurinol (Table 3). This is slightly more than rates reported 
in literature, but these differences are probably not significant [13, 32, 38]. The ADRs leading to 
withdrawal in this study are documented in the literature, except for fatigue [39]. 
We measured the serum oxipurinol levels to verify adherence to allopurinol. Patients with 
undetectable oxipurinol concentrations (<1.0 mg/l) were excluded from the analysis. The 
reported reference range for allopurinol 300 mg/day is 5.0-15 oxipurinol mg/l [40]. Most of the 
patients who did not attain the target treatment goal had serum oxipurinol concentration 
>5.0 mg/l (92%). This indicates that these patients were compliant with taking allopurinol 
treatment. For the purpose of therapeutic drug monitoring of allopurinol therapy, validaton of the 
proposed therapeutic reference values of serum oxipurinol is needed. 
In stage 2, we compared benzbromarone 200 mg/day and probenecid 2,000 mg/day. The 
results showed that significantly more patients attain target sUr concentrations with 
benzbromarone. The sUr lowering effects of benzbromarone and probenecid are consistent with 
previous findings [25-28, 30, 41]. The ADRs reported with probenecid (Table 3) are common 
side effects of this drug [42]. 
This study was conducted in patients with a cCrCl ≥50 ml/min. The results cannot be 
extrapolated to patients with renal insufficiency, because of several reasons (1) allopurinol 
dosage should be adjusted; (2) benzbromarone is considered ineffective in patients with cCrCl 
<25 ml/min; and (3) probenecid is considered ineffective in patients with cCrCl <50 ml/min [38]. 
We used sUr as a surrogate parameter for clinical success. Previous studies have shown that 
the attained sUr is inversely related to prevention of recurring gout flares and to velocity of size 
reduction of tophi [12-16]. Therefore, in clinical practice sUr is a well-established parameter for 
evaluating success of antihyperuricemic therapy for gout in the long-term. 
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More than 90% of the patients in our study were underexcretors of uric acid. From a pathogenic 
point of view, it has been suggested that allopurinol, as an inhibitor of uric acid production, is 
more effective in overproducer-type gout patients. However, this view is not supported by 
clinical data. Previous findings indicate that even patients with apparently high uUr relatively 
underexcrete urate [43]. When treatment goals are not achieved with allopurinol in 
overproducers, combination with a uricosuric drug (e.g. benzbromarone, probenecid) might be 
useful, considering the (relative) contra-indication of uricosuric drugs for patients with urinary 
urate excretion >4.2 mmol/day [29]. 
Besides the drugs used in this study, there are few therapeutic options available to lower sUr to 
target concentrations. The uricosuric drug sulfinpyrazone is not widely used due to its adverse 
effect profile [38]. In a recent study, 47-66% of patients taking febuxostat 80-120 mg/day 
reached sUr concentrations below 0.30 mmol/l compared with only 13% who were taking 
allopurinol 300 mg/day [25]. A new treatment option for patients with severe tophaceous gout, 
recombinant uricase and pegylated recombinant uricase, seems promising [29-47]. In short-
term studies, uricase-based drugs have been effective but they are expensive drugs. The 
impact of gout on absence from and productivity is substantial, so pharmaco-economic studies 
are necessary, comparing the newer and older (out of patent) drugs, such as allopurinol and 
benzbromarone [48]. 
It seems that benzbromarone is a highly efficacious oral sUr-lowering drug, that has been 
excessively withdrawn from the market. It may be preferable to reintroduce benzbromarone in 
the market instead of using the new, costly drugs that carry a risk for unknown ADRs. 




This study showed that allopurinol 300 mg/day has a poor efficacy and tolerability profile when 
used to attain a biochemical predefined target level of sUr ≤0.30 mmol/l, following 2 months of 
treatment. In stage 2, benzbromarone 200 mg/day was more effective and better tolerated than 
probenecid 2,000 mg/day. Trial registration number: ISRCTN21473387. 
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A lack of prospective long-term, high quality data exists that addresses the efficacy of 
antihyperuricemic treatment to prevent clinical symptoms, such as gouty arthritis. We conducted 
an observational follow-up study to assess the rate of recurrent gouty arthritis in patients 
receiving antihyperuricemic treatment after participating in a randomised controlled trial (RCT). 
Methods 
Eligibility criteria for the initial RCT were a diagnosis of gout, no history of allopurinol, 
benzbromarone or probenecid use, no relevant liver disease, a calculated creatinine clearance 
>50 ml/min, and an indication for starting antihyperuricemic therapy, defined as the presence of 
tophi or frequent gouty attacks (≥2/year). 
After completion of the trial period primary aiming at biochemical correction, the rheumatologist 
was free to adjust the urate lowering treatment according to patient preferences. Patients who 
completed the RCT, and suffered from ≥2 attacks/year at baseline, were included in this 
prospective follow-up study with cross-sectional analysis. Each six months, the patient visited 
the rheumatologist again, the serum urate concentration was measured, and the patient was 
asked for the number of gouty attacks in the last period. Patients who continued using 
colchicine or NSAIDs on a daily basis, were included in a subgroup for evaluation of potential 
bias effects. Primary endpoint was the relative reduction in the rate of recurrent gouty attacks 
before start of urate lowering treatment and during the follow-up period of the trial. 
Results 
Ninety-six patients were enrolled in the initial RCT, and 50 patients were enrolled in the follow-
up study; three patients were lost to follow-up. Twenty-four (48%) patients used allopurinol, 
22 (44%) used benzbromarone, and 4 (8%) used probenecid. Furthermore, six patients did not 
stop colchicine or NSAID after the RCT, and were further analysed in a subgroup. Average 
duration of follow-up was 10.6 months. The incidence of gout attacks was largely reduced 
during follow-up compared to baseline rates: 74% of patients were free of gouty attacks (100% 
reduction), and 17% of patients had 50-99% reduction of gout attacks. Serum urate 
concentrations were 0.28 [± 0.08] mmol/l (mean [± standard deviation]). 
Discussion 
A high reduction in incidence of gout attacks was found. Results are better than obtained in 
most previous studies. This might be explained by the strict control of serum urate, and possibly 
by a selection bias of gout patients with good adherence. No correlation was found between 
reduction of gout attacks and sUr or study drug used, due to lack of power. 
Conclusion 
This follow-up study demonstrates that antihyperuricemic therapy is highly effective in the 
reduction and prevention of gout flares in gout patients under strict control of serum urate. 
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Introduction 
Antihyperuricemic treatment in gout is indicated for patients suffering from recurrent gouty 
arthritis or tophaceous gout [1-2]. A lack of long-term, good-quality, prospective data exists 
addressing the efficacy of serum urate (sUr) lowering treatment to prevent clinical symptoms as 
gouty arthritis, Table 1 [3]. A number of studies shows that allopurinol (and other 
antihyperuricemic drugs like benzbromarone) does reduce serum urate, at least in the short 
term, and a well-documented relationship exists between serum urate and the incidence of 
acute gout [3, 11-12]. 
 
Table 1. Overview of trials that assessed reduction of gouty arthritis by 
currently available antihyperuricemic therapy with follow-up ≥6 months [3] 























1-2 g/day, or  
Sulphinpyrazone 
400 mg/day 
CT 21 vs. 19 10-24 38% vs. 39% 
(NS) 







CT 46 vs. 47 7.5 26% vs. 28% 
(NS) 





Baseline CT 408 9.7 34% vs. 0% 
(p <0.001) 




Baseline CT b 6 12 25% vs. 0% 
(p <0.001) 























Legend: CT = controlled trial, m = months; no. = number; RCT = randomised controlled trial; ref. = reference; sUr = serum urate 
concentration 
a Versus baseline; b Patients with renal function impairment; b No data available 
 
In one randomised controlled trial (RCT) of allopurinol versus febuxostat, a high percentage of 
patients suffered from recurrent gouty arthritis in all three treatment groups (64-70%) during 
week 9-48, despite sUr concentrations that were considered adequate (in the febuxostat 80 and 
120 mg groups) [10]. In another RCT, follow-up data of 25 patients with renal function impair-
ment showed that 20% suffered from gouty bouts during 6-12 months, 4% during 12-18 months, 
and 0% during 18-24 months after urate-lowering therapy with allopurinol or benzbromarone 
was started (colchicine was stopped at 6 months of urate-lowering therapy) [9]. These data, and 
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extensive clinical experience, suggest that sUr lowering treatment is effective and cost-effective 
in preventing recurrent gout [13]. 
We conducted an observational follow-up study to assess the rate of recurrent gouty arthritis in 
patients receiving urate-lowering treatment after participating in a RCT [14]. 
 
Methods 
Study design and inclusion criteria 
Patients recently diagnosed with gout by a rheumatologist were asked to participate in a two-
stage randomised controlled trial [10]. Eligibility criteria were: (1) a diagnosis of gout confirmed 
by microscopic evidence of urate crystals or otherwise complying with the American 
Rheumatology Association (ARA) criteria, (2) no history of use of one of the study drugs, (3) no 
history of liver disease, (4) no relevant renal disease defined as calculated creatinine clearance 
(cCrCl) ≥50 ml/min calculated by the formula of Cockcroft and Gault, and (5) an indication for 
sUr lowering therapy: presence of tophi or frequent attacks (≥2/year). 
In stage 1, patients were given allopurinol 300 mg daily. When allopurinol was not tolerated or 
when the treatment goal of sUr ≤0.30 mmol/l was not reached after 2 months, patients directly 
switched to stage 2 treatment: benzbromarone 200 mg once daily (Desuric®; OTL Pharma, 
Breda, The Netherlands) or probenecid 1,000 mg (Probenecid Weimer®; Biokanol Pharma, 
Rastatt, Germany) twice daily. Prophylaxis of gouty episodes with colchicine 0.5-1 mg/day was 
prescribed until target sUr level was reached (sUr ≤0.30 mmol/l); when colchicine was not 
tolerated, a non-steroidal anti-inflammatory drug could be prescribed as an alternative. Each 
treatment regimen was evaluated after a treatment period of 2 months by measuring sCr, sUr, 
uCr and uUr. 
After completion of the trial period, the rheumatologist was free to adjust the urate lowering 
agent or dose; a sUr target level of 0.30 mmol/l was used. Patients who suffered >2 attacks/ 
year before antihyperuricemic treatment, were included in the follow-up study. Each 6 months, 
the patients visited the rheumatologist again, serum urate concentrations were measured and 
patients were asked for the number of gouty attacks they experienced in the last year. A cross-
sectional analysis was performed, and patients with an evaluation after ≥6 months follow-up 
were eligible. Patients who still used colchicine or NSAIDs on a daily basis, were included in a 
subgroup for evaluation of potential bias effects. 
Primary endpoint of this follow-up study was the relative reduction of the rate of recurrent gouty 
arthritis before start of urate lowering treatment and during the follow-up period of the trial.  
The study was approved by the Medical Ethical Review Board of the participating hospitals, and 
written informed consent was obtained from all participating patients. 
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Results 
Ninety-six patients were enrolled in the randomised controlled trial. Nine patients were excluded 
from the follow-up study because of protocol violation (3) and poor adherence in stage 1 
(allopurinol 300 mg/day) based on measured plasma oxipurinol levels <1.0 mg/l (6). Also, nine 
patients were lost to follow-up in stage 1 (5) and stage 2 (4) of the RCT. Furthermore, 
22 patients did not suffer from 2 gouty attacks per year prior to start of urate lowering treatment 
and 6 patients were not willing to continue any urate lowering treatment after the initial trial 
period (predominantly because of intolerance). Thus, 50 patients were enrolled in the follow-up 
study (Table 2). 
 
Table 2. Demographic and clinical characteristics at baseline 
Characteristics (n=50)   
Age (y) 
 
mean [± SD] 
range 
58 [± 12] 
41-86 









Body mass index (kg/m2) mean [± SD] 
range 














sUr (mmol/l) mean [± SD] 
range 
0.54 [± 0.07] 
0.39-0.75 
uUr (mmol/day) mean [± SD] 
range 
3.3 [± 1.2] 
1.3-6.3 
UrCl (ml/min per 1.73 m2) 
 
mean [± SD] 
range 
3.5 [± 1.3] 
1.5-7.6 






Legend: SD = standard deviation; sUr = serum urate; uUr = urate excreted in urine; UrCl = urate clearance; y = year(s). 
1 Definitons of excretor-type: underexcretor UrCl <6.0 ml/min per 1.73 m2; overproducer uUr >6.0 mmol/day; normal excretor UrCl 
≥6.0 ml/min per 1.73 m2 and uUr ≤6.0 mmol/day. 
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Table 3. Results of antihyperuricemic treatment after one year of follow-up. 
Characteristics of antihyperuricemic treatment 
Allopurinol dosage (mg/day) n 
mean [± SD] 
range 
21 
362 [± 91] 
200-600 
Benzbromarone dosage (mg/day) n 
mean [± SD] 
range 
18 
147 [± 50] 
100-200 
Probenecid dosage (mg/day) n 
mean [± SD] 
range 
4 
1,750 [± 500] 
1,000-2,000 
Follow-up duration (months) n 
mean [± SD] 
range 
 
10.4 [± 3.8] 
4.8-19.7 
Outcome 





  5% 
  9% 
  7% 





  7% 
  5% 
  5% 
sUr (mmol/l) 
 
mean [± SD] 
range 
0.28 [± 0.08] 
0.15-0.55 
sUr decrease (%) 
 
mean [± SD] 
range 
46 [± 17] % 
12-71 
Legend: SD = standard deviation; sUr = serum urate. 
 
Three patients did not have an evaluation after ≥6 months (lost to follow-up). Six patients were 
not willing to stop colchicine or NSAIDs on a daily basis, and were further analysed in a 
subgroup. Results of remaining 47 patients are presented in Table 3. Average duration of 
follow-up was 10.6 months. Twenty-four (51%) patients used allopurinol, 19 (40%) benz-
bromarone, and 4 (9%) probenecid. Incidence of gout attacks was largely reduced during 
follow-up compared to baseline rates: 75% of patients were free of gouty attacks (100% 
reduction), and 17% of patients had 50-99% reduction of gout attacks. The results in the 
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subgroup of patients who continued colchicine or NSAID revealed that inclusion of this 
subgroup did not significantly affect the overall outcome results (Table 3). 
Serum urate concentrations were 0.28 [± 0.08] mmol/l (mean [± standard deviation]). We did not 
find a significant relationship between the incidence of gout attacks and serum urate 
concentration reached, or study drug used. 
 
Discussion 
This follow-up study demonstrates that antihyperuricemic drug therapy is highly effective in 
reducing and preventing gout attacks in gout patients with normal renal function. Results are 
better than obtained in most previous studies (Table 1). This might be explained by the strict 
control of serum urate in this study (mean 0.28 mmol/l), and possibly by a selection bias of 
patients with good adherence. In a retrospective study, it was found that lower sUr were 
significantly associated with better control of gout attacks [11]. Also, Pérez-Ruiz et al. found 
good control of gout attacks with a strict control of serum urate [9]. 
In our study, no correlation was found between the incidence of gout attacks and serum urate 
concentration reached, or study drug used. This is caused by lack of power: only nine patients 
with gout attacks were recorded. 
A matter of debate to which target sUr should be used, still exists [15]. The European 
recommendations use 0.36 mmol/l in general, while the British guideline uses 0.30 mmol/l [2, 
16]. It is important to consider that solubility of urate in joint fluids is influenced by temperature, 
pH, concentration of cations, level of articular dehydration, and the presence of nucleating 
agents such as insoluble collagens, chondroitin sulphate and non-aggregated proteoglycans 
[17]. Solubility of urate is 0.41 mmol/l at 37 °C in presence of sodium concentration of 
140 mmol/l, 0.36 mmol/l at 35 °C, and 0.27 mmol/l at 30 °C [18]. Since body temperature is the 
lowest in the extremities, gout symptoms usually occur in these parts. Therefore, as well as 
from clinical data, target sUr levels should be below 0.42 mmol/l at least, a value often 
mentioned in the literature from theoretically reasons, and preferably below 0.30 mmol/l, as 
advised in the British guideline [2]. 
 
Conclusion 
This follow-up study demonstrates that antihyperuricemic therapy with allopurinol, 
benzbromarone or probenecid, is highly effective in reducing and preventing gout attacks in 
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To compare the efficacy and tolerability of allopurinol 300-600 mg/day versus benzbromarone 
100-200 mg/day to attain a target sUr ≤0.30 mmol/l (5 mg/dl). 
Methods 
A randomised, controlled, open-label, multi-centre trial was conducted in gout patients with 
renal function defined as cCrCl ≥50 ml/min. Patients were treated with 300 mg allopurinol or 
100 mg benzbromarone once daily (stage 1). When sUr ≤0.30 mmol/l was not attained after 
2 months, dosage was doubled to allopurinol 300 mg twice daily or benzbromarone 200 mg 
once daily (stage 2). Primary endpoint was treatment success in either of both stages, defined 
as clinical tolerability and attainment of biochemical target serum urate concentration. 
Results 
Sixty-five patients were enrolled in stage 1, 36 patients received allopurinol and 29 received 
benzbromarone. Fifty-five patients (85%) were evaluated for analysis of stage 1. At stage 1, the 
success rates are 8/31=0.26 (26%) and 13/25=0.52 (52%), and difference is -0.26 (CI 95% from 
-0.486 to -0.005), p=0.049. At stage 2, the success rates are 21/27=0.78 (78%) and 18/23=0.78 
(78%), and difference is -0.005, (CI 95% from -0.223 to 0.220), p=1.00. Two patients stopped 
allopurinol and 3 patients stopped benzbromarone because of adverse drug reactions (ADR). 
Conclusion 
Increase of allopurinol dosage from 300 to 600 mg/day and benzbromarone dosage from 100 to 
200 mg/day according to target sUr, gives significantly higher success rates (both 78% success 
in sUr ≤0.30 mmol/l). No significant differences in treatment success between benzbromarone 
and allopurinol groups were found after dosage escalation (controlled-trials.com number 
ISRCTN49563848). 
A randomised controlled trial with dose-escalation on the efficacy and tolerability of 
allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout 
85 
Introduction 
Allopurinol is the drug of choice in the long-term treatment of gout in the 2006 EULAR evidence 
based recommendations [1]. Quite similar recommendations are given by the British Society of 
Rheumatology, with a remarkably lower biochemical target of serum urate (0.30 mmol/l versus 
0.36 mmol/l) [2]. In order to reach the target serum urate (sUr) concentration, the EULAR 
recommendations advise to titrate allopurinol dosage up to a maximum of 900 mg/day. 
However, historically a fixed dosage of 300 mg/day is mostly used in clinical research and 
clinical practice [3]. Data on clinical efficacy and tolerability of antihyperuricemic treatment are 
scarce, especially on higher than standard dosages [4]. In one study, allopurinol 600 mg/day 
was given to 19 patients, resulting in a sUr decrease of 44% [± 13%] (mean ± standard 
deviation) compared with baseline, and in 52% success in attaining sUr ≤0.30 mmol/l 
(5.0 mg/dl) [5]. In a dose-response study in patients with heart failure, sUr decreased from 0.41 
[± 0.11] mmol/l to 0.16 [± 0.06] mmol/l using allopurinol 600 mg/day [6]. In a randomised 
controlled trial of benzbromarone 200 mg/day versus probenecid 2,000 mg/day (ISRCTN 
21473387, www.controlled-trials.com), we found a decrease of sUr of 64% [± 9%] compared to 
baseline, and in 92% success in attaining sUr ≤0.30 mmol/l [7]. 
The goal of antihyperuricemic treatment is to reduce the serum urate (sUr) level below the 
threshold of supersaturation to prevent any gouty attack by allowing the dissolution of existing 
monosodium urate (MSUr) crystals in the joints and to stop the deposition of new crystals [1-2]. 
The solubility of urate in joint fluids is influenced by temperature, pH, concentration of cations, 
level of articular dehydration and the presence of nucleating agents such as insoluble collagens, 
chondroitin sulphate and non-aggregated proteoglycans [8]. The occurrence of acute gout 
attacks depends on the sUr level attained, and on mechanical stress as attacks might be 
predisposed to joints affected by osteoarthritis [9-13]. 
According to the EULAR 2006 recommendations, treatment goal of antihyperuricemic drug 
therapy is to reach target sUr levels below 0.36 mmol/l (6.1 mg/dl) [1]. Historically, the target 
serum urate level is based on the solubility of monosodium urate. For instance, the threshold 
level of deposition of monosodium urate is 0.36 mmol/l at 35 °C and 0.27 mmol/l at 30 °C [14]. 
However, gout attacks mostly occur in the extremities where body temperature is the lowest and 
the solubility of monosodium urate is smaller. It is shown that recurrent gouty attacks are better 
prevented and that tophi dissolve more quickly with target serum urate levels below 0.30 mmol/l 
(5.0 mg/dl) compared with levels 0.30-0.36 mmol/l [15-19]. For this reason, the British Guideline 
2007 sets the sUr treatment goal for gout patients at ≤0.30 mmol/l [2]. 
In order to get more evidence-based data, we investigated the efficacy and tolerability of dose-
escalation of allopurinol versus benzbromarone to attain a target sUr of ≤0.30 mmol/l. 
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Methods 
This prospective, multi-centre, open label, randomised controlled trial was carried out in 
successive patients, previously untreated, recently diagnosed with gout by a rheumatologist. 
Eligibility criteria were (1) a diagnosis of gout, confirmed by microscopic evidence of urate 
crystals in punctate from synovial fluid or peri-articular structures or presence of tophi, (2) no 
history of having used one of the study drugs, (3) no relevant liver disease, (4) renal function 
defined as calculated creatinine clearance (cCrCl) ≥50 ml/min calculated by the formula of 
Cockcroft and Gault, and (5) an indication for antihyperuricemic drug therapy: presence of tophi 
or frequent attacks (>2/year) [20-24]. Before entering the study and after each treatment period, 
liver function, serum creatinine (sCr) and calculated Cr clearance, sUr, urinary creatinine 
excretion (uCr), and urinary urate excretion (uUr) on unrestricted purine diet were measured. In 
addition, in patients using allopurinol, serum oxipurinol concentrations were measured after 
each treatment period. Underexcretion of urate was defined as urate clearance (UrCl) 
<6.0 ml/min per 1.73 m2 [24]. Urate clearance was calculated by urinary volume (converted to 
ml/min)*urinary urate concentration/sUr and normalised for a body surface area of 1.73 m2. 
Overproduction of urate was defined as uUr >6.0 mmol/day. Normal excretion of urate was 
defined as UrCl ≥6.0 ml/min per 1.73 m2 and uUr ≤6.0 mmol/day. Reported adverse events 
were checked on causality by the Naranjo Causality Scale [25]. Reported adverse events 
classified as doubtful were not included as adverse drug reactions in the tolerability evaluation. 
When included in the study, patients were assigned to an inclusion number by the 
rheumatologist (blinded) and consequently randomised to allopurinol or benzbromarone 
treatment. A computer-generated central randomisation schedule with a block size of six was 
used. Study recruitment and follow-up was from July 2006 until December 2007. 
Patients were given allopurinol 300 mg once daily (several generic brands) in a step-up dosage 
scheme (100-200-300 mg/day, dosage raised every week) or benzbromarone 100 mg once 
daily (Desuric®; Prostrakan, Galashiels, United Kingdom). When treatment was tolerated and 
the treatment goal of sUr ≤0.30 mmol/l was not reached after 2 months, allopurinol dosage was 
doubled at once to 300 mg twice daily and benzbromarone dosage to 200 mg once daily. The 
dosage interval of allopurinol was set at twice daily at the higher dosage, because gastro-
intestinal tolerability might be better. Also, from a pharmacodynamic point of view, twice daily 
dosage yields higher serum trough concentrations which might give better enzyme inhibition. 
Treatment was evaluated again after 2 months. When treatment was not tolerated and patient 
withdrew from treatment, this was categorised as failure. When treatment was tolerated and 
target sUr was reached patient was categorised as successful. Defined daily doses are 
allopurinol 400 mg/day and benzbromarone 100 mg/day. 
Prophylaxis of gouty episodes with colchicine 0.5-1 mg/day was prescribed until target sUr level 
was reached (sUr ≤0.30 mmol/l); when colchicine was not tolerated, a non-steroidal anti-
inflammatory drug could be prescribed as an alternative. 
A randomised controlled trial with dose-escalation on the efficacy and tolerability of 
allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout 
87 
Primary endpoint was the percentage of patients tolerating the antihyperuricemic medication 
and attaining sUr concentration below 0.30 mmol/l after stage 1 or stage 2. Secondary endpoint 
was the relative decrease of sUr concentration attained with each treatment regimen. 
The study was approved by the Medical Ethical Review Board of the participating hospitals, and 
written informed consent was obtained from all participating patients. 
 
Statistics 
Power calculation was performed indicating that at least 22 patients were needed for evaluation 
in each treatment arm to prove a statistically significant difference between allopurinol and 
benzbromarone (based on an estimated 55% success rate for allopurinol 600 mg/day versus 
90% for benzbromarone 200 mg/day, α=0.05, β=0.20) [5-7]. We expected a loss to follow-up of 
25%, rendering a minimum of 60 patients for the study. SPSS 15.0 and 16.0 for Windows 
(SPSS Inc., Chicago, IL, USA) were used for data collection, data validation, data selection, and 
statistical analysis. Student’s two-sided t-test and Fischer-Boschloo’s unconditional test were 
used to compare the effectiveness of allopurinol and benzbromarone; 95%-confidence intervals 
of proportions were calculated using binomial distribution, and 95%-confidence intervals of 
differences of proportions using Agresti-Caffo [26-27]. Normality was verified with Kolmogorov-
Smirnov analysis. A p-value <0.05 was considered statistically significant. 
 
Results 
Sixty-eight patients were enrolled in the study (Figure 1). Violation of inclusion protocol occurred 
in three patients (calculated creatinine clearance was <50 ml/min), leaving sixty-five patients for 
analysis of baseline characteristics (Table 1). Thirty-six patients received allopurinol and 29 
received benzbromarone. Fifty-five patients (85%) were eligible for analysis of stage 1 results 
and fifty patients (77%) for analysis of stage 1+2. 
Results of stage 1 and 2 are presented in Table 2 and Figure 2. Treatment target was reached 
in 8 out of 30 patients (26%) applying allopurinol 300 mg/day; after increase of dosage, overall 
treatment success with allopurinol 300-600 mg/day was 21 out of 27 patients (78%). With 
benzbromarone 100 mg/day, treatment target was reached in 13 out of 25 patients (52%); after 
increase of dosage, overall treatment target with benzbromarone 100-200 mg/day was reached 
in 18 out of 23 patients (78%). Two patients stopped allopurinol and 3 patients stopped 
benzbromarone because of adverse drug reactions (ADR), Table 3. No additional ADR were 
reported after increase of dosages of allopurinol and benzbromarone. At stage 1, the success 
rates are 8/31=0.26 and 13/25=0.52, and the difference is 0.26-0.52= -0.26 (CI95% from -0.486 
to -0.005), p=0.049. At stage 2, the success rates are 21/27=0.78 and 18/23=0.78, and the 
difference is -0.005, (CI95% from -0.223 to 0.220), p=1.00. 




Flow of participants through each stage of the study. 
Legend: cCrCl: calculated creatinine clearance. 
 
 
68 Assigned to treatment protocol
  6 Excluded from analysis:
       4  Lost to follow-up
       1  Protocol violation
  31 Included for analysis
       28  Completed
         2  Adverse events
8 Success after stage 1
Stage 1
  17  Included for analysis
  4 Excluded from analysis:
     2  Lost to follow-up
     2  Protocol violation
 1  Excluded from analysis:
  1  Lost to follow-up
  7  Included for analysis
  3 Did not meet inclusion criteria:
     3 cCrCl <50 ml/min
  36 assigned to allopurinol
300 mg/day
 29 assigned to benzbromarone
  100 mg/day
   4  Excluded from analysis:
         3  Lost to follow-up
         1  Poor adherence
  25 Included for analysis
       22  Completed
         3  Adverse events
 13 Success after stage 1
   1 Decrease in renal function
  21 assigned to allopurinol
600 mg/day
Stage 2
 8 assigned to benzbromarone
  200 mg/day
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Age (y) mean [± SD] 
range 
58.6 [± 12.3] 
33-77 
59.6 [± 11.3] 
39-80 
Male gender (%) 81% 83% 
Tophaceous gout (%) 53% 48% 









Body mass index (kg/m2) mean [± SD] 
range 
29.4 [± 4.8] 
21.5-42.6 
30.5 [± 6.9] 
17.2-54.9 









Research site Medisch Centrum Leeuwarden 
Ziekenhuisgroep Twente 








sUr (mmol/l) mean [± SD] 
range 
0.54 [± 0.09] 
0.39-0.83 
0.51 [± 0.08] 
0.34-0.70 
uUr (mmol/day) mean [± SD] 
range 
3.4 [± 1.3] 
1.5-7.7 
3.4 [± 1.3] 
1.3-6.3 
UrCl (ml/min/1.73m2) mean [± SD] 
range 
3.7 [± 1.3] 
1.5-6.8 






  3% 
  3% 
89% 
  3% 
  8% 
Legend: NS = non-significant (p>0.05); sUr = serum urate; uUr = urate excreted in urine; UrCl = urate clearance; y = year(s). 
1 Data shown as mean [± standard deviation] or percentage, unless stated otherwise. 
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Reduction of serum urate levels with allopurinol were 33% [± 13%] using 300 mg/day, and 49% 
[± 14%] using 600 mg/day, compared to baseline sUr. Increase of allopurinol dosage to 
600 mg/day in patients above target sUr after stage 1, resulted in an additional sUr decrease of 
32% [± 16%] compared to the sUr attained in these patients using allopurinol 300 mg/day. 
Using benzbromarone, reduction of serum urate levels: 42% [± 15%] using 100 mg/day, and 
46% [± 8%] using 200 mg/day, compared to baseline sUr. Increase of benzbromarone dosage 
to 200 mg/day in patients above target sUr after stage 1, resulted in an additional sUr decrease 
of 29% [± 6%] compared to the sUr attained in these patients using benzbromarone 
100 mg/day. 
 
Table 2. Efficacy of allopurinol 300-600 mg/day versus benzbromarone 100-
200 mg/day after stage 1 and stage 2 1 
 Allopurinol Benzbromarone p-value 
Stage 1 and 2 results (n=27) (n=23)  
Dosage (mg/day) 300-600 100-200  







Treatment goal not reached withdrawn due to ADR 
sUr 0.31-0.36 mmol/l 










Stage 1 results (n=31) (n=25)  
Dosage (mg/day) 300 100  
Duration (months) mean [± SD] 
range 
2.3 [± 0.8] 
1.5-4.9 
2.2 [± 0.7] 
1.6-3.2 
0.93 







Treatment goal not reached withdrawn due to ADR 
sUr 0.31-0.36 mmol/l 










sUr reached (mmol/l) mean [± SD] 
range 
0.34 [± 0.08] 
0.21-0.49 
0.29 [± 0.08] 
0.16-0.45 
- 
∆sUr from baseline -33% [± 13%] -42% [± 15%] 0.04 
uUr (mmol/day) mean [± SD] 
range 
2.2 [± 1.2] 
0.5-6.1 
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(Table 2 continued) 
 Allopurinol Benzbromarone p-value 
UrCl (ml/min per 1.73 m2) mean [± SD] 
range 
3.6 [± 1.5] 
1.0-8.0 
4.9 [± 2.2] 
3.0-20.6 
<0.001 
Serum oxipurinol (mg/l) mean [± SD] 
range 
13.1 [± 10.4] 
3.9-51.3 
- - 
Stage 2 results 2 (n=17) (n=7)  
Dosage (mg/day) 600 200  
Duration (months) mean [± SD] 
range 
2.5 [± 0.7] 
1.5-4.9 
2.3 [± 0.8] 
1.6-3.2 
0.71 
sUr reached (mmol/l) mean [± SD] 
range 
0.27 [± 0.07] 
0.18-0.38 
0.28 [± 0.04] 
0.23-0.35 
- 
Decrease of sUr  from baseline 
from stage 1 
-49% [± 14%] 
-32% [± 16%] 
-46% [± 8%] 
-29% [± 6%] 
- 
uUr (mmol/day) mean [± SD] 
range 
2.1 [± 1.0] 
1.1-3.5 
4.9 [± 2.2] 
2.1-8.1 
- 
UrCl (ml/min per 1.73 m2) mean [± SD] 
range 
4.3 [± 1.5] 
2.0-6.6 
10.3 [± 3.7] 
4.6-15.3 
- 
Serum oxipurinol (mg/l) mean [± SD] 
range 
17.0 [± 9.9] 
4.9-41.7 
- - 
Legend: CI95% = 95% confidence interval; NS = non-significant (p>0.05); sUr = serum urate; uUr = urate excreted in urine; UrCl = 
urate clearance. ADR = adverse drug reaction 
1 Data shown as n(%) or mean [± standard deviation] and range, unless stated otherwise. 
2 No statistical comparisons were done for stage 2 results because of incomparable groups due to selection bias 
 
 
 Chapter 3.4 
92 
Figure 2. Box-plot diagram for serum urate concentrations at baseline, and after 
stage 1 and stage 2 treatment with allopurinol or benzbromarone 
Results are depicted in 2 groups for each drug: all patients who completed stage 1 treatment, and all patients who 
completed stage 1 and 2, respectively. 
Legend: o = outlying value; dotted line = target serum urate concentration 
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Table 3. Results of reported adverse drug reactions (ADRs) leading to 
withdrawal, and all reported ADRs 1 




Number of patients with ADR  
  CI95% 
2 (7%) / 2 (7%) 
1-22% / 1-22% 
3(12%) / 5 (20%) 
3-31% / 7-40% 
Type of ADR   
  Dizziness and flushing - / - 1 (4%) / 1 (4%) 
  Gastro-intestinal - / - 2 (8%) / 2 (8%) 
  Hepatitis 2 - / - - / - 
  Gout flares  - / - - / 1 (4%) 
  INR increase  - / - - / 1 (4%) 
  Rash / skin reactions 
    severe skin reactions 
2 (7%) / 2 (7%) 
  - /   - 
- / - 
  - /   - 
Legend: CI95% = 95% confidence interval;  
1 Adverse drug reactions expressed as ADR leading to withdrawal (n(%)) / total ADR (n(%)) reported; one patient could report more 
than one ADR. 
2 Grade 2, 3 or 4 liver enzyme elevations. 
 
Discussion 
This study showed that treatment success, defined as reaching sUr ≤0.30 mmol/l, by 
administering allopurinol in patients with cCrCl ≥50 ml/min is significantly increased from 29% to 
78% by doubling the allopurinol dosage to 600 mg/day (p<0.001). Benzbromarone gives 
significant better treatment success at the starting dose (stage 1) compared to allopurinol, as 
was demonstrated in previous trials as well [28-29]. After dosage escalation (stage 2), no 
significant difference was found anymore in treatment success of allopurinol versus 
benzbromarone. 
We found a treatment success rate of allopurinol 300-600 mg/day (78%), which was higher than 
was reported in previous studies. Rundles et al. found a treatment success rate of 53% (CI95% 
29-76%) in 19 patients using allopurinol 600 mg [5]. Baseline sUr values in these 19 patients 
(sUr 0.56 [± 0.11] mmol/l) were comparable with values in our study. We might have obtained 
better results by using a twice-daily dosage scheme whereas Rundles et al. used once daily, as 
higher trough oxipurinol concentrations might give better xanthine oxidase inhibition. Allopurinol 
is approved for use up to 900 mg/day [2]. Even better results might be possible using this 
maximum dosage. In the Netherlands, a national guideline recommends a maximum of 700 mg 
allopurinol per day [30]. 
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Treatment duration of 2 months might be considered too short for treatment evaluation, 
especially in patients with poor renal urate excretion and consequently longer serum urate half-
lives. In non-gout subjects serum urate half-life is about 0.85 days [31]. In gout patients with 
severe underexcretion of urate of UrCl 1.5 ml/min (reference value is about 6 ml/min per 
1.73 m2), thus we estimated that corresponding serum urate half-life is about 4 days. As steady-
state is established within 5 half-lifes, a 2-months treatment period should be sufficient for 
evaluation of allopurinol treatment, even when we take the allopurinol step-up dosage scheme 
into account. In addition, decrease of sUr with allopurinol 300 mg/day in our study is 
comparable with previous studies with a longer treatment period [32]. 
Treatment success of benzbromarone increased from 52% to 78% by titrating dosage up to 
200 mg/day (p=0.075). Treatment success of benzbromarone was somewhat lower than 
expected from our previous study, in which we found a 92% treatment success with benz-
bromarone 200 mg/day in 24 patients [7]. A lower success percentage in the current study 
might be caused by some non-adherent patients, due to a different trial design (i.e. exclusion of 
patients with low medication adherence to allopurinol in subsequent benzbromarone or 
probenecid treatment group), and lower tolerability rate. We did not find other data on the sUr 
lowering effect and treatment success of benzbromarone 200 mg/day. 
Adherence to gout medication is reported to be low in general [33]. In this study, we measured 
serum oxipurinol concentrations in the allopurinol group. All patients had measurable serum 
oxipurinol concentrations, and oxipurinol concentrations increased in each individual in whom 
the allopurinol dose was increased; reported reference values for allopurinol 300 mg/day are 5-
15 mg/l, but higher values may be obtained [22, 34]. Poor adherence by some patients in the 
benzbromarone group cannot be excluded. 
In this study, all patients were referred to a rheumatologist, which might predispose to inclusion 
of patients with more severe gout. Better results might be obtained in patients with less severe 
gout having lower baseline sUr levels. 
Allopurinol of different (generic) brands was used, which might enhance the variance of results. 
In the Netherlands, the requirement for bio-equivalence is that the 90%-confidence interval must 
be within 80-125% of the reference value. 
A matter of debate to which target sUr should be aimed for, still exists [35]. In the recent EULAR 
recommendations, a less strict target sUr of ≤0.36 mmol/l is proposed for gout treatment in 
general, whereas in case of severe gout the treatment target might be set lower.[1] Using a 
treatment goal of sUr of ≤0.36 mmol/l, treatment successes would be 85% for allopurinol and 
87% for benzbromarone. 
Tolerability rates found for allopurinol and benzbromarone did not statistically differ from data in 
other studies. All adverse drug reactions reported for allopurinol and benzbromarone occurred 
in stage 1, and these reactions have been described before [5, 36-37]. Gout flares might be 
caused by starting antihyperuricemic drug therapy due to mobilisation of urate related to rapid 
decline of sUr. One patient developed generalised exanthema after allopurinol was started at 
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100 mg/day, and one patient developed exfoliative dermatitis during stage 1. No hepatitis, 
defined as grade 2, 3 or 4 liver enzyme elevations, was seen with allopurinol or benzbromarone 
during the study period. Severe hepatotoxicity of benzbromarone is seen in rare cases, and led 
to withdrawal of benzbromarone in many countries. Recently, a mechanism for this 
hepatotoxicity was reported [38]. Patients with high renal urate clearances, e.g. by using 
uricosurics, have an increased risk of urate nephrolithiasis. Therefore, benzbromarone is 
relatively contra-indicated in patients with normal renal urate clearances. In our group of 
patients receiving benzbromarone, no urate nephropathy, nephro- or urolithiasis was reported, 
and no nephropathy was found by calculating creatinine clearances before and after therapy. 
This study was conducted in patients with a cCrCl ≥50 ml/min. Results cannot be extrapolated 
to patients with cCrCl <50 ml/min, because (1) allopurinol dosage then should be adjusted to 
renal function, and (2) the efficacy of benzbromarone drops gradually with decreasing renal 
function to inefficacy in presence of cCrCl lower than about 25 ml/min. 
We used sUr as a surrogate parameter for clinical success. Previous studies found that attained 
sUr is inversely related to prevention of recurring gout flares and to velocity of size reduction of 
tophi [16-19]. Therefore, sUr is considered an important parameter in clinical practice to 
evaluate success of antihyperuricemic drug therapy for gout in the long-term. 
There are few therapeutic options available to lower sUr to target levels other than the drugs 
used in this study. The uricosuric drug sulfinpyrazone is not widely used due to its adverse 
effects profile [39]. Probenecid was found to be less effective and less tolerated than 
benzbromarone [7]. Febuxostat, a novel xanthine oxidase inhibitor, was found to be more 
effective than allopurinol [32], however allopurinol dosage was fixed at 300 mg/day [40]. On the 
other hand, febuxostat may prove beneficial in patients with diminished renal function, as it is 
not renally excreted. A higher allopurinol dosage (i.e. 600 mg/day) in the aforementioned 
comparative study might have given endpoint results in which allopurinol and febuxostat would 
be quite similar. 
Another antihyperuricemic drug under development is pegylated uricase, aimed for patients 
unresponsive to current antihyperuricemic treatments. Since combination therapy of allopurinol 
and a uricosuric (benzbromarone or probenecid) gives additional lowering of serum urate, this 
might also be a beneficial option [41]. The impact of gout on work absence and productivity is 
substantial, so pharmaco-economic studies between the newer and older (out of patent) drugs, 
like allopurinol and benzbromarone, are necessary [42]. 
 
Conclusion 
In patients with gout and renal function defined as cCrCl ≥50 ml/min, increasing allopurinol 
dosage up to 600 mg/day and benzbromarone dosage up to 200 mg/day gives better treatment 
successes (both 78% success regarding sUr ≤0.30 mmol/l). No significant differences in 
treatment success were found between allopurinol and benzbromarone after dosage increase, 
and this increased dosage was well tolerated for both drugs. 
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Allopurinol is an antihyperuricemic drug used in the treatment of gout and the prevention of 
tumor lysis syndrome. Allopurinol and its active metabolite oxipurinol inhibit xanthine oxidase, 
which forms uric acid from xanthine and hypoxanthine. Therapeutic drug monitoring is an 
important option for evaluation and optimisation of allopurinol treatment in case of renal 
impairment, interaction with uricosuric drugs or to verify patient adherence. In this study we 
developed and validated a simple quantitative assay using reversed-phase high-performance 
liquid chromatography (HPLC) with UV-detection as a method for quantification of allopurinol 
and oxipurinol in human serum in the presence of different frequently used drugs. 
Methods 
The HPLC-UV method uses a mobile phase consisting of sodium acetate (0.02 M; pH 4.5), at a 
flow rate of 1.0 ml/min. Allopurinol and oxipurinol are detected by UV-absorption at 254 nm with 
a retention time of 9.9 min for oxipurinol and 12.3 min for allopurinol. Aciclovir is used as 
internal standard. 
Results 
Validation showed for allopurinol lower and upper limits of quantification of 0.5 and 10 mg/l and 
for oxipurinol 1 and 40 mg/l, respectively. The assay was linear over the concentration range of 
0.5-10 mg/l (allopurinol) and 1-40 mg/l (oxipurinol). Intra- and inter-day precision showed 
coefficients of variation <15% over the complete concentration range; accuracy was within 5% 
for allopurinol and oxipurinol. Endogenous purine-like compounds were separated from 
allopurinol, oxipurinol and aciclovir with a resolution factor >1.5. Exogenous purine-like 
compounds and co-medication frequently used by gout patients did not hinder the analysis due 
to the dichloromethane washing step or to low UV-absorpion at 253 nm. Serum levels of 
66 patients prescribed allopurinol 300 mg/day were determined using this HPLC-UV method. 
Measured serum allopurinol and oxipurinol concentrations in clinical practice showed large 
variability with a range of <0.5-4.3 mg/l for allopurinol and <1.0-39.2 mg/l for oxipurinol, 
respectively. 
Conclusion 
We developed an easy-to-operate and validated HPLC-UV method for the quantification of 
allopurinol and oxipurinol in human serum. This method was proven valid for samples of gout 
patients frequently using concomitant medications. 
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Introduction 
Allopurinol is worldwide the mainstay of modern treatment of gout and prevention of tumor lysis 
syndrome. Allopurinol - an isomer of hypoxanthine - and its active metabolite oxipurinol (allo-
xanthine) act by inhibiting xanthine oxidase, an enzyme that forms uric acid (urate) from 
xanthine and hypoxanthine. 
Allopurinol can be administered either orally or intravenously. The oral bioavailability is about 
67% to 90% with a peak plasma concentration occurring within one hour; the volume of 
distribution is approximately 1.6 l/kg [1]. Allopurinol is principally metabolised by aldehyde 
oxidase to the active compound oxipurinol [2]. The peak plasma concentration of oxipurinol 
occurs within 3-5 h. Mean elimination plasma half lives range from 0.7 to 1.5 h for allopurinol 
and from 18 to 40 h for oxipurinol [1]. 
Allopurinol is excreted in urine for less than 10% unchanged and for 70% as oxipurinol; 20% is 
excreted in feces. In patients with renal impairment (creatinine clearance <80 ml/min [3]), the 
maintenance dosage of allopurinol must be reduced to prevent toxic effects related to increased 
oxipurinol serum levels [3-4]. When renal impairment is present, the initial allopurinol dosage 
can be calculated based on the estimated creatinine clearance (Table 1) [3]. Optimisation of 
individual allopurinol dosage can be done by targeting of the oxipurinol - steady state - serum 
concentrations [5-9] as advised in the product information of allopurinol [5]. Reference serum 
oxipurinol values that are considered therapeutic, range from 5 to 15 mg/l [9]. 
The renal excretion of oxipurinol is increased by co-administration of uricosuric drugs (e.g. 
probenecid and benzbromarone) that are also used to decrease serum urate levels, presumably 
by interaction at the URAT-1 transporter [10-11]. Combination of these drugs with allopurinol is 
frequently used in patients with severe gout, although, optimisation of allopurinol dosage by 
measuring oxipurinol serum levels might be necessary. Another indication for therapeutic drug 
monitoring (TDM) is to verify a patient’s adherence to the use of allopurinol, which in general is 
reported to be a point of concern [12-13]. 
Several methods are described for the analysis of allopurinol and oxipurinol in human serum. 
However, these published methods, using reversed-phase high-performance liquid 
chromatography, might have several limitations [14-22]. For example, (1) lack of information on 
chromatographic interference on detection and quantification of the analytes by concomitant 
medications frequently used by gout patients; (2) upper limits of quantification not covering the 
complete concentration range as observed in clinical practice; and (3) absence of stability data 
of allopurinol and oxipurinol in serum kept under refrigerated conditions. 
The objective of the present study was to develop and validate a new analytical method that 
enables measurement of allopurinol and oxipurinol in representative serum samples obtained 
from daily clinical practice. 
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Table 1. Maintenance dosage of allopurinol (for adults) based on individual 
creatinine clearance measurements [3, 8] 
Creatinine clearance (ml/min) Maintenance dosage of allopurinol 
0-20 100 mg daily 
20-60 200 mg daily 




The chromatographic system consisted of a Merck-Hitachi L-6200 pump (Merck-Hitachi, 
Darmstadt, Germany), a Series 200 autosampler (Perkin-Elmer, Wellesley, MA, USA), and a 
Spectroflow 757 variable absorbance detector (Kratos Analytical, Manchester, UK). Isocratic 
chromatographic separation was performed on a reversed-phase LiChrospher 100 RP-18 
column (5 µm; 250×4 mm; Merck, Darmstadt, Germany) connected to a precolumn (LiChroCart 
Guard column 4-4 packed with Lichrospher 100 RP-18, 5 µm, 15 mm; Merck, Darmstadt, 
Germany). The column temperature was maintained at 32.5 °C (Column heater 530; Alltech, 
Breda, The Netherlands). 
The mobile phase consisted of a 0.02 M sodium acetate solution adjusted with acetic acid 30% 
to pH 4.5. All samples and standard solutions were chromatographed using this mobile phase 
(flow rate 1.0 ml/min), an injection volume of 40 µl, and UV-detection at 254 nm. Time between 
injections was 25 min. 
Data from each chromatographic run were processed using TotalChrom version 6.2 (Perkin-
Elmer). Concentrations were calculated from the peak height ratios in relation to the internal 
standard. 
 
Preparation of the mobile phase 
The mobile phase was prepared by dissolving 2.72 g NaCH3COO·3H2O in 1,000 ml distilled 
water (Versol Sterile water for irrigation, Laboratoire Aguettant, Lyon, France) and correcting the 
pH to 4.5 with acetic acid 30%. The mobile phase was filtered and degassed before use. 
 
Preparation of standard solutions and samples 
Stock standard solution of allopurinol (0.25 mg/ml) and oxipurinol (0.25 mg/ml) were prepared in 
distilled water. For dissolution, 1% (v/v) 0.1 M sodium hydroxide was added. Aciclovir was 
dissolved in distilled water (0.1 mg/ml) and used as an internal standard. 
Stock solutions, stability samples and patient samples were stored at −20 °C for 5 months. 
Patient serum samples were prepared by adding aciclovir solution (10 µl) as an internal 
standard to serum (100 µl) followed by mixing with 10% perchloric acid solution (50 µl). 
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After cooling in the refrigerator for 10 min, dichloromethane (200 µl) was added. After shaking 
the mixture for 30 s, it was centrifuged at 4,000 rpm for 5 min. The aqueous supernatant 
solution was analysed with HPLC-UV. 
Quality control standards and samples for stability testing were prepared by spiking blank 




We used a method validation program based on the criteria developed by the European Agency 
for the Evaluation of Medical Products [23]. The limit of detection (LOD) was calculated using 
S/N = 3 and the lower limit of quantification (LLOQ) was calculated using S/N = 10 (S/N = 
signal-to-noise ratio). Peak height was used for quantification. Linearity was examined over the 
complete concentration range of allopurinol (0.5-10 mg/l) and oxipurinol (1-40 mg/l) by testing 
nine different concentrations in duplo. Linearity was analysed using the lack of fit test and the 
goodness of fit test. 
Selectivity was examined by studying the possible interference of endogenous peaks and 
various co-medications with the determination of allopurinol, oxipurinol and the internal standard 
aciclovir. Acceptance criterion for lack of interference was a resolution factor (Rs) between the 
peaks of allopurinol, oxipurinol and internal standard and the peak of each potentially interfering 
substance greater than 1.5. Substances were evaluated by preparing test solutions. Drugs and 
endogenous substances studied were non-steroidal anti-inflammatory drugs (acetylsalicylic 
acid, diclofenac, etoricoxib, ibuprofen, indomethacine, naproxen, piroxicam, propyphenazone, 
salicylic acid), cardiovascular drugs (bisoprolol, furosemide, hydrochlorothiazide, lisinopril, 
losartan, metoprolol), endogenous purines and xanthines test-solution (adenine, adenosine, 
creatinine, hippuric acid, hypoxanthine, guanine, guanosine, inosine, orotate, pseudo-uridine, 
thymine, uracil, urate, xanthine, xanthosine), xanthine derivatives (caffeine, paraxanthine, 
theobromine, theofylline), acetaminophen, colchicine, metformine, omeprazole and simva-
statine. 
The intra-day reproducibility was examined by analyzing four independent preparations of each 
standard concentration, each injected five times, on the same day. Inter-day reproducibility was 
examined by analyzing four independent preparations of each concentration, each injected five 
times, on three different days within a period of two weeks. For each day, freshly prepared 
standard solutions were made. All standard solutions were prepared from an independent 
standard stock solution. The calibration curve used for calculating patient samples was the 
calibration curve determined from all data of the four separate repetitions of intra-day 
reproducibility testing. These data were fitted using least sum of squares analysis. Criteria for 
acceptance for each separate calibration curve were a regression coefficient of >0.99 and a 
back-calculated concentration within 15% of the respective target concentration. 
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Stability testing was based on the guidance of the Food and Drug Administration [24]. Stability 
of allopurinol 0.5 and 8 mg/l and oxipurinol 1 and 30 mg/l in human serum was studied by 
repeated, duplicate analysis. The solution was divided into 3 ml aliquots and kept frozen at 
−20 °C until the moment of analysis. Samples were analysed at week 0, 1, 2, 4, 10 and 22. 
Furthermore, stability after two freeze-thaw cycles and after 24 h storage at room temperature 
was tested. Also, the stability of stock solutions kept frozen at −20 °C for 5 months was verified. 
 
Chemicals 
Dichloromethane and sodium acetate trihydrate were purchased from Merck (Darmstadt, 
Germany). Allopurinol was purchased from Bufa (Uitgeest, The Netherlands) and oxipurinol 
from Sigma-Aldrich (St. Louis, USA). Aciclovir was purchased from Mayne Pharma (Melbourne, 
Australia). Perchloric acid was purchased from Mallinckrodt Baker (Phillipsburg, USA). 
Human serum was purchased from a pool of anonymous and unpaid, healthy volunteers. 
 
Patient samples 
All consecutive patients visiting our outpatient department of rheumatology from June 2005 to 
June 2006 were asked to participate in a study for evaluation of allopurinol 300 mg/day 
(ISRCTN21473387, http://www.controlled-trials.com). After eight weeks of treatment a single 
venous blood sample in anticoagulant free containers was taken for determination of allopurinol 
and oxipurinol concentrations. After sampling, blood was directly centrifuged and serum was 
kept frozen at −20 °C. Directly prior to analysis, samples were processed as described above. 
In case of serum concentrations of allopurinol or oxipurinol above the upper limit of 
quantification, samples were diluted 1:1 with blank human serum and reanalysed. All patient 
samples were injected twice, comparable to standard and control samples. 




With the described method, Rs >1.5 of allopurinol, oxipurinol and the internal standard 
(aciclovir) was achieved (Figure 1). The retention times of oxipurinol, allopurinol and aciclovir 
are 9.9, 12.3 and 17.7 min, respectively. Chromatographic performance depended on column 
temperature. Because no cooling device and air conditioning was available, we used a column 
heater and evaluated column temperatures 30-40 °C. Best results were obtained with a column 
temperature of 32.5 °C. Recovery after deproteinising and washing with dichloromethane was 
estimated at 65% for allopurinol and 75% for oxipurinol. 
Chromatogram of blank human pooled serum sample is displayed in Figure 1a. Testing 
endogenous purine- and xanthine-like compounds showed several peaks (which were not 
further identified); important peaks for validation eluted at 8.9 min, 11.8 min and 19.4 min. 
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Exogenous purine- and xanthine-like compounds and co-medication frequently used by gout 
patients did not show any peaks (due to the dichloromethane washing step or low UV-absorpion 
at 253 nm). 
The LOD was calculated as 0.1 mg/l (4 ng) for allopurinol and 0.2 mg/l (8 ng) for oxipurinol and 
the LLOQ was calculated as 0.4 mg/l (16 ng) for allopurinol and 0.6 mg/l (24 ng) for oxipurinol. 
The calibration curve for allopurinol and oxipurinol was linear over the full concentration ranges 
of allopurinol 0.5-10 mg/l and oxipurinol 1.0-40 mg/l. 
Table 2 shows the results of the intra-day and inter-day reproducibility, respectively. Coefficients 
of variation and accuracy for intra-day and inter-day reproducibility are within 15% over the 
concentration ranges of allopurinol 0.5-10 mg/l and oxipurinol 1.0-40 mg/l. Based on these 
results, using this method the lower and upper limits of quantification of allopurinol are 0.5 and 
10 mg/l, respectively, and the lower and upper limits of quantification of oxipurinol are 1.0 and 
40 mg/l, respectively. 
Results from the assays for studying long-term stability, freeze-and-thaw stability and 
autosampler stability of allopurinol and oxipurinol are shown in Table 3. Samples show 
acceptable long-term stability for at least 5 months, with differences between the baseline 
concentration and concentration at follow-up <20% for the samples at the lower limit of 
quantification and <15% for samples at the higher limit of quantification. Good stability of 
allopurinol and oxipurinol was found after two freeze-thaw cycles and after 24 h storage at room 
temperature. Furthermore, good stability of stock solutions was found for at least five months 
(data not shown). 
 
Table 2. Intra- en inter-day reproducibility for assay of allopurinol and oxipurinol 
in human serum by high-performance liquid chromatography 















0.52 0.53 ± 0.01 2.1 1.4 0.53 ± 0.05 10.1 2.4 
2.6 2.53 ± 0.11 4.2 –2.2 2.49 ± 0.10 3.9 –3.7 
Allopurinol 
7.8 7.96 ± 0.11 1.3 2.5 7.74 ± 0.22 2.9 –0.4 
1.0 1.02 ± 0.04 3.6 0.3 1.07 ± 0.07 6.6 4.7 
10.2 10.2 ± 0.14 1.4 –0.1 10.2 ± 0.28 2.7 –0.4 
Oxipurinol 
30.7 31.3 ± 0.32 1.0 1.8 30.5 ± 1.2 3.8 –0.6 
Legend: CV = coefficient of variation; 1 five repetitions each; 2 three separate days, five repetitions each day; 3 mean ± standard 
deviation; 4 relative deviation (%). 
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Figure 1. Chromatograms of allopurinol and oxipurinol analysis in human serum 
 
Retention times are 9.9 min for oxipurinol (1), 12.3 min for allopurinol (2), and 17.7 min for aciclovir (3; internal standard).  
(A) Blank pooled human serum; (B) allopurinol 0.5 mg/l and oxipurinol 1.0 mg/l; (C) allopurinol 4.0 mg/l and oxipurinol 20 mg/l. 
 
Patient samples 
Sixty-six blood samples were taken for determination of allopurinol and oxipurinol 
concentrations. Patient characteristics are given in Table 4. Measured serum concentrations 
show large variability, ranging from <0.5 to 4.3
 
mg/l for allopurinol and from <1.0 to 39.2
 
mg/l for 
oxipurinol. Median concentrations are <0.5
 
mg/l for allopurinol and 11.5
 
mg/l for oxipurinol 
(43 patients with allopurinol serum concentration <0.5 mg/l). 
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Table 3. Stability results of allopurinol and oxipurinol in human serum. Test 
samples were measured in 2-fold; reference samples were measured in 5-fold. 1 
 Allopurinol Oxipurinol 
Long-term stability (–20 °C) 
reference (n=5) mean 0.52 mg/l 7.89 mg/l 0.98 mg/l 30.7 mg/l 
1 week (n=2) deviation –2.4% –6.4% –0.7% –2.9% 
2 weeks (n=2) deviation –15.1% –1.7% –4.9% 0.6% 
4 weeks (n=2) deviation –0.8% –1.9% 5.8% –1.9% 
10 weeks (n=2) deviation –4.6% –1.1% 7.4% –0.1% 
22 weeks (n=2) deviation 13.9% –5.4% 1.1% 0.6% 
Freeze-and-thaw stability 
reference (n=4) mean 0.58 mg/l 8.52 mg/l 1.09 mg/l 31.3 mg/l 











reference (n=5) mean 2.87 mg/l  10.6 mg/l  







Legend: CV= coefficient of variation. 
1 Stability results stated as relative deviation from reference (%); 
 
Table 4. Characteristics of patients included for determination of allopurinol and 
oxipurinol concentrations. 1 
Characteristics TDM population 
Number of patients 66 
Age (y) mean [± SD] 58 [± 13] 
Male gender (%) 91% 
Body mass index (kg/m2) mean 
range 
29 [± 4.7] 
20.3-48.9 




Prescribed daily allopurinol dose (mg) 300 
Legend: SD = standard devation. 
1 Calculated by Cockcroft and Gault formula. 
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Discussion 
Our HPLC-UV method for the quantification of allopurinol and oxipurinol in human serum 
samples is easy-to-operate, valid, and advantageous over other methods described in literature. 
Our method shows acceptable intra- and inter-day accuracy and precision over the allopurinol 
concentration range 0.5-10
 
mg/l and oxipurinol concentration range 1-40
 
mg/l. We did not 
investigate concentrations allopurinol >10 mg/l and oxipurinol >40 mg/l, because we considered 
it not clinically relevant. Because allopurinol, and to a lesser extent oxipurinol, are soluble in 
dichloromethane, no complete recovery was found after deproteinising and washing. 
Endogenous serum peaks and concomitant medication frequently used by gout patients, did not 
interfere with the detection and quantification of allopurinol and oxipurinol in the current HPLC-
UV method. The method is not appiclable to patients using aciclovir or valaciclovir due to the 
choice of internal standard. 
Short-term stability of allopurinol and oxipurinol in human serum kept frozen at −20
 
°C is shown 
for at least 5 months until the moment of analysis, which enables collection of samples for 
periodical analysis in clinical practice. 
Hyperuricemia is frequently accompanied by cardiovascular risk factors and the metabolic 
syndrome [25], which results in hypertension, hyperglycemia and dyslipidemia. Therefore, gout 
patients often have multiple drug use. Prior research had several major limitations regarding (1) 
information on interference of detection and quantification of allopurinol and oxipurinol by 
endogenous compounds and frequently used co-medication by gout patients; (2) an upper limit 
of quantification of oxipurinol that did not cover the complete concentration range expected to 
be obtained in patient samples; (3) information about the stability of the analyte [14-22]. In 
addition, we used a washing step with dichloromethane to extract relatively hydrophobic 
substances, thereby reducing the amount of possible interferences and late-eluting substances 
(e.g. caffeine). 
Looking at the blank plasma chromatogram (Figure
 
1a), several peaks elute in the front. We did 
not identify these peaks individually, because we used a combined purine test-solution. 
However, giving these and previous results [16,
 
21], the front peaks might include uric acid, 
hypoxanthine and xanthine, which can be of interest when a method for biochemical or 
metabolic purpose is needed. 
The samples injected are very acidic (pH
 
0.5). Previously, it was suggested to use ammonium 
sulfate for precipitation instead of a strong acid solution (perchloric acid as in our method or 
trichloroacetic acid as described by Kramer et al. [22]), because itwas found that the low pH of 
the injected samples could shorten column
 
life [26]. Recently, Tada et al. did not find any 
column deterioration using acidic samples and a buffered mobile phase (100 mM potassium 
phosphate; pH
 
4.0) [14]. Using a buffered mobile phase, we injected more than 300
 
samples as 
described in the methods section. We did not experience any deterioration in the performance 
of analyzing allopurinol and oxipurinol (nor in the routine analysis of flecainide using the same 
column). 
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We used and validated this method with flow of 1.0
 
ml/min resulting in a runtime of 24
 
min, 
which was rapid enough for our purpose. When a more rapid method is preferred, a method 
might be set up with a flow of 2
 
ml/min, as described previously [14]. 
To study the applicability of the validated method in clinical practice, a series of patient serum 
samples were analysed for allopurinol and oxipurinol concentrations. The serum concentrations 
found are characterised by large inter-individual variation. This might be explained by 
differences in therapy adherence, sampling time compared to the last drug intake, variations in 
renal function and variations in body composition. The upper limit of quantification of our 
method covers all of the allopurinol and oxipurinol concentrations found in the patient samples 
in our study. The LLOQ of allopurinol and oxipurinol was based on the detection limit of our 
method. The LLOQ of oxipurinol is sufficient for use in clinical practice with regards to the 
therapeutic range (results below the lower limit of quantification questions patient’s adherence 
to allopurinol). Because of the short elimination half-life of allopurinol of 0.5-2 h, serum trough 
concentrations found for allopurinol are predominantly below the LLOQ. However, since peak 
serum levels of allopurinol range from 1-5 mg/l, measuring serum allopurinol can provide 
additional information about the dosing-sampling interval and consequently puts the measured 
serum oxipurinol concentration in perspective. 
 
Conclusion 
We developed an easy-to-operate and validated HPLC-UV method for the quantification of 
allopurinol and oxipurinol in human serum for use in clinical practice. The method was shown to 
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Summary 
A 74-year-old female patient with gout, presented because of ongoing tophaceous 
accumulation. Seventeen years ago, she had a renal transplant. At presentation, her serum 
urate was 0.71 mmol/l (11.9 mg/dl) with a urinary excretion of 2.7 mmol/day (45 mg/day); the 
calculated glomerular filtration rate (cGFR) was 30 ml/min. Antihyperuricemic treatment was 
started with low dose allopurinol, adjusted to cGFR. Because of low urate clearance, 
benzbromarone was added to allopurinol. Doses were gradually increased up to allopurinol 
150 mg/day and benzbromarone 150 mg/day: serum urate level stabilised at 0.32-0.41 mmol/l 
(5.4-6.9 mg/dl). Because of recurrent febrile periods due to arthritic gouty periods, she was 
admitted repetitively to the hospital. Uricolytic treatment with weekly rasburicase up to three 
months was started successfully. The use of rasburicase in this case is discussed and review of 
its use in gout is presented. 
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Case report 
A 74-year-old female patient suffered from severe tophaceous gout with massive tophaceous 
accumulation, particularly in the lower extremities, Figure 1. Renal transplantation was 
performed 17 years ago for the diagnosis: cystic kidney disease with end-stage renal failure. 
She presented at the rheumatology department in 2002, because of accumulation of 
subcutaneous white material without recurrent arthritis. Tophaceous gout was confirmed by 
polarisation microscopy. Calculated glomerular filtration rate (cGFR) of the donor kidney was 
30 ml/min, serum urate (uric acid) concentration (sUr) was 0.71 mmol/l (11.9 mg/dl) and urinary 
excretion of urate (uUr) was 2.7 mmol/day (45 mg/day). Urate lowering treatment (UrLT) was 
started with the xanthine oxidase inhibitor allopurinol, and because of low urate clearance, the 
URAT-1 modulator benzbromarone was added. In an attempt to lower sUr below 0.30 mmol/l 
(5.0 mg/dl), doses were gradually increased up to allopurinol 150 mg/day and benzbromarone 
150 mg/day since 2005. Because of her decreased renal function, serum steady state oxipurinol 
concentrations were measured regularly. The values ranged between 13.0 and 16.0 mg/l, which 
is at the higher range of the therapeutic window (5-15 mg/l). With the allopurinol/benzbromarone 
combination 150mg/150mg daily, sUr was lowered to 0.32-0.41 mmol/l (5.4-6.9 mg/dl). Co-
medication consisted of acenocoumarol, dipyridamole, doxazosin, enalapril, fluvastatin, 
furosemide, lactulose, metoprolol, mycophenolate mofetil, pantoprazole, prednisolone, 
temazepam and tramadol. Despite UrLT, serum urate levels did not reach target level and tophi 
did not diminish. She also suffered from frequent febrile periods with simultaneous arthritic 
attacks of the knee, in which monosodium urate crystals were proven. 
For debulking tophaceous disease, treatment with 9 mg rasburicase (Fasturtec®) infusion was 
started in July 2006: 0.15 mg/kg every week infused in 30 min, after testing serum uric acid 
concentrations and urinary urate excretion during one week, Figure 2. To check for in vitro 
degradation of urate by rasburicase pesent in the serum sample, all samples were taken in two-
fold, and one of them was cooled and processed immediately. No significant in vitro degradation 
of urate was encountered. 
Rasburicase is obtained by recombinated DNA technique from a genetically modified strain of 
Saccharomyces cerevisia that expresses urate oxidase cDNA, cloned from a strain of 
Aspergillus flavus. In its present form it is available from 1996 and licensed in 2001 for tumor 
lysis syndrome. It breaks down urate to hydrophilic allantoin, which is excreted easily in urine 
even in diminished renal function. Prior to rasburicase infusion, clemastine 2 mg and methyl-
prednisolone 100 mg were given intravenously to prevent potential allergic reactions, and 
antibody formation. Colchicine 0.5 mg daily was added to prevent gouty attacks by urate 
mobilisation. The sUr level rapidly (within 4 hours) declined to <0.10 mmol/l (<1.6 mg/dl) 
following the first rasburicase infusion, and remained below 0.10 mmol/l during 2 days and even 
below <0.20 mmol/l (<3.2 mg/dl) during 4 days following infusion. Serum urate levels remained 
below 0.30 mmol/l (5.0 mg/dl) during the first 14 days after one rasburicase infusion, and uUr 
remained below 1.0 mmol/day (16 mg/day), Figure 2. Renal complications were not seen, i.e. 
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cGFR remained between 30 to 35 ml/min. Rasburicase was restarted 2 weeks after the first 
infusion in order to aim at monosodium urate debulking. These infusions were given weekly 
during a period of 3 months, Figure 2. However, she missed one infusion due to fever and 
malaise: she was unable to visit to our outpatient clinic for the rasburicase infusion. 
 
Results 
After 11 infusions, tophi were largely diminished, Figure 1. Erosive (sub)cutaneous defects were 
healing and arthritic febrile periods had vanished. After the first infusion, sUr levels decreased to 
below detection levels for a period of several days. Within a week serum urate concentrations 
increased, but remained below the target of 0.30 mmol/l (5.0 mg/dl). Serum urate 
concentrations were 0.28-0.31 mmol/l (4.7-5.2 mg/dl) during 9 months after the last rasburicase 
infusion was given, and febrile attacks had vanished. 
 
Figure 1. Result of debulking of tophi before rasburicase (A), and after 
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Figure 2. Serum urate concentration (sUr) and daily urinary urate excretion (uUr) 
during rasburicase treatment 
(A) 2 weeks following one intravenous rasburicase infusion (arrow) at day 0, administered promptly following the 
baseline values; 
(B) 14 weeks following weekly intravenous rasburicase infusions (n=11) during 12 weeks, values demonstrated were 
measured each time just prior to rasburicase infusion 
Legend: 1.0 mg/dl urate = 0.6 mmol/l urate. 
 
Discussion 
Long-term persistence of a positive urate balance may have serious sequelae, besides tophus 
formation. Tophaceous gout frequently occurs in renal transplant patients, they are often 
predisposed because of diminished renal function and use of cyclosporin A [1]. In untreated 
chronic gout, urate accumulation may cause lesions mimicking malignancy, purulent abscesses, 
neurological compression, heart-valve defects, intestinal wall perforation, and cutaneous 
calcinosis [2]. Optimal treatment of tophaceous gout aims at a negative urate balance. 
Commonly, this is attained using a diet poor in purines plus xanthine oxidase inhibition 
(allopurinol, possibly in the near future febuxostat). In resistant cases, allopurinol is combined 
with benzbromarone or probenecid [3]. 
Treatment with benzbromarone gives good response in treatment of tophaceous gout patients, 
possibly better than allopurinol [4-5]. However, because of location of the site of action of 
URAT-1 modifiers (uricosurics) in the proximal tubulus, uricosurics are less effective in 
moderate to severe renal disease. Benzbromarone is not effective with a GFR <25 ml/min and 
probenecid is not effective with a GFR <50 ml/min [6]. 
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Treatment of severe (tophaceous) gout with traditional antihyperuricemic agents is by definition 
not effective when a negative urate balance cannot be reached. Persistence of a long-term 
positive urate balance, either because of compliance or because of tolerance problems, may 
result in the severe aforementioned sequelae. An area of uncertainty is still the risk-benefit 
balance of high-dose allopurinol (300-900 mg/day, depending on renal function), especially in 
patients with rena; function impairment, and related therapeutic serum oxipurinol reference 
values. 
When a tophaceous patient is compliant to and does tolerate the classic antihyperuricemic 
treatment, but has frequent gouty attacks and fever as in the case here described, treatment 
with a rasburicase for a fixed period should be considered. One has to realise though, that 
rasburicase is expensive, and not licensed for this indication. Furthermore, as patient numbers 
are small, clinical trials large enough for licensing of rasburicase for treatment of severe 
tophaceous gout are not likely to be performed. Therefore, all available information in literature 
must be collected and reviewed to build up evidence. 
 
Table. Overview of 6 tophaceous gout cases from literature and current case, in 
whom rasburicase was administered. 
Reference [2] [7] [8] 
Age (y) 65 33 57 
Gender male female male 
History advanced gout; 
acute abdomen; 
sUr = 0.71 mmol/l 
8 y post RT; 8-12 attacks/y, 
disabling tophaceous gout; 
sUr = 0.85 mmol/l 
chronic gout >30 y; 
destructive tophi, 
sUr = 0.40-0.60 mmol/l 
Prior UrLT 
  allopurinol 
  benzbromarone 
















q 1 d (for 7 d) 
0.15 mg/kg; 
q 2 w (for 6 m) + q 4 w (for 3 y) 
0.20 mg/kg; 
q 1 w (for 16 m) 
Corticosteroids + - + 
Indication fever colchicine-resistant gout UrLT-resistant gout 
Results sUr <0.39 mmol/l on day 
74, improvement of 
clinical condition and 
inflammatory markers 
sUr <0.66 mmol/l for 3 y, 
no gout attacks; improvement 
of functional capacity 
large reduction of tophi, 
sUr = 0.25-0.27 mmol/l 
Legend: CS = corticosteroid; d = day(s); m = month(s); RT = renal transplantation; UrLT = urate lowering treatment;  w = week(s); y 
= year(s). 
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Table (continued). 
Reference [9] [10] Current case 
Age (y) 56 72 74 
Gender female female female 
History duodenal ulcer; urate 
nephropathy;  
sUr = 0.60 mmol/l 
tophi; 
renal stones; diclofenac 
and colchicine intolerance 
17 y post RT; tophi; 
1 attack per y 
Prior UrLT 
  allopurinol 
  benzbromarone 

















10 infusions in 16 m 
14 mg; 
during 5 d 
0.15 mg; 
1 w (3 m) 
Corticosteroids - - + 
Indication allopurinol allergy allopurinol allergy 
urisocuric contra-
indication 
febrile periods with 
admissions 
Result restoration of functional 
capacity of hands, 
no gout attack after 6th 
infusion, sUr <0.36 mmol/l 
rapid lowering of sUr; 
no attacks after day 4 for 
2 m after starting anakinra 
no febrile periods, 
sUr 0.28-0.30 mmol/l for 
9 m 
Legend: CS = corticosteroid; d = day(s); m = month(s); RT = renal transplantation; UrLT = urate lowering treatment;  w = week(s); y 
= year(s). 
 
The use of rasburicase and other uricases in gout 
Several case reports have already indicated clinical success using rasburicase treatment as 
ultimate treatment option in complicated tophaceous disease, Table [2, 7-10]. 
Rasburicase remains in the bloodstream exerting its enzymatic action. As a non-human protein 
it is rapidly degraded in the body, shortening its time of action. Therefore, every 1-2 weeks 
infusions must be given to maintain the negative urate balance. Infusions that are more frequent 
do not seem rational, because time is required for urate stores to dissolute and move into the 
bloodstream. In a recent study, rasburicase was effective in 6 monthly infusions in 5 patients, 
but not in 5 daily infusions in another 5 patients [11]. 
It is clear that rasburicase is capable of urate debulking in severe tophaceous gout. In this way, 
rasburicase might used as a bridging therapy, after which classic antihyperuricemic therapy can 
be used as preventive therapy for maintaining a negative urate balance [12]. Drawbacks may be 
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the risk of hypersensitivity reactions and adverse effects associated with hydrogen peroxide 
production in catalase deficient or glucose-6-phosphate dehydrogenase deficient patients [13-
14]. 
A novel approach is the pegylation technique of the urate oxidase enzyme, thereby slowing 
down the degradation process of the enzyme and prolonging the duration of action. In an open-
label phase I trial, single subcutaneous injections of PEG-uricase (4 to 24 mg) were 
administered to 13 subjects (tophaceous gout in n=11) [15]. In 5 out of 13 (38%) patients 
plasma uricase could not be detected beyond 10 days after injection due to IgM and IgG 
antibodies, remarkably against PEG. In another phase I clinical trial, single intravenous 
infusions of PEG-uricase (0.5 to 12 mg) were administered to 24 patients [15]. IgG antibodies to 
PEG-uricase were found in 9 out of 24 (38%) patients, resulting in a rapid enzyme clearance. 
Possibly, because the investigators asssumed that PEG-uricase has low immunogenic 
potential, the PEG-uricase infusions were not combined with corticosteroids, as we did in our 
case. Further studies with pegylated urate oxidase are to be awaited, and look promising in 
regards to efficacy. 
 
Conclusion 
In cases where antihyperuricemic or uricolytic therapy is contra-indicated, an option is to just 
inhibit attacks. If renal dysfunction is a contra-indication, just colchicine in low dosage and 
prednisolone can be considered. When renal function is adequate, NSAIDs and coxibs may be 
considered as well. An ultimate anti-inflammatory treatment option may be applied: anakinra, 
infliximab, or etanercept [10, 17-18]. However, these latter expensive therapies, merely 
focussing on quality of life, clearly do not aim at debulking of tophi, i.e. do not decrease serum 
urate levels. If more expensive treatment options are considered, it seems to be preferable to 
aim at rational options resulting in decrease of monosodium urate accumulations [19]. 
In our patient, who was compliant to allopurinol and benzbromarone, but did not reach target 
serum urate concentrations, weekly rasburicase infusion was successful in decreasing the urate 
bulk and resulted in a life free of episodic arthritic fevers. Uricase-derived therapies deliver a 
promising, but costly treatment option in the arsenal of therapies for complicated and treatment-
resistant gout patients. 
In patients with bulky disease refractory to classic antihyperuricemic therapy, rasburicase must 
be considered for debulking of tophi. Int his way, rasburicase might used as a bridging therapy, 
after which classic antihyperuricemic therapy can be used as preventive therapy. 
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Abstract 
We recently encountered a destructive case of tophaceous gout in a 57-year-old patient. 
Despite good therapy compliance, the patient failed in the conventional urate-lowering 
treatment, accounting for the ongoing urate retention and accumulation with progressive 
tophaceous bulky disease. Application of an experimental scheme of uricolytical therapy on this 
patient was able to reduce bulky disease significantly. In modern medicine, potent urate-
debulking medication with urate oxidase (uricase) derivatives is at our disposal, and it is a 
challenge for rheumatologists to install the right strategy including innovative approaches with 
potent uricolytic therapy on the right patient at the right time. 
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Introduction 
Gout, already described by Hippocrates in the 5th century BC, has become one of the best 
manageable rheumatic diseases due to availability of potent urate-lowering regimens [1-2]. 
More than 30 years ago, benzbromarone was marketed as the leading uricosuric in Europe, 
with probenecid and sulfinpyrazone as the most prominent uricosuric agents in North America. 
Allopurinol, the most prominent urate-production-reducing agent acting via xanthine oxidase 
inhibition, is combined with a uricosuric, the mainstay of the current treatment for gout [2-5]. In 
gout patients with a low urate excretor status, i.e. defined as <3.6 mmol/day while under a diet 
low in purines, uricosuric strategy was often the first-choice treatment. Since benzbromarone 
was withdrawn from the market in 2003, probenecid became the first-choice uricosuric in 
Europe as well as in America [6]. Still in less than 1% of gout patients, progressive tophaceous 
accumulation occurs, and then, a rational uricolytic regimen or merely a symptomatic anti-
inflammatory regimen is to be considered, as is recently described for etanercept [7]. We 
describe a patient in whom uricolytic therapy, i.e. rasburicase, was given as treatment for 
refractory bulky tophaceous disease, and indeed, rasburicase was able to reduce bulky disease 
significantly. Furthermore, an update on urate-lowering treatment is given. 
 
Case report 
A 57-year-old man (born in 1947) has been suffering from attacks of gouty arthritis since the 
late 1960s, i.e. when he was about 20 years of age. An attack took on average about 10 days, 
and the frequency of attacks increased to once every 4-6 weeks. Otherwise, he was healthy 
and used alcohol only sporadically. Family anamnesis did not reveal any other cases of gout. 
Over the years, he developed multiple tophi over his elbows, metacarpophalangeal joints, 
Achilles tendons and the first metatarsophalangeal joints. Upon presentation in 1989, he was 
given colchicine 0.5 mg twice daily, indomethacine 50 mg and allopurinol 300 mg daily. Despite 
this treatment, he had elevated serum urate (sUr) levels of about 0.40-0.60 mmol/l, and he kept 
having attacks of arthritic flares frequently. Biochemistry revealed elevated levels of cholesterol 
9.5 mmol/l (normal 3.6-5.9 mmol/l), triglycerides 19.8 mmol/l (normal 0.5-0.7 mmol/l) and 
gamma glutamyl transpeptidase 100 U/l (normal <45 U/l), but further laboratory findings were 
normal, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hematology 
parameters, thyroidstimulating hormone, electrolytes and glucose, creatinine phosphokinase 
and renal functions. A 24-h urine collection revealed uric acid excretion of 2.4 mmol on a normal 
diet. Upon physical examination, the results obtained were as follows: weight 90 kg, length 
1.92 m, blood pressure 160/90 mmHg. Multiple tophi were found which restricted the function of 
several joints. The levels of allopurinol and its metabolite oxipurinol in the serum indicated an 
adequate intake. He experienced gouty attacks at regular intervals even when the allopurinol 
dosage was increased to 600 mg daily. The size of the tophi gradually increased, and new tophi 
kept appearing. The addition of benzbromarone 200 mg and the increase of allopurinol to 
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900 mg daily did not improve his condition. Thus, probenecid was tried instead of 
benzbromarone, but he developed a severe itchy skin rash. In 1998, the largest tophi over the 
extensor sides of the olecranon were removed surgically. sUr level normalised for half a year, 
only to increase again gradually to 0.68 mmol/l. Finally, the allopurinol dosage was increased up 
to 1,800 mg daily. No side effects occurred despite the potentially toxic levels of allopurinol 
(13 mg/l) and oxipurinol (45 mg/l): sUr levels decreased slightly to 0.45-0.55 mmol/l. He kept 
having gouty attacks. 
 
Figure. Reduction of tophaceous bulky disease by rasburicase. 
At start (A) and after 1 year (B) of rasburicase infusions: debulking effect was clinically highly significant. 
 
In March 2002, he was admitted to receive daily rasburicase 0.2 mg/kg intravenously. The first 
dose was administered over a 30-min period. He started to complain of headache and dizziness 
during the first infusion. The next administrations were given the following 3 days over a 60-min 
period, and rasburicase was well tolerated during these infusions. Photographs of hands and 
feet were taken (see Figure 1). The sizes of two tophi dorsal from the third proximal 
interphalangeal (PIP) joint and the second metacarpophalangeal (MCP) joint of the right hand 
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were taken: both tophi measured 3.0×3.0 cm. Blood was drawn for sUr measurements twice 
during the first week, but concentrations were below detection limit: <0.01 mmol/l. 
The oral medication was continued unaltered: allopurinol 1,800 mg daily, colchicine 0.5 mg 
twice daily, and indomethacine as needed. After the first week, he continued to receive weekly 
infusions with the same dosage of rasburicase. Despite this medication, he had the tendency to 
develop a gouty attack following each rasburicase infusion. These attacks were prevented by 
simultaneous dexamethasone infusion. After three months of weekly infusions, dexamethasone 
could be stopped without the recurrence of the attacks. Prior to each infusion, sUr level was 
measured, but it showed a wide range from normal to >0.60 mmol/l. This was not considered as 
a failure in the treatment as the size of tophi continued to decrease. From November 2002, sUr 
level stabilised within the normal range, and no arthritic attacks occurred anymore. When 
intervals between two rasburicase infusions were changed from 1 to 2 weeks, he again 
experienced arthritic attacks, and sUr level promptly rose to >0.60 mmol/l. In January 2003, 
about 10 months after starting rasburicase, the size of both index tophi had decreased to 
1.5×1.5 cm. Since March 2003, he received a stable weekly dosage of rasburicase infusion and 
did not suffer from any attacks anymore. sUr level was stable between 0.25 and 0.27 mmol/l. 
Photographs were taken after 1 year of rasburicase infusions, clearly demonstratinga significant 
reduction in tophaceous bulk (Figure 1b). From the summer of 2003, 16 months after starting 
the rasburicase infusions, the infusion interval could be decreased from 1 to 2 weeks without 




Gout affects 0.5-2.8% of adult men and 0.1-0.6% of women, with a peak incidence in the fifth 
decade in men, rising substantially with aging [1-2]. Over the last decades, the incidence of gout 
has risen, which has been related to the changing dietary trends, increasing obesity and insulin 
resistance, rising longevity and increasing use of diuretics and/or prophylactic low-dose aspirin 
[1-2]. Recently, it was confirmed that the dietary content of meat and seafood consumption is 
associated with an increased risk of developing gout [8]. Several reviews considering the 
pharmacotherapeutic options have been published, Table 1 [2-4]. One may try to correct urate 
metabolism by a urate production inhibitor, allopurinol, and/or a stimulator of urate excretion, a 
uricosuric agent [5]: benzbromarone in Europe and primarily probenecid in North America. In 
2003, the benzbromarone prescription density in Europe has been diminished following the 
request of Sanofi-Synthélabo, the pharmaceutical company favoring the prescription density of 
probenecid in Europe [6]. The aforementioned conservative medication options only have a 
minor lytic effect on urate stores. More acutely, uricolysis can be attained by surgery and, 
theoretically, with uricase derivatives as well. Rasburicase is available for therapy-resistant 
gout, though it has only been licensed for tumor lysis syndrome in hematologic malignancies [9]. 
A uricase containing regimen may be indicated only in a minor group of gout patients with 
 Chapter 5.2 
132 
severe gout and failure in allopurinol treatment combined with a uricosuric regimen. Previously, 
Rozenberg et al. [10] have described the efficacy of uricase in heart transplant patients 
developing severe gout but who had contra-indications for allopurinol due to simultaneous 
treatment with azathioprine: combined use of allopurinol and azathioprine poses an increased 
risk of leukocytopenia. 
 
Table 1. Treatment options for gout 
I. Acute gout: anti-inflammatory drugs 
A. Licensed 
       Non-steroidal anti-inflammatory drugs (NSAIDs) 
       Colchicine 
       Glucocorticosteroid 
B. Experimental 
       Anti-TNFα: etanercept 
       Anti IL-1: anakinra 
II. Prophylactic use: urate-lowering drugs 
A. Low excretor status (inadequate urine excretion of urate): uricosuric agents 
       Benzbromarone 50-100-200 mg daily 
       Probenecid 250-500-1,000-2,000 mg daily 
       Sulfinpyrazone (not licensed in Europe) 
B. High producer: xanthine oxidase inhibitor 
       Allopurinol 50-100-200-300-600-900 mg daily 
C. Refractory gout: uricolytic drugs 
Rasburicase 0.2 mg/kg within 60-min infusion at days 1-4, then from month 16, one infusion weekly to one 
infusion every 2 weeks, then combined with dexamethasone 2.5 mg until the third month 
Abbreviations: IL = interleukin, TNF = Tumor nevrosis factor 
 
The major aim in tophaceous cases is depletion of urate stores. The total amount of urate in 
tophaceous cases can only be estimated. sUr levels can be measured during follow-up. 
Biochemically, the physical limit on solubility of uric acid in human serum (pH 7.4) at 37°C is 
0.404 mmol/l [11-12]. Uric acid is solubilised from monosodium urate crystals at ambient urate 
levels below 0.416 mmol/l and precipitated at levels above this [12]. Therefore, the physico-
chemical definition of hyperuricemia, elevated sUr, in men is any level above 0.41 mmol/l. This 
is the biochemical hallmark of gout. Clinically, gout is only proven by polarisation microscopy 
when urate crystals are found in the aspirate. Most patients with primary gout have developed 
hyperuricemia due to reduced renal urate excretion, i.e. most patients are underexcretors, 
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defined by a daily excretion of <3.6 mmol uric acid in urine while under a diet low in purines for 
at least a week. In a minority of gouty patients, hyperuricemia results from an increased rate of 
de novo purine biosynthesis, characterised by daily excretion of excessive quantities of uric acid 
>3.6 mmol on a diet low in purines. In the treatment phase, one may aim at the lowest 
concentrations; one can get somewhere below 0.36 mmol/l, but even then, arthritic flares have 
occurred [13]. In tophaceous gout treated with allopurinol and/or uricosurics, it may take years 
to fully clear the body from urate stores. 
Gout nearly always occurs in the setting of chronic hyperuricemia, though it is not a prerequisite 
[14]. In the treatment of acute attack, one may use colchicine, a non-steroidal, anti-inflammatory 
drug (NSAID) or, particularly in patients without additional cardiovascular risks, a COX-2 
selective inhibitor (coxib) or even corticosteroids. Colchicine and corticosteroids are not capable 
of decreasing renal function and, therefore, may have advantages in a selected group of gouty 
patients. Caution should be taken regarding the overconsumption of corticosteroids and 
colchicine, i.e. with respect to dosage and period of application. In the case of two or more 
attacks per year, sUr-lowering treatment is already cost-effective [15]. It should also be installed 
in tophaceous disease. Therapy non-compliance, however, is an important problem that may 
hinder adequate therapy in individual cases. 
With rasburicase, potent uricolytic treatment is available, and it has been proven capable of 
reducing bulky disease in severe tophaceous gout; as presented in this study, lysis of tophi 
occurred quite rapidly in the patient. Among the expensive treatment options, uricolytic therapy 
appears to be a more rational treatment option than to just reduce attacks, as was recently 
described for etanercept [7]. Currently, it is a challenge to define at which time and in which 
case the expensive uricolytic therapy should be installed. The presented case clearly shows 
that uricolytic treatment can be started even late in the course of a disease. Optimisation of the 
exact uricase regimen is a second challenge for clinicians in the near future, particularly the 
corticosteroid scheme given to prevent formation of rasburicase antibodies; corticosteroids may 
have extra advantages of inhibiting arthritic attacks and possibly preventing further lysis of cells 
that could potentially be an ongoing source of uric acid. The scheme we describe herein did not 
give serious adverse events in the presented case. 
We here described the first rasburicase-treated patient with severe bulky tophaceous gout 
responding very well to this modern treatment. Therefore, we conclude that the availability of 
rasburicase is a promising option to be considered by clinicians when a rapid lysis of tophi is 
called for. The status of this uricase derivative and the exact treatment strategy in severe gout 
remains to be determined in future studies. 
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Summary 
Numerous publications identify that gout management is often sub-optimal, despite detailed 
understanding of the pathogenesis and pathophysiology of the disorder, the ability to establish 
the diagnosis with certainty, and the likely effectiveness of lifestyle and pharmacological 
interventions. Barriers to successful gout management include diagnostic inaccuracy, a paucity 
of guidelines, sub-optimal patient education and patient adherence, co-morbidities and drug-
drug interferences that complicate treatment of gout, and limited urate-lowering alternatives. 
Furthermore, a lack of information exists on the risk-benefit ratios of antihyperuricemic drugs for 
gout treatment. 
This thesis studies the clinical pharmacology of antihyperuricemic dugs in the treatment of gout 
in clinical practice, with focus on efficacy and tolerability. Studies and reviews of this thesis 
focus on: management of gout, outcome research with antihyperuricemic drugs, therapeutic 
drug monitoring of allopurinol, and rasburicase for treatment of gout. 
 
Management of gout 
In chapter 2.1, we reviewed the literature on management of gout and presented a therapeutic 
strategy. Limited information on drugs indicated for the treatment of gout is available, making it 
difficult for physicians to make informed treatment decisions. The current therapeutic strategy is 
often based on clinical experience. Lifestyle advice is of limited value in the prevention of gout, 
particularly with regard to restricting alcohol, losing weight in cases of obesity, ensuring 
adequate diuresis and adhering to a low-purine diet, as most patients are reluctant to make 
such changes. Therefore, the condition is often treated with pharmacological therapies. 
Presently, oral colchicine and non-steroidal anti-inflammatory drugs (NSAIDs) are first-choice 
agents for systemic treatment of acute gout. In the absence of contra-indications, NSAIDs are a 
convenient and well-accepted option for treatment of acute gout. In case of tophaceous or 
recurrent gout, the use of urate-lowering drugs is recommended. Allopurinol is currently the first 
choice drug despite its AE profile at the population level. Many of the currently available 
treatment options for gout have unwanted side effects highlighting the importance of emerging 
therapeutics for the treatment of the disease. 
Benzbromarone (chapter 2.2) is an old, but very potent urate-lowering drug, and possesses 
some distinct, recently discovered pharmacological features, which are important for effective 
and safe use in treatment of gout. Although benzbromarone is on the market for several 
decades, its place in treatment of gout compared to allopurinol is unclear, because of 
insufficient trials of good quality. The toxicity of benzbromarone is generally limited, but serious 
benzbromarone-induced hepatic failure is reported in rare cases. The underlying mechanism 
has not yet been fully explained, but formation of reactive metabolites by CYP2C9 resulting in 
mitochondrial toxicity, and CYP2C9 allelic variants might play a role. Important drug-drug 
interactions may occur with CYP2C9-substrate drugs, but clinical data are lacking up until now. 
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Outcome research with antihyperuricemic drugs 
In chapter 3, several studies concerning the efficacy and tolerability of antihyperuricemic drugs 
in the treatment of gout in clinical rheumatologic practice are presented. In 2003, 
benzbromarone was withdrawn from the global market. In the Netherlands, suggested 
alternative treatments were allopurinol (in standard dosage) or probenecid. We studied the 
market withdrawal of benzbromarone in gout patients in chapter 3.1, and investigated the 
efficacy of two alternative treatment strategies: allopurinol (standard dosage) and allopurinol-
probenecid combination therapy. A prospective, open study was carried out in 51 patients. 
Patients were given 200-300 mg allopurinol (stage 1); when allopurinol failed to attain the target 
serum urate concentration, sUr ≤0.30 mmol/l (5.0 mg/dl), probenecid 1,000 mg/day was added 
(stage 2). We found that previous treatment with benzbromarone monotherapy (mean dosage 
138 mg/day) resulted in 92% of patients reaching target levels sUr ≤0.30 mmol/l with a mean 
sUr decrease of 61% compared to baseline. In stage 1, 32 patients completed treatment with 
allopurinol monotherapy (mean dosage 256 mg/day), which resulted in 25% of patients attaining 
sUr target levels. Decrease in sUr levels was 36%, which was significantly less compared to 
treatment with benzbromarone. In stage 2, 14 patients received allopurinol-probenecid 
combination therapy, which resulted in 86% of patients attaining target sUr levels (after failure 
on allopurinol monotherapy), which was comparable to previous treatment with benzbromarone. 
Decrease in sUr levels was 53%, which was a non-significant difference compared to previous 
treatment with benzbromarone. From the results, it was concluded that benzbromarone is a 
very effective sUr-lowering drug. Allopurinol in standard dosage was shown to be a less potent 
alternative for most selected patients to attain target sUr levels. In patients failing on allopurinol 
monotherapy, the addition of probenecid proves to be an effective treatment strategy for 
attaining sUr target levels. The results of this study stress the need for effective, evidence-
based treatment strategies for lowering of serum urate in gout patients. 
In The Netherlands, the use of benzbromarone is restricted to gout patients allergic to 
allopurinol, or otherwise not treatable with this drug. The Dutch general practitioners’ guideline 
also includes patients who cannot be treated sufficiently with allopurinol. In chapter 3.2, we 
investigated the efficacy and tolerability of allopurinol (standard dosage) as first-choice 
antihyperuricemic treatment for gout, and compared the efficacy and tolerability of 
benzbromarone and probenecid as second-choice treatment. A multi-centre, open-label, 
randomised controlled trial was carried out in 96 gout patients with a calculated creatinine 
clearance >50 ml/min who were prescribed 300 mg allopurinol daily for 2 months (stage 1). In 
82 eligible patients, 24% attained target sUr ≤0.30 mmol/l, and sUr concentrations decreased 
36% from baseline; 11% stopped allopurinol because of adverse drug reactions. Then, 
62 patients failing on allopurinol were randomised to benzbromarone 200 mg/day or probenecid 
2,000 mg/day (stage 2). After 2 months, 22 out of 24 patients (92%) were treated successfully 
with benzbromarone, with a sUr decrease of 64% on average. Treatment success with 
probenecid was 20 out of 31 patients (65%), with a sUr decrease of 50%. This study showed a 
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poor efficacy and tolerability profile of allopurinol 300 mg/day to attain a biochemical predefined 
target level of sUr ≤0.30 mmol/l after 2-months treatment. Whether higher doses of allopurinol 
would increase treatment success, remains subject of further research (chapter 3.4). In patients 
failing on allopurinol 300 mg/day, benzbromarone 200 mg/day is significantly more effective and 
better tolerated than probenecid 2,000 mg/day. 
Serum urate is a well-accepted surrogate parameter for short-term evaluation of gout treatment. 
Furthermore, information on clinical outcomes, such as prevention of recurrent gout attacks and 
diminishment of tophi, is essential. A lack of long-term, good-quality, prospective data exists 
addressing the efficacy of serum urate (sUr) lowering treatment to prevent these clinical 
symptoms. We conducted an observational follow-up study (chapter 3.3) to assess the rate of 
recurrent gouty arthritis in 50 patients with a history of recurrent gouty attacks, normal renal 
function, using antihyperuricemic treatment, and who completed a randomised controlled trial. 
After 10.6 months on average, incidence of gout attacks was largely reduced compared to 
baseline rates: 74% of patients were free of gouty attacks (100% reduction), and 18% of 
patients had 50-99% reduction of gouty attacks. Serum urate concentrations were 0.28 [± 0.08] 
mmol/l. We found a high reduction in incidence of gout attacks, that was better than obtained in 
most previous studies. This might be explained by the good control of serum urate in this study. 
No correlation was found between reduction of gout attacks and sUr or study drug used, due to 
lack of power. We concluded that antihyperuricemic therapy is highly effective in reducing and 
preventing gout attacks in gout patients with normal renal function. 
In chapter 3.4, we investigated the efficacy and tolerability of allopurinol 300-600 mg/day 
versus benzbromarone 100-200 mg/day to attain a target sUr ≤0.30 mmol/l. A multi-centre, 
open-label, randomised controlled trial was carried out in 65 patients recently diagnosed with 
gout, who were randomised to allopurinol 300 mg/day or benzbromarone 100 mg/day (stage 1). 
When the target sUr was not reached, the dosage was doubled. After stage 1 treatment 
success was 8 out of 31 (26%) with allopurinol 300 mg/day, and 13 out of 25 (52%) with benz-
bromarone 100 mg/day. Overall treatment success with allopurinol 300-600 mg/day was 
21 out of 27 (78%), and with benzbromarone 100-200 mg/day was 18 out of 23 (78%), a non-
significant difference. In this study, dosage increase of allopurinol and benzbromarone did not 
affect tolerability. This study showed that efficacy of allopurinol (and to a lesser extent 
benzbromarone) in gout patients can be markedly increased with increasing dosage. The 
overall efficacy of allopurinol and benzbromarone was not significantly different. 
 
Therapeutic drug monitoring of allopurinol 
Chapter 4 concerns the therapeutic drug monitoring of allopurinol treatment. From previous 
studies it is known that antihyperuricemic efficacy of allopurinol is related to the serum 
concentration of oxipurinol, the active metabolite of allopurinol. Reference values of oxipurinol 
5-15 mg/l (trough) are suggested, but poorly investigated. Given the poor efficacy results of 
allopurinol in literature and clinical practice, optimisation of allopurinol therapy is warranted. 
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Therapeutic drug monitoring of allopurinol might be particularly useful in case of patients with 
renal impairment, oxipurinol-lowering drug-drug interactions, or suspected poor adherence. 
In chapter 4.1, a reversed-phase high-performance liquid chromatography method with UV-
detection (HPLC-UV) to obtain a method for the quantification of allopurinol and oxipurinol in 
human serum, was validated technically and clinically. The method showed acceptable 
performance on all major aspects of the validation (linearity, intra- and inter-day precision, 
accuracy, specificity, and lower/upper limits of quantification). For clinical validation, the serum 
allopurinol and oxipurinol concentrations in 66 gout patients were determined using this HPLC-
UV method. Measured serum allopurinol and oxipurinol concentrations in clinical practice 
showed large variability with a range of <0.5-4.3 mg/l for allopurinol and <1.0-39.2 mg/l for 
oxipurinol, respectively. From these results, we concluded that the proposed method could be 
employed for the assay of allopurinol and oxipurinol in gout patients. 
 
Uricase for gout treatment 
Recently, a new class of powerful urate-lowering drugs has become available with rasburicase, 
recombinant uricase. Rasburicase is developed for the treatment and prevention of tumour-lysis 
syndrome. In chapter 5, the potential role of rasburicase in treatment of severe, treatment-
resistant gout was reviewed, and explored in two cases. 
 
Future perspectives 
From the chapters 2.1, 2.2, and 3.1, we conclude that a need for more evidence and education 
on treatment of gout exists, although the pathogenesis of the disease is well understood and 
antihyperuricemic therapies are available for decades. Indeed, (only) very recently two 
important guidelines have been developed: the EULAR recommendations on gout (2006) and 
the British guideline (2007). The - in some countries temporarily - withdrawal of benzbromarone 
made clear that this was not in the benefit of gout patients in general, because of scarcity of 
drugs for antihyperuricemic treatment. The benefit-risk evaluations of alternative drugs might 
not have been addressed properly, and better efforts might have been done for vigilance and 
understanding of the hepatotoxicity. Since allopurinol is the only drug currently available 
worldwide, it is very important to know how to use this drug safely and effectively. Chapter 3.2, 
3.4 and 4, show that at least in patients with normal renal function, allopurinol often is 
inadequately dosed and that target serum urate concentrations can be reached with good 
tolerability by increase of allopurinol dosage and by optimising serum oxipurinol trough 
concentrations. In the end, good control of serum urate is associated with good control of gout 
symptoms (chapter 3.3). 
Subject of further research is to what extent these findings can be generalised to patients with 
renal dysfunction, a large group in gout. This is important, because uricosuric drugs are likely to 
be less effective in renal dysfunction, and a need for optimisation of allopurinol dosage 
regimens according to renal function exists. 
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Currently, new antihyperuricemic drugs have been developed for gout treatment: febuxostat, a 
xanthine oxidase inhibitor, and pegloticase, a pegylated form of uricase. New drugs for 
treatment of gout are welcomed. However, the benefit-risk profiles of these drugs are not 
undisputed, since febuxostat is associated with liver enzyme elevations, and pegloticase with 
antibody formation. These new drugs might help management of gout, but more issues require 
attention to bridge the gap between clinical practice and potential treatment possibilities, such 
as optimisation of current treatment regimens, evidence of benefit of long-term treatment of gout 
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Samenvatting 
Talrijke publicaties hebben aangetoond dat de behandeling van jicht verbetering behoeft. Dit 
ondanks het feit dat de oorzaak en het ontstaan van deze aandoening goed bekend is, dat de 
diagnose met zekerheid gesteld kan worden en dat er effectieve leefstijladviezen en 
geneesmiddelen beschikbaar zijn. Barrières voor een succesvolle behandeling van jicht 
bestaan uit diagnostische onnauwkeurigheid, een tekort aan richtlijnen, onvoldoende 
patiëntenvoorlichting, onvoldoende therapietrouw, aanwezigheid van andere aandoeningen en 
van geneesmiddelinteracties en een tekort aan beschikbare geneesmiddelen. Bovendien zijn de 
beschikbare urinezuurverlagende geneesmiddelen voor de behandeling van jicht erg oud en is 
de effectiviteits-/veiligheidsbalans van deze middelen onvoldoende bekend. 
In dit proefschrift wordt de klinische farmacologie van urinezuurverlagende middelen onderzocht 
in de dagelijkse praktijk bij de behandeling van jichtpatiënten met het focus op effectiviteit en 
verdraagbaarheid. De onderzoeken en literatuuroverzichten van dit proefschrift gaan 
achtereenvolgens over de behandeling van jicht, uitkomstenonderzoek met urinezuur-
verlagende behandeling, “therapeutic drug monitoring” van allopurinol en rasburicase voor de 
behandeling van jicht. 
 
Behandeling van jicht 
In hoofdstuk 2 wordt een overzicht gegeven van de behandeling van jicht en wordt een 
behandelstrategie voorgesteld. Er is beperkt informatie over geneesmiddelen tegen jicht 
beschikbaar, hetgeen het lastig maakt voor behandelaars om afgewogen beslissingen te 
maken. De huidige behandelstrategieën zijn voor een groot deel gebaseerd op klinische 
ervaring. Leefstijladviezen hebben een beperkte betekenis voor de preventie van jicht. 
Patiënten met jicht zijn moeilijk te motiveren om hun levensstijl aan te passen wat betreft het 
gebruik van alcohol, gewichtsverlies, voldoende diurese en het volgen van een purine-arm 
dieet. Daarom wordt jicht vaak met geneesmiddelen behandeld. 
Op dit moment zijn colchicine en niet-steroïde anti-inflammatoire middelen (NSAID’s) eerste-
keus middelen voor (systemische) behandeling van acute jichtaanvallen. Mits er geen contra-
indicaties zijn, vormen NSAID’s een goede en gemakkelijke keus. In geval van tofeuze jicht of 
terugkerende jichtaanvallen wordt urinezuurverlagende behandeling geadviseerd. Allopurinol is 
momenteel het middel van eerste keuze en in sommige landen het enige middel dat 
beschikbaar is. Alle wereldwijd beschikbare urinezuurverlagende middelen kennen specifieke, 
potentieel ernstige bijwerkingen; er is daarom behoefte aan nieuwe, alternatieve urinezuur-
verlagende middelen. 
Benzbromaron is een oud, maar krachtig urinezuurverlagend middel en bezit een aantal 
kenmerkende, kort geleden ontdekte, farmacologische eigenschappen die van belang zijn voor 
een veilig en effectief gebruik in de behandeling van jicht. Hoewel benzbromaron al enkele 
tientallen jaren op de markt is, is zijn plaats in de behandeling van jicht in vergelijking met 
allopurinol onduidelijk wegens onvoldoende onderzoek van goede kwaliteit. Benzbromaron 
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wordt over het algemeen goed verdragen, maar er zijn enkele meldingen van zeer ernstige en 
fatale leverafwijkingen. Het onderliggende mechanisme is nog onvoldoende bekend, hoewel de 
vorming van reactieve metabolieten waarschijnlijk een rol speelt. Daarna zijn mogelijk het 
bestaan van genetische verschillen in het metabolisme, in samenhang met eventuele 
geneesmiddelinteracties, van belang. Er kunnen belangrijke interacties optreden tussen 
benzbromaron en andere middelen op het CYP2C9 enzym, maar klinische gegevens ontbreken 
tot op heden. 
 
Uitkomsten onderzoek met urinezuurverlagende geneesmiddelen 
In hoofdstuk 3 worden enkele onderzoeken naar de effectiviteit en verdraagbaarheid van 
urinezuurverlagende middelen beschreven. In 2003 werd benzbromaron wereldwijd van de 
markt gehaald. In Nederland werden als alternatief allopurinol (in standaard dosering) en 
probenecide geadviseerd. Wij bestudeerden de effecten van het van de markt halen van 
benzbromaron en onderzochten de effectiviteit van twee alternatieve behandelstrategieën: 
allopurinol (in standaard dosering) en de combinatiebehandeling allopurinol plus probenecide 
(hoofdstuk 3.1). Een prospectief, open onderzoek werd uitgevoerd in een groep van 51 jicht-
patiënten die noodgedwongen waren gestopt met benzbromarone. In stap 1 werd allopurinol 
200 tot 300 mg voorgeschreven. Indien de gestelde streefwaarde van serum urinezuur (uraat) 
0,30 mmol/l (5,0 mg/dl) niet werd bereikt, werd vervolgens probenecide 100 mg/dag toe-
gevoegd in stap 2. Wij vonden dat de voorafgaande behandeling met benzbromaron 
(gemiddelde dosering 138 mg/dag) succesvol was bij 92% van de patiënten met een 
gemiddelde daling van serum urinezuur van 61% vergeleken met de uitgangswaarde. In stap 1 
volbrachten 32 patiënten de behandeling met allopurinol (gemiddelde dosering 256 mg/dag), 
hetgeen resulteerde in 25% succes in het behalen van de serum urinezuur streefwaarde. De 
daling van het serum urinezuur was 36% en dat was significant lager dan met de voorafgaande 
behandeling met benzbromaron. In stap 2 kregen 14 patiënten de combinatie allopurinol plus 
probenecide voorgeschreven. Dit resulteerde in 86% succes, wat vergelijkbaar was met 
voorgaande behandeling met benzbromaron. De daling van serum urinezuur was 53%. Met 
deze resultaten concluderen we dat benzbromaron een zeer effectief urinezuurverlagend 
middel is. Allopurinol in standaard dosering was significant minder effectief en dus niet een 
gelijkwaardig alternatief voor benzbromaron. Tenslotte biedt de toevoeging van probenecide 
aan allopurinol een effectieve strategie voor het behalen van streefwaarden serum urinezuur. 
De resultaten van dit onderzoek onderstrepen de behoefte aan meer onderzoek naar effectieve 
behandelstrategieën met urinezuurverlagende middelen. 
In Nederland is het gebruik van benzbromaron beperkt tot jichtpatiënten die niet behandeld 
kunnen worden met allopurinol vanwege allergische reacties of andere contra-indicaties. De 
Standaard van het Nederlands Huisartsen Genootschap (NHG) voegt hieraan nog toe patiënten 
die onvoldoende resultaat boeken met allopurinol. In hoofdstuk 3.2 onderzochten we de 
effectiviteit en verdraagbaarheid van allopurinol (standaard dosering) als eerste-keus middel. 
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Vervolgens vergeleken we de effectiviteit en verdraagbaarheid van benzbromaron en 
probenecide als tweede-keus middelen. Een multi-centre, open-label, gerandomiseerd 
gecontroleerd onderzoek werd uitgevoerd bij 96 patiënten met een voldoende nierfunctie 
(berekende creatinineklaring >50 ml/min) die recent de diagnose jicht hadden gekregen. 
Allopurinol 300 mg/dag werd voorgeschreven voor tenminste 2 maanden. De gegevens van 
82 patiënten konden geanalyseerd worden met als resultaat dat 24% de streefwaarde serum 
urinezuur van 0,30 mmol/l bereikte. Daarnaast was de gemiddelde daling van het serum 
urinezuur 36% en moest 11% de behandeling staken wegens bijwerkingen. Vervolgens kregen 
62 patiënten volgens randomisatie benzbromaron 200 mg per dag of probenecide 2000 mg per 
dag voor tenminste 2 maanden. In de benzbromaron groep werden 22 van de 24 (92%) met 
succes behandeld tegen 20 van de 31 (65%) in de probenecide groep. Verlaging van het serum 
urinezuur was gemiddeld 64% met benzbromaron en 50% met probenecide. Dit onderzoek laat 
zien (1) dat allopurinol 300 mg/dag van beperkte waarde is om de vooraf gestelde streefwaarde 
van serum urinezuur 0,30 mmol/l te behalen en (2) dat het door 11% niet goed wordt verdragen. 
De vraag of allopurinol in hogere doseringen effectiever is, blijft onderwerp van verder 
onderzoek (zie hoofdstuk 3.4). Voor patiënten die geen succes hebben op allopurinol 
(standaard dosering), is benzbromaron een beter keuze dan probenecide wat betreft effectiviteit 
en verdraagbaarheid. 
Serum urinezuur is een goede parameter voor de evaluatie van behandeling van jicht op de 
korte termijn. Daarnaast is informatie op klinische eindpunten van groot belang, zoals het 
voorkomen van terugkerende jichtaanvallen, het verdwijnen van tofi of het voorkomen van 
gewrichtsschade. Er is een tekort aan gegevens over de resultaten van urinezuurverlagende 
behandeling bij jicht op deze klinische symptomen. Wij voerden een observationeel follow-up 
onderzoek uit (hoofdstuk 3.3) bij 50 patiënten van het vorige onderzoek om de mate van 
terugkerende jichtaanvallen vast te stellen gedurende urinezuurverlagende vervolgbehandeling 
van 1 jaar. Na gemiddeld 11 maanden was de incidentie van jichtaanvallen aanmerkelijk terug-
gedrongen: 74% was klachtenvrij en bij 18% was het aantal jichtaanvallen met meer dan de 
helft teruggedrongen. Het serum urinezuur was gemiddeld 0,28 mmol/l. Wij vonden een betere 
effectiviteit dan de meeste eerdere onderzoeken en dat zou veroorzaakt kunnen worden door 
een beter controle van het serum urinezuur. Wij concluderen dat urinezuurverlagende 
behandeling zeer effectief is in het voorkomen van jichtaanvallen. 
In hoofdstuk 3.4 werd de effectiviteit en verdraagbaarheid van allopurinol 300-600 mg tegen 
benzbromaron 100-200 mg onderzocht. Er werd een multi-centre, open-label, gerandomiseerd 
gecontroleerd onderzoek uitgevoerd bij 65 jichtpatiënten met een voldoende nierfunctie 
(berekende creatinineklaring >50 ml/min) die recentelijk de diagnose jicht hadden gekregen. In 
stap werd gerandomiseerd naar behandeling met allopurinol 300 mg of benzbromaron 100 mg. 
Als de streefwaarde serum urinezuur van 0,30 mmol/l niet werd bereikt, werd de dosering 
verdubbeld (stap 2). Na stap 1 waren 8 van 31 (26%) patiënten succesvol met allopurinol 
300 mg/dag tegen 13 van 25 (52%) met benzbromaron 100 mg/dag. Na stap 1+2 waren 
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21 van 27 (78%) patiënten succesvol met allopurinol 300-600 mg/dag tegen 18 van 23 (78%) 
patiënten met benzbromaron 100-200 mg/dag. Dit onderzoek laat zien dat de effectiviteit van 
allopurinol belangrijk verbeterd kan worden door gebruik van hogere doseringen dan de 
veelgebruikte dosering van 300 mg/dag. De effectiviteit van allopurinol en benzbromaron was 
niet meer verschillend na verdubbeling van de dosering in stap 2. 
 
Therapeutic drug monitoring van allopurinol 
Hoofdstuk 4 betreft de therapeutic drug monitoring van allopurinol. Van eerdere onderzoeken 
is bekend dat het serum urinezuur verlagend effect van allopurinol gerelateerd is aan de serum 
concentratie van oxipurinol, de actieve metaboliet van allopurinol. Referentiewaarden van 5-15 
mg/l (serum oxipurinol dal concentratie) worden genoemd, maar zijn onvoldoende vastgesteld 
of onderzocht. Gezien de matige effectiviteit van allopurinol in de literatuur en de klinische 
praktijk, is optimalisatie van allopurinol behandeling wenselijk. Therapeutic drug monitoring zou 
met name van belang zijn in geval van verminderde nierfunctie, geneesmiddelinteracties 
waarbij oxipurinol verlaagd wordt, of verdenking van matige therapietrouw. 
In hoofdstuk 4.1 is een reversed-phase high-performance vloeistofchromatografie met UV-
detectie (HPLC-UV) opgezet en gevalideerd voor het verkrijgen van een methode voor de 
kwantificering van allopurinol en oxipurinol in serum. Deze methode voldeed aan alle 
belangrijke aspecten van de validatie: lineariteit, intra-dag en inter-dag precisie, juistheid, 
specificiteit en boven- en ondergrenzen voor de kwantificering. Voor de klinische validatie 
werden met deze methode de allopurinol en oxipurinol concentraties bepaald van 66 jicht 
patiënten. De gemeten waarden vertoonden grote verschillen met een bereik van <0,5 tot 
4,3 mg/l voor allopurinol en <1,0 tot 39,2 mg/l voor oxipurinol, respectievelijk. Op basis van de 
resultaten, concludeerden wij dat deze methode geschikt is voor de bepaling van allopurinol en 
oxipurinol serum concentraties in jicht patiënten. 
 
Uricase voor de behandeling van jicht 
Onlangs is een nieuwe groep van krachtige urinezuurverlagende middelen beschikbaar 
gekomen met rasburicase, recombinant uricase. Rasburicase is ontwikkeld voor preventie en 
behandeling van het tumor lysis syndroom. In hoofdstuk 5 is een overzicht opgenomen van de 
mogelijke rol van rasburicase in de behandeling van ernstige jicht die onvoldoende behandeld 
kan worden met conventionele middelen. 
 
Toekomstperspectieven 
Vanuit hoofdstukken 2.1, 2.2 en 3.1 wordt geconcludeerd dat er behoefte is aan meer 
onderzoek naar de evidence en begrip van de behandeling van jicht, hoewel de pathogenese 
van jicht goed bekend is en er tientallen jaren geneesmiddelen beschikbaar zijn. Pas zeer 
recent zijn er een (internationale) richtlijnen ontwikkeld voor diagnose en behandeling van jicht 
door reumatologen: de EULAR Recommendations (2006) en de Britse richtlijn (2007). De 
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terugtrekking van benzbromaron in 2003 maakte duidelijk dat dit in het algemeen niet in het 
voordeel was van de jichtpatiënten, gezien de beperkte alternatieven. De effectiviteit-
veiligheidsbalans van urinezuurverlagende middelen is niet voldoende bekend en onvoldeonde 
onderling vergeleken. Tevens zou meer onderzoek gedaan moeten worden naar het optreden 
van (ernstige) bijwerkingen en de achterliggende mechanismen. Gezien het feit dat allopurinol 
het enige urinezuurverlagende middel is dat wereldwijd beschikbaar is, is het van groot belang 
om dit middel op een effectieve en veilige manier te kunnen inzetten. Hoofdstuk 3.2, 3.4 en 4, 
laten zien dat, althans in patiënten met een voldoende nierfunctie, allopurinol vaak te laag wordt 
gedoseerd (vanwege het potentiële risico op bijwerkingen) en dat serum urinezuur 
streefwaarden vaker bereikt kunnen worden door de allopurinol dosering te verhogen tot 
600 mg/dag. Tenslotte is een assocoiatie gevonden tussen een strikte verlaging van het serum 
urinezuur en het voorkomen van jichtaanvallen. 
In hoeverre deze conclusies doorgetrokken kunnen worden naar jichtpatiënten met verminderde 
nierfunctie, blijft onderwerp van verder onderzoek. In het bijzonder zijn uricosurische middelen 
(zoals benzbromaron en probenecide) minder effectief bij deze groep en dient de allopurinol 
dosering aangepast te worden aan de nierfunctie. 
Op dit moment zijn er nieuwe urinezuurverlagende middelen in ontwikkeling voor de 
behandeling van jicht: febuxostat (een xanthine oxidase remmer) en pegloticase (een 
gepegyleerde vorm van uricase). Nieuwe middelen voor de behandeling van jicht zijn welkom. 
Echter van deze nieuwe middelen zal ook de effectiviteit-veiligheidsbalans eerst voldoende 
duidelijk moeten worden. Deze nieuwe middelen kunnen de behandeling van jicht verbeteren, 
maar er zijn meer aspecten die de kloof tussen klinische praktijk en behandelings-
mogelijkheden, zoals optimalisatie van huidige behandelstrategieën, evidence op klinische 
eindpunten op de lange-termijn en de therapietrouw van de patiënt. 
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